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BEHAVIORAL ASSESSMENT AND HPLC/MS/MS IDENTIFICATION OF THE 
ABUSED SYNTHETIC CANNABINOID, CP47,497, IN MICE 
By Kimberly Lynne Samano, M.S. 
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     CP47,497 and other synthetic cannabinoid compounds were incipiently synthesized 
as research tools to investigate the mechanisms by which marijuana affects the brain 
and to aid in the development of therapeutic agents. Recently, these cannabinoid 
compounds have resurfaced in the designer drug market, marketed as “herbal incense 
products” (HIPs). Their popular use has resulted in an alarming rate of reported adverse 
effects and toxicities. Current legislation classified CP47,497 and several other synthetic 
!13 
cannabinoids compounds as Schedule I agents, but abuse of these compounds persists 
with serious consequences to public health and safety. In vivo studies examining the 
behavioral consequences of abused synthetic cannabinoids are limited. As a result, the 
goals of this research were to elucidate the acute and chronic pharmacological effects 
of CP47,497 and to develop a bioanalytical method for CP47,497 drug detection in mice. 
Cannabimimetic effects were evaluated in well-established in vivo models, the tetrad 
paradigm and drug discrimination assay. The tetrad test is comprised of four outcome 
measures sensitive to the primary psychoactive cannabinoid present in marijuana, 
delta-9-tetrahydrocannabinol (THC): catalepsy (bar test), antinociception (tail withdrawal 
latency), hypothermia, and decreases in spontaneous locomotor activity. While many 
pharmacological agents can produce one or a subset of these tetrad effects, drugs that 
activate CB1 receptors produce characteristic effects in all four parameters.  
 An HPLC/MS/MS method was developed and confirmed the presence of 
CP47,497 in brain. We investigated whether CB1 receptors mediate the 
pharmacological effects of CP47,497.  Cumulative dose-response experiments 
determined CP47,497 is more potent than THC in vivo in using multiple behavioral 
assays. Complementary pharmacological (CB1 receptor antagonist, rimonabant) and 
genetic (CB1 (-/-) mice) approaches were used to investigate whether CB1 receptors 
mediate the effects of CP47,497. Rimonabant (3 mg/kg or 10 mg/kg, depending on 
!14 
independent measure) blocked all cannabinoid-like pharmacological effects of 
CP47,497. Supporting these findings, CB1(-/-) mice were resistant to cannabimimetic 
effects of CP47,497. CP47,497 fully substituted for THC in the drug discrimination assay, 
with a potency of more than 5 times that of THC. Collectively, these results indicate that 
CP47,497 is markedly more potent (i.e. 5-8 fold) than THC, and its repeated 
administration produces tolerance to the cataleptic, antinociceptive, hypothermic and 
hypolocomotor effects in mice, with significant presentation of somatic withdrawal signs 
(paw flutter and head shakes) upon drug cessation. These findings are consistent with 
the high incidence of adverse events in humans abusing synthetic cannabinoids. 
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Chapter 1 – The Endogenous Cannabinoid System  
 
1.1 Discovery and Isolation of THC 
 
 Cannabis sativa has been used for recreational and medicinal purposes for 
centuries (Mikuriya 1969; Schultes 1969) and marijuana is still today the most widely 
abused illicit drug worldwide (UNDOC 2013). Despite its prevalent use, most of our 
current knowledge about marijuana’s effects in humans, and more specifically of delta-
9-tetrahydrocannabinol (THC), has been largely elucidated over the last several 
decades. In the early 1930’s, the structure of THC was first isolated in the laboratory of 
R.S. Cahn, and its subsequent synthesis occurred in 1940 by Adams et al. in the United 
States and Jacob et al. in Europe (Adams et al. 1940; Jacob & Todd 1940; Pertwee 
2006). More than twenty years passed before Gaoni and Mechoulam identified THC as 
the major active constituent of hashish and published the first detailed description of its 
isolation, and confirmed the absolute structural configuration of THC including its 
stereospecific synthesis (Mechoulam et al. 1967; Mechoulam & Gaoni 1967). The 
isolation and synthesis of THC was a scientific breakthrough, and as a result, structure-
activity relationship (SAR) studies, discussed further in Chapter 2, were performed to 
dissect which THC functional groups were important for binding and responsible for its 
biological activity.  
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 These SAR studies were foundational to the exploration of the endocannabinoid 
(EC) system as they provided pharmacological tools that enabled the identification and 
cloning of cannabinoid receptors, discovery of endogenous cannabinoids, and a 
thorough examination of their physiological effect on neurotransmission in the central 
nervous system. Unfortunately, this research that allowed these important discoveries to 
be made has been commandeered in the illicit marketing of synthetic cannabinoid 
(SCB) compounds as described in Chapter 2. Synthetic cannabinoids were exclusively 
developed for research purposes and within the last several years have been falsely 
advertised as “natural” plant-derived components in herbal incense products (HIPs), 
most often called “K2” and “Spice”. While these “legal high” alternatives to marijuana 
were originally a misnomer, their chemical identification did not deter human users. 
More than 6,000 synthetic cannabinoid exposures were reported to poison control 
centers in 2011, versus less than 20 incidents in 2009 (Wood 2013). Consequently, 
abuse of SCB’s has dramatically escalated in the United States and Europe; reported 
toxicity and mortality make their consumption a significant public health concern.  
1.2 Identification of Cannabinoid Receptors  !
 Early experiments were aimed at understanding how THC elicits its actions on 
the central nervous system (CNS). Since cannabinoid compounds were unlike nitrogen-
containing drugs of abuse (LSD, psilocybin), but similar to anesthetic compounds in 
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their lipophilicity profiles, it was hypothesized that the pharmacological effects of THC 
were due to ordered perturbations of lipid membranes (Lawrence & Gill 1975; Martin 
1986). In one study, THC disordered cholesterol/lecithin lipid bilayers in a qualitative 
manner similar to a sub-effective dose of an anesthetic agent; therefore, it was believed 
THC and other cannabinoids could act as partial anesthetics (Lawrence & Gill 1975). 
Later studies interrogated the relationship between lipophilicity and in vivo 
pharmacological activity and concluded that while behaviorally active compounds 
exhibited high lipophilicity, as evidenced by water/octanol partition coefficients, there 
was no clear correlation between lipophilicity and behavioral potency (Thomas et al. 
1990). Important physiochemical information was provided by this work, even though 
these experiments were unable to definitively characterize the pharmacological action of 
cannabinoids. 
 As a result, a concerted effort to identify the receptor responsible for cannabinoid 
actions included studies that investigated the stereoselectivity of cannabinoid effects 
using in vitro and in vivo approaches. Harris et al. provided initial evidence for the 
presence of specific cannabinoid binding sites that are displaceable and potentially 
stereospecific in cultured hepatoma cells and rat brain homogenates (Harris et al. 1978). 
Using neuroblastoma cells, Howlett et al. disproved the hypothesis that the 
stereoselective and specific inhibition of adenylate cyclase (AC) by psychoactive 
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cannabinoids was mediated by secretin, α-adrenergic, and muscarinic cholinergic 
receptors (Howlett & Fleming 1984). The effects of cannabinoids on AC inhibition were 
shown to require functional Gi-proteins as ADP-ribosylation of Gi-protein subunits by 
pertussis toxin coincided with cannabimimetic (of, or pertaining to THC-like 
pharmacological effects (Weissman et al. 1982)) inhibition of AC (Howlett et al. 1985). 
Subsequent studies postulated that the same receptor responsible for in vitro effects of 
AC inhibition by cannabimimetic compounds was also responsible for mediating 
analgesic effects across several pain assays in vivo (Howlett et al. 1987). Cannabinoid-
induced behavioral effects by synthetic cannabinoid compounds levonantradol and 
CP55,940 were potent and stereoselective versus their respective enantiomers 
(dextronantradol and CP 56,677) (Little et al. 1988). Taken together, these findings 
provided strong pharmacological evidence that non-classical cannabinoid compounds’ 
actions were receptor-mediated, thus, research around this time was published on the 
identification and characterization of a cannabinoid receptor (Devane et al. 1988). A 
series of elegant binding studies in rat membranes and synaptosomes were optimized 
and definitively illustrated displacement of [3H]CP55,940 binding by THC, 11-OH-THC, 
cannabinol, and CP55,940 (Devane et al. 1988). Importantly, the data indicated this 
effect was saturable, rapid, reversible, and determined a single class of binding sites 
(Devane et al. 1988). Moreover, this work demonstrated using a non-hydrolyzable 
guanosine triphosphate (GTP) analog that [3H]CP55,940 binding was affected in a 
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manner consistent with G-protein activation. Specificity of this binding interaction was 
observed using plant-derived (THC, 11-OH-THC) and synthetic cannabinoid compounds 
which each successfully displaced [3H]CP55,940 from receptor binding in a 
concentration-dependent fashion, and inhibited adenylyl cyclase in a potent, reversible 
and stereoselective manner (Devane et al. 1988).  
 
1.3 Cloning of Cannabinoid Receptors !
 In 1990, Matsuda and colleagues published the successful cloning of rat cerebral 
cDNA (complimentary DNA), 473 amino acids in length, and this sequence was found to 
belong to a G-protein-coupled receptor (GPCR) family identified as the cannabinoid 
receptor type 1 (CB1). The human isoform (472 amino acids) which shares 
approximately 97% sequence homology to the cloned rat receptor was subsequently 
identified (Gerard et al. 1991). Furthermore, Chinese hamster ovary (CHO) K1 cells 
stably transfected with either the rat or human cloned receptor inhibited forskolin-
stimulated accumulation of cAMP with THC and CP55,940 in a concentration-
dependent and stereoselective fashion; inhibition of cAMP was observed with pertussis 
toxin, indicating Gi-protein signaling  treatment (Matsuda et al. 1990; Gerard et al. 1991). 
In situ hybridization studies in rats revealed strong CB1R mRNA (messenger RNA) 
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signal in cerebellum, hippocampus, amygdala, and hypothalamus and basal 
ganglia/striatum regions that correlate to known psychotropic cannabinoid actions on 
memory, cognition and complex motor behaviors (Matsuda et al. 1993).  
 Since CB1 receptors are expressed at high levels in the CNS, the non-
psychoactive effects of cannabinoids were thought to be mediated by cannabinoid 
receptors in the periphery or indirectly by non-cannabinoid receptors. To test this 
hypothesis, Munro and colleagues used a human promyelocytic leukemia HL-60 cell 
cDNA library to screen for a peripheral cannabinoid receptor and identified what would 
later be termed cannabinoid receptor type 2 (CB2). They reported a 360 amino acid 
sequence, demonstrating 44% sequence homology with the CB1R, present in cells of 
leukocyte lineage including macrophage/monocytes, B-lymphocytes, NK cells and 
immune tissue (tonsils, spleen and lymph nodes). These findings suggested that in 
contrast to the CNS-mediated effects of CB1, the CB2 receptor was crucial in immune 
system regulation and inflammation (Munro et al. 1993). As we are interested in 
investigating the psychoactive effects of cannabinoids at CB1 receptors, this document 
will focus primarily on actions at the CB1 receptor. 
1.4 Endogenous Cannabinoid Ligands: Anandamide and 2-Arachidonylglycerol !
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  Since receptor-mediated actions of cannabinoids were stereospecific and 
selective depending on ligand, researchers predicted the existence of an endogenous 
cannabinoid compound.  Shortly after cannabinoid receptors were cloned, the first 
endogenous cannabinoid ligand, anandamide (N-arachidonyl-ethanolamine, AEA), was 
isolated by Devane et al. in 1992.  AEA (Figure 1) was separated from pig brain tissue 
fractions and purified by thin-layer chromatography (TLC), high performance liquid 
chromatography (HPLC), and gas-chromatography-mass spectrometry (GC/MS) 
methods (Devane et al. 1992). Binding of this endogenous cannabinoid was confirmed 
through the use of radioligand cannabinoid assays in which AEA to displaced [3H]HU-
243 from CB1 receptors in the nanomolar range (Ki = 52 nM) (Devane et al. 1992). AEA 
behaved as a partial agonist at CB1 receptors with varying efficacy dependent on the 
system, and acts as a weak partial agonist at CB2 receptors (Felder et al. 1993). 
Biological cannabinoid activity of AEA was illustrated using vas deferens preparations, 
as AEA inhibited the electrically evoked mouse twitch response ex vivo; furthermore 
AEA produced decreases in spontaneous activity, induction of immobility, hypothermia 
and analgesia in mice (Devane et al. 1992; Smith et al. 1994).  
 Studies conducted by Di Marzo et. al. described the release of AEA and related 
N-acyl-ethanolamine species from cultured rat neurons after stimulation of intracellular 
Ca+2 with ionomycin using an [3H]ethanolamine tracer that led to the elucidation of 
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AEA’s structure by 1H-NMR (nuclear magnetic resonance). These experiments 
supported AEA’s de novo formation via a phosphodiesterase-mediated cleavage of an 
unidentified phospholipid precursor, N-arachidonyl-phosphatidylethanolamine (Di Marzo 
et al. 1994). Further work demonstrated AEA is synthesized via two pathways: directly 
by the N-acylation of ethanolamine or indirectly by phospholipase D-mediated synthesis 
(Di Marzo et al. 1994; Di Marzo 1998; Schmid et al. 1990). Degradation of AEA is 
achieved by the enzyme fatty acid-amide hydrolase (FAAH) to ethanolamine and 
arachidonic acid (Piomelli et al. 1998; Di Marzo 1998; Cravatt et al. 1996). Genetically 
modified mice which lack the catabolic FAAH enzyme show increased levels of AEA in 
brain accompanied by potent and hypersensitive CB1 mediated behavioral effects 
(Cravatt et al. 2001). 
!
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 The discovery of a second endocannabinoid, 2-arachidonylglycerol (2-AG), was 
identified by GC/MS, with its structure (Figure 1) elucidated using NMR (Mechoulam et 
Figure 1.1 – Structure of endogenous cannabinoid compounds anandamide and 2-AG.  
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al. 1995; Stella et al. 1997; Sugiura et al. 1995). Although 2-AG was first isolated from 
canine gut, it was later found in brain at higher levels than AEA (Mechoulam et al. 1995; 
Sugiura et al. 1995). In contrast to AEA, 2-AG acts as a full agonist at both CB1 and CB2 
receptors. 2-AG competed with [3H]HU-243 binding at the CB1R with a Ki value of 472 ± 
55 nM, whereas AEA exhibited a Ki value of 252 ± 47 nM. Effects of CB1 activity were 
examined using in vitro and in vivo methods. 2-AG (IC50 = 4.8 μM) less potently inhibited 
electrically evoked twitch response in mouse vas deferens than AEA (IC50 = 52 nM ) 
(Mechoulam et al. 1995). In mice, exogenous administration of 2-AG elicited classical 
CB1-mediated behaviors (hypomotility, hypothermia, antinociception, catalepsy) 
equipotent to AEA but less potent than THC. The modest in vivo effects of 2-AG are 
likely due to its rapid degradation in animals (Willoughby et al. 1997; Vyvoda & Rowe 
1973).   
 Cellular 2-AG rapidly increases upon stimulation from arachidonic acid rich 
membranes and is released on demand, which strongly argues it plays a pivotal role as 
a mediator of intracellular signaling. 2-AG is synthesized by digestion of 
phosphatidylinositol by phospholipase C (PLP C) into diacylglycerol (DAG) that is further 
metabolized by diacylglycerol lipase (DAGL). Another metabolic pathway includes 
degradation of phosphatidylinositol by phospholipase-A1 into lysophophatidlyinositol 
which is converted by PLC into 2-AG (Piomelli et al. 1998; Prescott & Majerus 1983; 
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Stella et al. 1997; Sugiura et al. 1995). Although FAAH is capable of hydrolyzing 2-AG 
to some extent in vitro, studies with FAAH (-/-) mice showed no significant difference in 
hydrolysis rates of 2-AG when compared to littermates which illustrates another enzyme 
is principally responsible for 2-AG degradation (Lichtman et al. 2002). A sophisticated 
series of experiments by Dinh et al. demonstrated 2-AG is metabolized into glycerol and 
free fatty acid by monoacylglycerol lipase (MAGL). They reported high expression of 
MAGL mRNA within the brain, specifically in regions containing high cannabinoid 
receptor density (cortex, hippocampus, cerebellum). Furthermore, overexpression of 
MAGL in cortical neurons by adenovirus delivery abolished receptor-stimulated 
production of 2-AG, but did not affect 2-AG synthesis nor AEA accumulation, indicating 
it selectively degraded 2-AG (Dinh et al. 2002).    
 !
1.5 Cannabinoid Receptor Activation and Signaling !! An agonist is a drug that activates receptors in some measurable way, which is 
dependent on the assay; a full agonist elicits a maximal effect within set experimental 
parameters whereas a partial agonist (at full receptor occupancy) produces a detectable, 
but submaximal effect (Negus 2006). Furthermore, agonists possess variable intrinsic 
efficacies, which underlie differential effects of G-protein activation upon ligand binding 
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to GPCRs (Selley et al. 1997).!Coupling of cannabinoid receptors to inhibitory Gi/o-
proteins in rat membranes and whole brain using [35S]-GTPγS autoradiography studies 
have demonstrated THC binds to CB1 receptors as a low efficacy partial agonist, AEA 
behaves similar as a partial agonist, whereas 2-AG, WIN55,212-2, and CP55,940 act as 
full efficacy agonists (Breivogel et al. 1997; Breivogel & Childers 1998; Burkey, Quock, 
Consroe, Roeske, et al. 1997; Burkey, Quock, Consroe, Ehlert, et al. 1997; Selley et al. 
1996; Sim et al. 1996).  
 Binding and subsequent stimulation of CB1 receptors to Gi/o-proteins through 
endogenous or exogenous cannabinoid application inhibits adenylyl cyclase, and thus 
decreases cAMP (cyclic adenosine monophosphate) in a pertussis toxin sensitive 
manner (Felder et al. 1995; Howlett & Fleming 1984; Howlett 1985; Howlett et al. 1985). 
Cannabinoid receptor activation also promotes cyclic AMP-dependent phosphorylation 
events including activation of protein kinase A (PKA) activation resulting in modulation 
of potassium channels (Hampson et al. 1995; Mu et al. 2000). The resultant dissociation 
of Gi-proteins after CB1 activation produces decreases in Ca+2 conductance of N-type 
voltage-gated ion channels (Caulfield & Brown 1992; Felder et al. 1993; Mackie et al. 
1993; Pan et al. 1996), increases K+ conductance of G-protein inwardly-rectifying 
(GIRK) and A-type channels (Deadwyler et al. 1995; Henry & Chavkin 1995; Mackie et 
al. 1995; Mu et al. 1999) and activates MAP kinase cascades (Bouaboula et al. 1995; 
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Wartmann et al. 1995). Cannabinoid-mediated activation of the MAP kinase pathway 
allows regulation of various cellular functions including cell growth and death through 
phosphorylation of nuclear proteins and activation of early immediate genes (Bouaboula 
et al. 1995), which shapes neuroplasticity within the endocannabinoid system.  
 The activation of CB1 and subsequent fluctuations in intracellular Ca+2 
concentrations results in events known as depolarization-induced suppression of 
inhibition (DSI) or excitation (DSE). These phenomena were discovered by Alger et al. 
and Llano et al., who demonstrated through electrophysiological experiments that 
depolarization of cerebellar and hippocampal neurons produced a transient suppression 
of GABAergic synaptic input; and coined the term, “depolarization-induced suppression 
of inhibition”.  Their studies demonstrated that an increase in intracellular Ca+2 is 
necessary for depolarization and that decreases of inhibitory post-synaptic current 
(IPSC) frequency are observed with no changes in peak magnitude. Additionally, 
recordings from neurons exposed to exogenous GABA did not induce DSI, which 
supports a presynaptic origin of signaling (Alger & Pitler 1995; Alger et al. 1996; Llano et 
al. 1991; Pitler & Alger 1992; Pitler & Alger 1994). Evidence was provided in 1994, by 
Pitler and Alger that this presynaptic phenomenon is Gi- or Go-coupled as DSI was 
nearly abolished in hippocampal slices from rats treated with pertussis toxin (Pitler & 
Alger 1994). These observations lead scientists to probe the involvement of the 
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Figure 1.2 - Schematic of Cannabinoid Receptor Activation and Signaling.   CB1 and CB2 receptor 
activation by endogenous, phytocannabinoid and synthetic cannabinoid agonists stimulate Gi/o 
heterotrimeric proteins; thus, inhibition of adenylyl cyclase (AC) prevents phosphorylation events of 
protein kinase A (PKA) and mitogen-activated protein kinase (MAPK) pathways. Dissociation of Gi/o-α 
subunit from Gβγ-complex elicits inhibition of voltage-gated Ca2+ channels and activation of inwardly-
rectifying K+ channels that results in the inhibition of excitatory and inhibitory neurotransmitter release in 
nerve cells. Image modified from (Di Marzo et al. 2004). 
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lower susceptibility of CB1 knockout mice to develop
obesity following a high-fat diet57.
Cardiovascular disorders. Elevated levels of macrophage
and/or platelet endocannabinoids are found in the
blood of rats during haemorrhagic and septic shock, or
following liver cirrhosis and experimental myocardial
infarction; these endocannabinoids produce the
hypotension typical of these pathological states58–61.
The levels of CB1 receptors and endocannabinoids are
also elevated in the liver and blood, respectively, of
cirrhotic patients60.
Gastrointestinal disorders. The concentration of anan-
damide, and/or the expression of cannabinoid CB1
receptors, is elevated in three mouse models of intestinal
disorders: small intestine inflammation62; cholera-toxin-
induced intestinal hyper-secretion and diarrhoea63; and
peritonitis-induced paralytic ileus64. Interestingly,
although enhanced signalling at CB1 receptors affords
tonic protection against the symptoms in the first two
disorders, it contributes to a reduction of intestinal
motility during paralytic ileus. A recent study showed
that genetically engineered mice lacking either the CB1
receptor or the major enzyme that catalyses anandamide
inactivation are more and less susceptible, respectively,
to developing colonic inflammation when treated with
di-nitro-benzene-sulphonic acid65. The importance of
the role of the endocannabinoid system in the control of
intestinal functions in men is indicated by the occurrence
of occasional diarrhoea after the repeated administration
of rimonabant (see below).
Reproductive disorders. There are a number of similarities
between mice and humans in the endocannabinoid
control of reproductive functions.Anandamide, by acting
preferentially at cannabinoid CB1 receptors, has a dual
function in mouse embryo implantation, which it
stimulates at low concentrations and inhibits at higher
concentrations66. Accordingly, defective anandamide
hydrolysis leads to high levels of this compound in the
blood of pregnant women, which correlates with pre-
mature abortion or failure of implanted oocytes fertilized
in vitro67,68.
Cancer. Finally, increased endocannabinoid signalling is
found in some human malignancies compared with the
corresponding healthy tissues69,70, as well as in human
cancer cells with a high degree of invasiveness69,71. These
observations — together with the finding that stimula-
tion of either CB1 or CB2 receptors causes blockage of
the proliferation of cancer cells or induction of their
apoptosis in vitro69,71,72, and inhibition of cancer growth,
angiogenesis and metastasis in vivo73–76 — indicate that
endocannabinoids might represent one of the many
adaptive responses aimed at counteracting tumour-cell
growth69. This possibility is supported by the recent
finding that inhibitors of endocannabinoid inactivation
can retard tumour growth both in vitro and in vivo69,77.
By contrast, aberrant overexpression of CB2 receptors on
haematopoietic precursor cells has been suggested to be
protection in this disorder by activating CB2 receptors, and
possibly by interfering with inflammatory reactions51.
In animal models of Huntington’s chorea, by contrast,
CB1-expressing fibres in the basal ganglia are progres-
sively lost from the early stages of the disorder
onwards, which results in impaired levels of both
endocannabinoids and CB1 receptors — this subse-
quently contributes to the hyperkinesia typical of the
first phase of the disease52,53. Importantly, lower levels
of CB1 receptors have also been found in post-mortem
brains from patients with Huntington’s chorea54.
It is interesting to note, with respect to the role of
endocannabinoids in food intake and energy balance,
how the endocannabinoid system seems to become
overactive in both the hypothalamus and adipocytes
of animal models of genetic obesity39,55. This observa-
tion might explain the transient inhibition of food
intake and the more persistent reduction in fat mass
that is observed following treatment of mice and rats 
with the CB1-receptor antagonist/inverse agonist
56
SR141716 (Rimonabant; Sanofi-Synthelabo), and the
ATP
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Figure 3 | Major signalling pathways associated with cannabinoid receptor activation
by agonists. Activation of both cannabinoid CB1 and CB2 receptors, and the subsequent
stimulation of Gi/o heterotrimeric proteins, is well known to be coupled to inhibition of
adenylate cyclase (AC) with corresponding inactivation of the protein kinase A (PKA)
phosphorylation pathway, or to stimulation of mitogen-activated protein kinase (MAPK). 
These intracellular events lead to, among other effects, the regulation of expression of several
genes. However, more complex protein phosphorylation cascades — specifically, those
involving phosphoinositide-3-kinase and protein kinase B — are also proposed to be
trig ered by CB1 receptors
14–18. Furthermore, stimulation, rather than inhibition, f AC by 
CB1, but not CB2, rec ptors, via Gs p oteins, has also been described occasionally. CB1-, 
but not CB2-, receptor stimulation of Gi/o proteins is also directly coupled to inhibition of
voltage-activated Ca2+ channels and stimulation of inwardly rectifying K+ channels in neurons,
with subsequent inhibition of neurotransmitter release. The choice between which of these
pathways is modulated by cannabinoid receptor activation also depends on the type of
agonist under study14–18. cAMP, cyclic AMP.
AEA, 2-AG, THC, 
CP55,940 
β!! α!! !γ! 
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endocannabinoid system in this mechanism and, in 2001, three separate research 
groups made the exciting scientific discovery that the retrograde signaling molecule 
responsible for DSI was an endocannabinoid (Kreitzer & Regehr 2001; Ohno-Shosaku 
et al. 2001; Wilson & Nicoll 2001).  
 Wilson and Nicoll’s work demonstrated that selective CB1 antagonist drugs, 
SR141617A and AM251, both significantly attenuated the magnitude of DSI, whereas 
WIN55,212-2 recapitulated the effect of DSI on inhibitory transmission. Further studies 
illustrated that unlike classical neurotransmitter release, the release of this retrograde 
signal did not require vesicle fusion; the effect of Ca+2 influx via depolarization step or by 
liberation of Ca+2 from a photoliable chelator produced DSI; and finally, treatment with a 
metabotropic glutamate receptor (mGluR) antagonist did not affect DSI (Wilson & Nicoll 
2001). Ohno-Shosaku et al. (2001) used synthetic cannabinoid agonists and 
antagonists that confirmed the presynaptic nature of DSI. Their work extended findings 
of Wilson et al. that a selective GABAB antagonist in addition to an mGluR antagonist 
were ineffective in eliciting DSI (Ohno-Shosaku et al. 2001). Concomitantly, Kreitzer et 
al. reported that depolarization-induced suppression of excitation (DSE) in glutamatergic 
excitatory synapses was endocannabinoid dependent. Experiments illustrated DSE 
occurs in purkinje cells after an inhibition of presynaptic calcium influx; and this is 
prevented by AM251 pretreatment, and occluded with WIN55,212-2 treatment (Kreitzer 
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& Regehr 2001). Taken together, this body of work provides scientifically sound 
evidence that DSI/DSE results from endocannabinoid production in postsynaptic 
neurons, which diffuse in a retrograde manner and bind to presynaptic cannabinoid 
receptors resulting in a suppression of GABA or glutamate release, respectively.  
 Studies performed at single-cell resolution utilizing double in situ hybridization of 
CB1 mRNA and neurotransmitter mRNA demonstrate that CB1 expressing cells within 
mouse forebrain regions exhibit clear subpopulation divisions; for example, cells 
expressing high mRNA levels of CB1 are co-localized on GABAergic interneurons, 
whereas low, but physiologically relevant, expression of CB1 mRNA is detected on non-
GABAergic cells, considered to be principal projection neurons, in regions of the 
hippocampus, amygdala, entorhinal cortex (Marsicano & Lutz 1999). In contrast, 
activation of cannabinoid receptors in lateral amygdala can decrease glutamatergic as 
well as GABAergic neurotransmission, as WIN55,212-2 decreased the amplitude of 
AMPA-evoked EPSCs and IPSCs in CB1(+/+) mice, but not in CB1(-/-) mice (Azad et al. 
2003). Studies have shown FAAH and MAGL are distinct in their subcellular loci, with 
FAAH located in presynaptic somato-dendritic compartments of the cerebellum and 
MAGL preferentially located postsynaptically in axons, which further supports a 
mechanism for 2-AG in retrograde signaling (Gulyas et al. 2004).  
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1.6 Cannabinoid Receptor Localization !
 CB1 receptors are the most highly expressed GPCRs in the brain (Devane et al. 
1988; Herkenham et al. 1991) and their localization was first described quantitatively in 
1991 by Herkenham et al. using in vitro autoradiography with [H3]-CP55,940. 
Experiments demonstrated coupling of CB1 receptors with guanine nucleotide regulatory 
proteins in a concentration-dependent manner using nonhydrolyzable analogs of GTP. 
Anatomical distribution of receptor binding was observed in brain regions primarily 
responsible for motor function and cognition (Herkenham et al. 1991). 
Figure 7. Autoradiography of 10 nM 3H-CP55,940 binding in sag&al (a) and horizontal (b,c) sections selected to show overall distribution of 
cannabinoid receptors but especially the patterns of dense distribution in the outflow nuclei of the basal ganglia. See Appendix for abbreviations. 
Scale bar, 2 mm for a-c. 
 
Figure 1.3 - Distribution of cannabinoid receptors in sagittal section of rat brain using [3H]-CP55,940 
autoradiography; receptor distribution is densest in regions of frontal cortex (Fr/FrPaM), hippocampus (Hi), 
cerebellum (Cb), and output nuclei of the basal ganglia (GP, EP, SNR); image from Herkenham et al. 
1991. 
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 Comprehensive evaluation of CB1 receptor localization using mRNA expression 
and immunohistochemical approaches in rats extended earlier findings that CB1 
receptor populations are most dense in basal ganglia nuclei, substantia nigra (pars 
reticulate), and globus pallidus with high binding reported in the molecular layer of the 
cerebellum, hippocampus and dentate gyrus (Matsuda et al. 1993; Tsou et al. 1998). 
Investigation of fetal and adult human cannabinoid receptor distribution supports a 
similar CNS localization and distribution (Glass et al. 1997; Biegon & Kerman 2001).  
 Studies have identified cannabinoid receptor immunolabeling on most neuronal 
cell types which involves inhibitory and excitatory neuromodulation (Moldrich & Wenger 
2000). For instance, the EC system has been implicated in learning/memory and 
emotion/motivation via presynaptic endocannabinoid release in cholecystokinin-positive 
GABAergic nerve terminals within hippocampal and amygdala brain areas (Katona et al. 
1999; Katona et al. 2001). Additionally, bath application of WIN55,212-2 or CP55,940 
produced a reduction in glutamatergic neurotransmission in nucleus accumbens of mice, 
a brain region implicated in both natural and drug associated rewards (Robbe et al. 
2001). Modulation of excitatory and inhibitory neurotransmitter release by 
endocannabinoids through DSI and DSE mechanisms are well documented, as 
described above (Pitler & Alger 1992; Chevaleyre et al. 2006; Hermann et al. 2002; 
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Ohno-Shosaku et al. 2001; Wilson & Nicoll 2001). Taken together, these data describe 
several mechanisms by which the endocannabinoid system interacts with other 
neuronal receptor systems within the CNS; this neuronal modulation can be transient in 
nature or have long-term consequences on learning, memory, and habitual drug use.  
1.7 Consequences of Acute and Chronic Cannabinoid Administration in Rodents !
 While continued exploration of the endocannabinoid system posits discovery of 
potential therapeutic applications, the clinical use of cannabinoids has largely been 
dismissed due to their undesirable side effects, including THC-like subjective high, 
abuse liability, and potential for tolerance development upon repeated administration. In 
humans THC affects mood and perception, delayed internal clock, memory impairment, 
anxiety, reward, and motor impairment and are consistent with associated function of 
brain regions expressing CB1 receptors (Casswell & Marks 1973; Herkenham et al. 
1991; Karniol & Carlini 1973).  
Tetrad and Drug Discrimination Behavioral Assays 
 While it is difficult to measure affective components (perception, motivation, 
reward) resulting from THC use in laboratory animals, preclinical evaluation of putative 
cannabimimetic drugs can be easily accomplished. Administration of cannabinoids in 
rodents elicits a characteristic profile of behavioral effects called the “tetrad” including 
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catalepsy, antinociception, hypothermia, and hypomotility, which permits screening of 
putative CB1 compounds (Martin et al. 1991). Tetrad outcome measures are sensitive to 
the primary psychoactive cannabinoid present in marijuana, THC, and have been 
extensively correlated to CB1 receptor binding and activation (Compton et al. 1996; Little 
et al. 1988; Martin et al. 1991; Monory et al. 2007; Pertwee 2008; Smith et al. 1994; 
Wiley 2003). While many pharmacological agents can produce one or a subset of these 
tetrad effects, drugs that activate CB1 receptors produce measurable effects in all four 
parameters (Wiley 2003). Moreover, these behaviors are prevented by the CB1R 
antagonist, rimonabant (SR141617A), and in CB1(-/-) mice, which supports a CB1-
mediated mechanism in vivo (Compton et al. 1996; Ledent et al. 1999; Monory et al. 
2007; Rinaldi-Carmona et al. 1994; Rinaldi-Carmona et al. 1995; Zimmer et al. 1999). 
For decades, the tetrad has proven to be a rapid, reliable and reproducible screening 
tool to assess cannabimimetic effects, thus, it has been used extensively throughout this 
dissertation research. 
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-  Catalepsy: fixed/rigid posture  
-  Antinociception: decreased responding to noxious stimuli 
-  Hypothermia: decrease in body temperature 
-  Locomotor Activity: locomotor suppression; immobility 
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Figure 1.4 - Behavioral Test Components of the Tetrad.  Catalepsy assessed with the bar test, 
antinociception measured by tail immersion in a 52.0 °C warm water bath, hypothermia determined used 
a rectal thermometer probe, and locomotor activity is monitored in activity chambers. 
 
 Examination of the endocannabinoid system, particularly in regards to the 
anatomical localization and activation of cannabinoid receptors, has corroborated those 
behavioral effects of THC with CB1R activation in the brain.  For example, functional 
studies in the rat indicate that the acute activation of brain regions after THC exposure, 
measured indirectly by glucose metabolism, correspond closely with temporally 
observed physiologic and behavioral effects (Whitlow et al. 2002). Additionally, THC 
administration produced dose-dependent effects in cerebral glucose metabolism, an 
effect that can be attenuated by rimonabant pretreatment (Freedland et al. 2002). Both 
dose- and time-dependent effects were regionally specific (Freedland et al. 2002; 
Whitlow et al. 2002), which supports the unique behavioral profile observed after 
cannabinoid administration. 
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 Furthermore, a positron emission tomography (PET) study using the dopamine 
(D2/D3) receptor tracer [14C]-raclopride, illustrated that THC inhalation exposure in seven 
healthy volunteers resulted in significant release of dopamine in the striatum, 
demonstrating activation of the mesolimbic reward pathway in humans (Bossong et al. 
2009). This reward pathway projects from the ventral tegmental area to the nucleus 
accumbens and is a circuit involved in recognition of natural reward (i.e. food and sex); 
however, cannabinoids can activate this pathway and stimulate release of dopamine, 
which is thought to underlie the reinforcing and rewarding properties of known drugs of 
abuse (Oleson & Cheer 2012; Solinas et al. 2008). Experiments utilizing in situ 
hybridization in mouse forebrain demonstrate colocalization of CB1 receptors with 
dopamine (D1 and D2) and serotonin (5-HT1B and 5-HT3) receptors (Hermann et al. 
2002).  A myriad of studies, including those utilizing CB1(-/-) animals, have documented 
the functional interaction of the cannabinoid system with GABAergic, gluatamatergic, 
and dopaminergic neurotransmitter systems among others (Azad et al. 2003; Gardner 
2005; Hungund et al. 2003; Katona et al. 1999; Katona et al. 2001; Kreitzer & Regehr 
2001; Mascia et al. 1999; Monory et al. 2007; Ohno-Shosaku et al. 2001; Tanda & 
Goldberg 2003; Wilson & Nicoll 2001). Fundamentally, modulations of dopaminergic 
signaling in the mesolimbic pathway are believed to contribute to both the rewarding 
effects of THC as well as to the development of physical dependence seen with chronic 
exposure (Wise & Koob 2014; Solinas et al. 2008; Tanda & Goldberg 2003). 
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 One approach to measuring a drug’s “rewarding/reinforcing” effects is through 
self-administration studies. Whereas reinforcement can be positive (food) or negative 
(foot shock) in nature, a reward generally refers to positive reinforcement of a given 
behavior, as seen with repeated drug taking (Panlilio et al. 2010; Solinas et al. 2006; 
Solinas et al. 2008; Tanda & Goldberg 2003).  In humans, continuous drug taking 
correlates with drug reward (Wise & Koob 2014), but THC self-administration studies in 
rodents have not been met with success (Gardner 2005; Justinova et al. 2003). 
However, drug naïve mice will self-administer synthetic cannabinoid agonists, HU-210, 
CP55,940, and WIN55,212-2 (Martellotta et al. 1998; Navarro et al. 2001). Interestingly, 
THC effects are species- dependent as squirrel monkeys have been reported to self-
administer THC (Justinova et al. 2003; Tanda et al. 2000); which is blocked by CB1R 
antagonist rimonabant (Tanda et al. 2000).  
 As laboratory animals do not readily self-administer THC, the drug discrimination 
paradigm serves as a useful tool for investigating drugs of abuse in preclinical research 
settings (Justinova et al. 2005). In humans, marijuana or THC exposure produces a 
unique profile of subjective (interoceptive) affects that including drug liking, pleasure and 
craving, and are often used as an indirect measure of a drugs reinforcing effect. Drug-
discrimination procedures can be used to evaluate the presence or absence of 
interoceptive stimulus effects of drugs in animal models, and experiments have 
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established that rodents will readily learn to discriminate cannabinoids using a two-lever 
paradigm (Justinova et al. 2005; Wiley 1999). As an alternative to self-administration, 
drug discrimination serves as a pharmacologically selective behavioral model to infer 
subjective effects of drugs in rodents. Once trained, animals make an operant response 
(e.g. lever press or nose poke) to distinguish the discriminative cues between a training 
drug (e.g. THC) and a test compound (e.g. novel cannabinoid). The extent to which the 
test drug substitutes for the training drug provides insight into the interoceptive effects of 
novel drugs (Wiley 1999).  
 It has been well documented that pigeons, rats, and monkeys discriminate THC 
from vehicle; and in general, drugs that bind to CB1 receptors substitute for THC. 
Conversely, drugs that do not bind to CB1 receptors do not exhibit similar discriminative 
stimulus properties to THC, which has been demonstrated with cannabinol, CNS 
stimulants and depressants, and morphine among various other compounds examined 
(Järbe & Henriksson 1974; Wiley et al. 1995). An exception is seen with (+)-
methamphetamine and diazepam which exhibit partial substitution in rats trained to 
discriminate 3.0 mg/kg THC from vehicle (Barrett et al. 1995). Crucially, experiments 
have demonstrated cannabinoid discriminative effects are prevented by pretreatment 
with rimonabant (Wiley et al. 1995). Other cannabinoids used to serve as the 
discriminative cue in mouse discrimination studies include CP55,940 and WIN55,212-2 
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(McMahon et al. 2008). Even though AEA is a partial agonist similar to THC, studies 
using AEA or its stable analog (methanandamide, MAEA) do not fully substitute for THC 
(Wiley, Matthew Walentiny, et al. 2011).  This discrepancy can be explained by the 
rapid metabolism of AEA to arachidonic acid by FAAH in comparison to THC (Deutsch, 
DG & Chin 1993). Bolstering this hypothesis, a recent study reported FAAH (-/-) mice 
successfully discriminated between AEA and vehicle in a dose-dependent fashion 
(Walentiny et al. 2011). Rimonabant antagonized the discriminative cue of AEA, which 
implicates a CB1 mediated receptor mechanism.  Finally, THC fully substituted for AEA, 
which suggests these two share similar stimulus properties through a CB1 receptor 
mechanism of action.   
Tolerance 
 Due to the desired subjective “high” effects, people use marijuana on a continual 
basis; thus, repeated administration studies in animals are important to assess long-
term drug effects that better resemble drug abuse in humans. Chronic cannabinoid 
exposure leads to tolerance of acute effects including locomotion (Abood et al. 1993; 
Oviedo et al. 1993), hypothermia (Pertwee et al. 1993; Fan et al. 1996), analgesia 
(Adams & Martin 1996) and memory disruption (Deadwyler et al. 1995; Wise et al. 
2011). 
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 In addition to behavioral tolerance, adaptations at the molecular level have been 
examined. In post-mortem human tissue, chronic use (defined in the study as daily use 
for multiple years) of marijuana elicited decreases in cannabinoid receptor binding in the 
hippocampus using [3H]SR141617A when compared to normal brains (cannabis free) 
with decreased mRNA (CB1-positive neuronal cells) expression observed caudate, 
putamen, nucleus accumbens and hippocampus regions of chronic cannabis smokers 
(Villares 2007). In a separate study, chronic cannabis users (daily consumption of 
multiple marijuana cigarettes or blunts for an average of 12 years) showed reversal of 
CB1 brain receptor downregulation after 4 weeks of abstinence (Hirvonen et al. 2012). 
Desensitization of CB1R-coupled G-proteins has been documented in several brain 
regions (Rubino et al. 1994; Rubino et al. 1997; Rubino, Vigano’, et al. 2000; Rubino, 
Viganò, et al. 2000; Sim et al. 1996), with temporal development of downregulation and 
desensitization observed in a brain-region specific manner (Breivogel et al. 1999). 
Chronic CP55,940 treatment (0.4 mg/kg, 11 days) in rats produced decreases in Gαi, 
Gαs and Gαo mRNA in a brain region specific manner, without concomitant changes in 
subunit protein levels (Rubino et al. 1997). Additionally, in vivo autoradiography of 
agonist-stimulated [35S]-GTPγS binding was reduced in rats chronically administered 
THC (10 mg/kg, 21 days) (Sim et al. 1996).  Furthermore, repeated THC induces 
adaptations at the receptor level and downstream at second messenger signaling of 
cAMP and PKA (Rubino, Vigano’, et al. 2000). However, conflicting studies have 
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reported no alteration in cAMP/PKA levels (mRNA) after chronic CP55,940 in both mice 
(Fan et al. 1996) and rats (Rubino, Viganò, et al. 2000), which is thought to be a result 
of differences in efficacy with THC and CP55,940. In mice, long-term THC treatment (15 
days) with escalating doses (10 mg/kg initial dose to 160 mg/kg final dose) produced 
CB1 receptor downregulation and desensitization of cannabinoid-agonist stimulated G-
protein activation coincident with inhibition of adenylyl cyclase (Selley et al. 2004). 
Overall, the magnitude of cannabinoid responses varies greatly (Burkey, Quock, 
Consroe, Ehlert, et al. 1997; Burkey, Quock, Consroe, Roeske, et al. 1997; Fan et al. 
1996; Rubino et al. 1994; Rubino et al. 1997; Rubino, Vigano’, et al. 2000; Selley et al. 
1996; Sim et al. 1996) with complex and diverse alterations in intracellular signaling 
pathways after chronic cannabinoid treatment dependent on agonist efficacy, drug 
dosage, treatment interval, brain region and species. Interestingly, cross-tolerance to 
the tetrad behavioral effects have been observed between THC and cannabimimetic 
agents CP55,940, WIN55,212-2 and AEA (Fan et al. 1994; Pertwee et al. 1993).  
Dependence 
 Neuroplasticity after repeated drug exposure is thought to underlie the behaviors 
that ultimately manifest into drug abuse and addiction. Upon cessation of marijuana, 
humans report restlessness and sleep disturbances, accompanied with symptoms of 
irritability, anxiety, nervousness, aggression, appetite suppression, and weight loss. 
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While underscored, this marijuana withdrawal syndrome has clinical importance and 
has been likened to tobacco (nicotine) discontinuation; as a result, detriments to daily 
life often lead to relapse of marijuana use (Budney et al. 2008). 
 Likewise, documenting THC withdrawal in laboratory animals in THC-dependent 
animals has been challenging to assess and quantify. Dependence is assessed in 
rodents by measuring somatic withdrawal signs (paw flutters/tremors, wet dog shakes, 
rearing, piloerection). Cannabinoid withdrawal can be determined after spontaneous 
(abrupt cessation of drug) or precipitated (by receptor antagonism) withdrawal. 
Spontaneous withdrawal occurs once the parent drug has been transformed to inactive 
metabolite(s), whereas precipitated withdrawal produced a rapid onset of somatic 
withdrawal signs. Spontaneous and precipitated somatic withdrawal signs in rats have 
been reported after treatment with WIN55,212-2 (Aceto et al. 2001). In contrast, THC 
withdrawal signs are more readily obtained with rimonabant challenge (Diana et al. 
1998). As documented for other cannabinoid effects, there are species differences as 
cannabinoid antagonist administration produced withdrawal in morphine-dependent rats 
(Navarro et al. 1998) but not in mice (Lichtman et al. 2001). 
 The molecular mechanisms believed to underlie dependence include activation of 
second messenger signals such as cAMP, PKA and AC (Rubino, Vigano’, et al. 2000; 
Tzavara et al. 2000). Interestingly, rats treated with chronic THC then with rimonabant 
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showed increases in cAMP and PKA activity in brain regions (cerebellum, striatum, 
cortex) that have also undergone CB1 receptor downregulation (Rubino, Vigano’, et al. 
2000). Mice exhibit withdrawal signs after THC with concomitant increase in AC within 
cerebellum after rimonabant administration (Hutcheson et al. 1998). 
 Repeated exposure to THC and synthetic cannabinoid agonists WIN55,212-2 
and CP55,940 causes desensitization of cannabinoid mediated G-protein activity, CB1 
receptor downregulation, and alterations in downstream signaling in rodents (Martin et 
al. 2004; Sim-Selley 2003; Sim-Selley & Martin 2002). Additionally, rats chronically 
treated with cannabinoid receptor agonists’ display somatic withdrawal signs after 
rimonabant challenge (Rubino et al. 1998; Tsou et al. 1995). Not surprisingly, prolonged 
use of synthetic cannabinoids found in “K2” and “Spice” have led to the development of 
tolerance and withdrawal symptoms similar to, and potentially more disruptive, than 
those observed with prolonged cannabis use, due most likely to their increased potency 
and efficacy at CB1 receptors (Berry-Cabán et al. 2013; Zimmermann et al. 2009). 
Therefore, it is relevant to preclinically evaluate the development of tolerance and 
withdrawal symptoms after repeated administration of abused synthetic cannabinoid 
compounds.  
!!
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Chapter 2 - Synthetic Cannabinoid Compounds  !
2.1 Synthetic Cannabinoid Abuse is a Serious Public Health Concern !! As a “legal” alternative to marijuana, synthetic cannabinoid (SCBs) compounds, 
intended for research uses only, are being added to herbal incense/botanical material 
and sold openly to the public, without age restrictions. This is dangerous to consumers 
as very few in vivo studies have been published regarding effects of these potent 
synthetic cannabinoids in laboratory animals, and no clinical studies have been 
conducted to test safety or hazardous effects after human consumption.      
 Despite serious toxicities reported and recent regulatory efforts to eliminate the 
use of synthetic cannabinoids in herbal incense products (HIPs), the abuse of synthetic 
cannabinoid compounds continue to threaten public health and safety (United States 
Congress 2012). In 2013, more than 2,500 calls were made to national poison control 
centers concerning adverse effects after SCB exposure which was a massive increase 
from the 14 calls received in 2009 (Wood 2013). In 2012, synthetic cannabinoids were 
the second most commonly used illicit drug among 10th and 12th grade high school 
students, and approximately 8% of high school and college students reported having 
ever used synthetic cannabinoids (Hu et al. 2011; Johnston et al. 2014). Additionally, 
the Drug Abuse Warning Network (DAWN) reported over 11,400 emergency department 
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visits as a result of synthetic cannabinoid ingestion, which mostly involved male patients 
12 to 29 years old (SAMSHA 2012). 
  Furthermore, the consequences of inhaling pyrolysis products created from 
burning the herbal material are unknown. While case reports of toxicity and mortality 
associated with SCB exposure have been reported, lack of validated analytical 
screening and confirmation methods for the detection in biological samples have limited 
the identification of the specific synthetic cannabinoid compound(s) responsible for 
these untoward effects. SCB-containing products continue to pose challenges for 
clinicians, toxicologists, law enforcement and public health officials as they are readily 
available online, with rapidly evolving chemical constituents marketed in a variety of 
formulations. The research presented in this dissertation will provide much needed in 
vivo pharmacological and analytical toxicology data related to the synthetic cannabinoid, 
CP47,497, which is known to be contained in HIPs.  
2.2 Development of Synthetic Cannabinoids as Research Tools  !! Synthetic cannabinoids were originally created as pharmacological tools to 
understand the effects of marijuana on the brain and to investigate the endogenous 
cannabinoid system. For decades, researchers have questioned how THC elicits its 
antinociceptive actions on the central nervous system (CNS). As a result, medicinal 
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chemists explored how alterations in the cannabinoid structure could be used to develop 
novel analgesic agents with the expectation that intelligently designed compounds could 
perform similar to morphine, but lack addictive properties (Lemberger 1980). 
Experiments first examined whether parent delta-9-THC or its primary active metabolite, 
11-OH-THC, and structural derivatives such as 9-nor-9-hydroxyhexahydrocannabinol 
(HHC), were responsible for the analgesic effects of THC observed in animals (Wilson & 
May 1975; Wilson & May 1976). Results of these studies showed that 11-hydroxy and 
β-hydroxy metabolites of THC and HHC, respectively, acted as potent analgesics in 
mice; this subsequently fueled structure activity relationship studies for the development 
of novel cannabinoid compounds to be used as analgesics. In 1975, scientists at Pfizer 
initiated a program to design a prototypical drug that would include structural 
components necessary for analgesia, yet be structurally and pharmacologically unique 
from potent opioid and cannabinoid analgesics (Johnson et al. 1981; Lemberger 1980). 
While undesired cannabimimetic side effects prevented these SAR studies from 
creating new pharmacological drugs to treat pain, they provided novel cannabinoid 
compounds that served as useful tools to both understand THC effects in the brain and 
elucidate the endogenous cannabinoid system.  
 Cannabinoid receptor agonists have been classified according to their chemical 
structure and Figure 2.1 illustrates pharmacophores of major cannabinoid agonists, 
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including the prototypical compounds from each classification. Dibenzopyran derivatives, 
or compounds that are structurally similar to THC compose the “classical” cannabinoid 
group. Compounds from this series were developed beginning in the 1960’s and 
examples include nabilone, with HU-210 and HU-211 synthesized by researchers at 
Hebrew University (HU) (Mechoulam et al. 1988). The “nonclassical” group is comprised 
of bicyclic and tricyclic analogs of THC that lack the pyran ring moiety. Commonly 
referred to as the cyclohexylphenols (CP) series, this class was developed by scientists 
at Pfizer chemical company and notably include the prototypical synthetic cannabinoid 
CP47,497, and the well-characterized compound CP55,940 (Weissman et al. 1982). 
Due to its increased potency at CB1 receptors, CP55,940 has been an instrumental tool 
in elucidating the endogenous cannabinoid system and was used to demonstrate 
specific cannabinoid binding in the brain (Devane et al. 1988), which ultimately 
contributed to the discovery of cannabinoid receptors.     
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 Preclinical research by scientists from the Winthrop-Sterling group on a new 
compound, pravadoline, showed analgesic promise with a mechanism of action 
separate from opioids and cyclooxygenases (Haubrich et al. 1990). Although 
pravadoline was found to cause nephrotoxicity, continued SAR studies led to the 
development of the novel aminoalkylindole cannabinoid, WIN55,212-2, which behaves 
as a high efficacy agonist at both CB1 and CB2 receptors (Compton, Gold, et al. 1992; 
Haubrich et al. 1990; Pacheco et al. 1991). Stemming from this research, John W. 
Huffman (JWH) continued development of an aminoalkylindole class of synthetic 
cannabinoids and derivatives which include compounds such as JWH-018, JWH-073, 
and JWH-250 (Aung et al. 2000; Huffman et al. 1994; Huffman et al. 2005; Wiley et al. 
1998). These synthetic cannabinoid SAR studies yielded a spectrum of 
cyclohexylphenol and aminoalkylindole derived compounds that were intended for 
Figure 2.1 – Prototypical cannabinoid compounds.  
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research purposes, but recently emerged as novel psychoactive cannabinoid drugs of 
abuse.  
  
2.3 Emergence of Synthetic Cannabinoids as Drugs of Abuse 
 
Botanical Composition of Herbal Incense Products 
 
 HIPs were initially touted as herbal blends that produced a “natural” or “legal” 
high similar to marijuana, but lacked legal restrictions like the natural psychoactive 
botanicals khat (Catha edulis) and salvia (Salvia divinorum) (EMCDDA 2009). These 
products contain botanical material of diverse origins: damiana (Turnera diffusa), indian 
warrior (Pedicularis densiflora), lion’s ear (Leonotis leonurus), and dwarf skullcap 
(Scuttelaria nana) among others, and are reported as having mild anxiolytic, muscle 
relaxant, and aphrodisiac effects (Cornara et al. 2013; EMCDDA 2009; Ogata et al. 
2013; Rosenbaum et al. 2012). Until laboratories identified the presence of synthetic 
cannabinoids, people largely assumed that the natural botanical ingredients were 
responsible for the marijuana-like high (EMCDDA 2009). 
 Cornaro et al. utilized DNA barcoding with microscopic examination of structural 
and morphological botanical characteristics coupled to GC/MS and LC/MS to identify 
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both the plant and chemical constituents of several HIPs (Cornara et al. 2013). The 
botanical material examined was a mixture of plants from several families with multiple 
synthetic cannabinoid compounds added exogenously. This multidisciplinary approach 
enabled differentiation of herbal/botanical material adulterated with synthetic 
cannabinoid drugs from other blends which contain naturally occurring plant-based 
alkaloids such as the mu-opioid receptor agonist, Kratom (Mitragyna speciosa) (Cornara 
et al. 2013). While Ogato et al. demonstrated that damiana and Lamiaceae herbs are 
commonly detected in HIPs, their analysis confirmed that listed ingredients are often 
inaccurate, as the herbs listed on the packaged material were often missing entirely 
(Ogata et al. 2013).   
 In addition, various SCB samples contained other bioactive ingredients not listed 
including THC, CBD, Kratom, salvia, caffeine, nicotine and O-desmethyltramadol, 
identified using GC/MS and LC/MS (EMCDDA 2009; Dresen et al. 2010; Ogata et al. 
2013; Uchiyama et al. 2010). The sleep-inducing lipid signaling molecule, oleamide, and 
the lipophilic anti-oxidant α-tocopherol (vitamin E), have also been identified in 
numerous SCB-containing products. Oleamide is presumably added due to its publicly 
perceived cannabinoid-like effects, and the common and abundant presence of α-
tocopherol is thought serve as a masking agent in these products (EMCDDA 2009; 
Ogata et al. 2013; Uchiyama et al. 2010). Further complicating the issue, botanical 
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material can also be adulterated with designer drugs of other classes including 
psychomotor stimulants (commonly referred to as “bath salts”) and hallucinogens (Seely 
et al. 2013).  Product surveillance demonstrated no consistency in HIP composition 
between the same brands over time and disturbingly, drug distribution is non-
homogenous within a single packet due to the haphazard method of adulterating bulk 
herbal material with SCB drugs (Griffiths et al. 2010; Hillebrand et al. 2010; Logan et al. 
2012; Seely et al. 2013; Shanks et al. 2012). Accordingly, approximately 10% of survey 
respondents reported variable and unpredictable effects with multiple uses of the same 
brand of HIP (Vandrey et al. 2012).  
 
Packaging, Availability, and Cost of Herbal Incense Products 
 
 Interestingly, the original name of “Spice” along with packages depicting a 
prominent open eye (Figure 5, Panel A) is thought to derive from Frank Herbert’s 1965 
science-fiction series, “Dune”; where the highly addictive drug “mélange” was often 
referred to as “[the] Spice” (Lindigkeit et al. 2009). Initially sold as “Spice” and “K2”, the 
appearance of other brand name quickly ensued: “Spice Silver”, “Spice Gold”, “Spice 
Diamond”, “Yucatan Fire”, “Skunk”, “Genie”, etc. (EMCDDA 2009; Fattore & Fratta 2011; 
Rosenbaum et al. 2012). The products are marketed in attractive and colorful packages, 
which are sold in smoke shops (specializing in tobacco and smoke related products 
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including pipes, water bongs, hookahs, etc.), convenience stores, and online (Figure 4). 
Surreptitious packaging led users to believe these products were a natural, safe, and 
legal substitution for marijuana.  
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including Spice, Yucatan Fire, Smoke, Sence, K2, Skunk, Space, K2 Citron, and K2 
Blonde.   Literature reports and intern l analyses have identified the following analytes in 
these herbal mixtures HU-210; JWH-018; CP 47,497; JWH-073; and JWH-200 (1-3).  
These synthetic analytes have a varying degree of selectivity and affinity for 
cannabino ds (CB1 and CB2) receptors and are used as an alternative to cannabis.  In 
addition to analytes that have been identified in h rbal incense prod cts, standard  ar  
available for several other known CB  and CB2 receptor gonists which could poten i lly 
be used in a similar manner including JWH-015, JWH-019, JWH-250, CP 55,940 an  
WIN 55,212-2.  While HU-211, an enantiomer of HU-210, has been identified in herbal 
incense products, t is not a CB receptor ag nis . WIN 55,212 also has an enantiomer 
(WIN 55,212,-3) that is not a CB receptor agonist. 
 
In early 2009, the US Customs and B rder Protection (CBP)  Chicago Laboratory 
(Illinois) announced seizure of herbal incense containing HU-210 and over a period of 3 
months proceeded to confiscate over 100 pounds of laced herbal material in five separate 
shipments (4). 
 
Currently only HU-210 is controlled on the federal level; it is a schedule I drug; HU-211 
is not controlled.  It may be possible that other synthetic cannabinoids could be controlled 
under the Federal Analogue Act. However the law only applies to s bstances sold for 
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is more difficult to prosecute these analytes under this act (5).  Many states are in the 
process of controlling specific synthetic cannabinoids. 
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rapid increase (Wood 2013). The use of Spice is increasing
among youth i the USA. In the most recent Monitoring the
Future survey, 11.3 % of high school seniors nationwide
admitted to using Spice i the previous year, ompared to
36.4 % who adm tte to usi g cann bis in th past year
(NIDA 2012). In th AAPCC data, the most represented
age group was 13–19-year olds, comprising 48.8 % of the
calls (Wood 2013).
Synthetic cannabinoids: the principal psychoactive
constituents of Spice
Phytocannabinoids, or plant-derived cannabinoids, include
THC, the principal psychoactive component of cannabis.
THC is a low-efficacy partial agonist of cannabinoid (CB)
receptors. There are at least two identified CB receptors:
CB1 receptors (CB1R) and CB2 receptors (CB2R). CB1Rs are
expressed primarily in the brain and are responsible for the
psychoactive effects of cannabinoids. In contrast, CB2Rs are
localized primarily in the periphery on immune cells
where they mediate the immunomodulatory effects of
cannabinoids (Devane et al. 1988; Pertwee 2008; Schatz
et al. 1997). Over the last three decades, a number of canna-
binoids have been synthesized. Unlike THC, the synthetic
cannabinoids in Spice are high-potency full agonists at the
brain CB1 receptor (see Table 1) (Atwood et al. 2010, 2011;
Huffman and Padgett 2005; Huffman et al. 2005b; Lindigkeit
et al. 2009; Marriott and Huffman 2008). The synthetic
cannabinoids present in Spice are classic cannabinoids,
naphthoylindoles, benzoylindones, or phenylacetylindoles
Fig. 1 Spice pro ucts
Fig. 2 Deceptive labeling of spice products
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Figure 2.2 - Illicit synthetic cannabinoid herbal incense product (HIP) contents with “Not for consumption” 
disclaimer (Panel A, center photo) and varieties of decorative product packaging (Panel B). Images 
modified from (Spaderna et al. 2013) and National Medical Services, Inc. 2010 (www.nmslabs.com). 
 
 
 Synthetic cannabinoids are sprayed or laced onto bulk botanical material, which 
is sold in foil-packets containing 0.4-3.0 grams of product to buy rs at retail or online 
with no minimum age requirements (EMCDDA 2009; Fattore & Fratta 2011). Due t  
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recent changes in drug legislation, HIPs are primarily purchased online, which may 
actually further facilitate the ease and anonymity of SCB drug use (UNDOC 2013; 
United States Congress 2012). As with cannabis preparations, herbal incense products 
(HIPs) are typically smoked (via pipe, cigarette, blunt, water pipe/bong) although 
vaporization, oral ingestion, and rectal routes of administration have been reported 
(Vandrey et al. 2012). However, HIPs are advertised as “potpourri” and “incense” that 
are “not for human consumption”.  
 In the U.S., Europe and Australia, SCBs are sold in 3 gram packages, with the 
average price of $10-12 (7-9 €) per gram of plant material, depending on the brand and 
source (Barratt et al. 2013; EMCDDA 2009; Wells & Ott 2011; Wiley, Marusich, et al. 
2011). Recently, synthetic cannabinoid product composition has extended from herbal 
or plant-based materials to the availability of highly pure powder drug form which can be 
added to any plant material by users (Jankovics et al. 2012; Seely et al. 2013).  This 
shift is partially attributed to cost-effectiveness, as preparing homemade HIP blends is 
less expensive than purchasing pre-packaged HIPs (Kikura-Hanajiri et al. 2011; Wells & 
Ott 2011). Additionally, creating homemade mixtures allows users to titrate their dose 
and combine multiple SCB drugs in specific ratios, which is presumably advantageous 
to experienced users, who believe they can control desired subjective effects and avoid 
!53 
the development of tolerance from less-potent products available at retail (Wells & Ott 
2011).  
2.4 Synthetic Cannabinoid Compounds: Legislation and Rapid Evolution of HIP 
Constituents  !
 The emergence of synthetic cannabinoids as drugs of abuse began in Europe 
around the mid-2000’s, with the first identification of the synthetic cannabinoid 
compound, JWH-018, in several “Spice” products in December 2008 in Austria and 
Germany which was later corroborated by five other European countries (EMCDDA 
2009). According to the United Nation’s World Drug Report, the majority of reporting 
countries indicated Asia as the primary source for novel psychoactive compounds, 
including SCBs (UNDOC 2013).  
 In January 2009, Auwarter et al. published the identification of synthetic 
cannabinoid compounds CP47,497, its C8 homologue (CP47,497-C8 or 
cannabicyclohexanol), and the endogenous fatty acid amide, oleamide, in several 
products tested (Auwärter et al. 2009). Monitoring and analysis of HIPs by GC/MS and 
NMR identified the presence of CP47,497, CP47,497-C8, JWH-018, and JWH-073 as 
the most commonly encountered SCBs in 140 herbal products in Germany from 2008-
2009 (Dresen et al. 2010). 
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 Conclusive drug identification in these products prompted European countries to 
initiate legislative actions beginning in 2009. Despite regulatory efforts, in a short period 
of time HIPs gained popularity and their use spread to numerous European nations, 
Australia, and the United States. Consequently, by 2011, the U.S. Attorney General 
added five SCBs commonly encountered in HIPs (CP47,497 CP47,497-C8, JWH-018, 
JWH-073 and JWH-200) to Schedule I of the Controlled Substances Act (CSA) and by 
2012, the United States Congress amended the Food and Drug Administration 
Innovation Act (S.3187) to permanently designate these drugs as Schedule I 
compounds (Department of Justice 2013; The Drug Enforcement Administration 2011; 
United States Congress 2012). This law prohibits all preparations containing 
cannabimimetic agents, their salts, isomers, and salts of isomers. Within the legislation 
a cannabimimetic is defined as, “any substance that is a cannabinoid receptor (CB1) 
agonist, as demonstrated by binding studies and functional assays” (United States 
Congress 2012).  
 While legislative efforts were aimed at reducing SCB abuse, initial prohibition of 
specific SCBs led to the synthesis of a second- and third-generation SCBs, with each 
new SCB class masquerading as chemical iterations of the last generation in a 
concerted effort to evade legislative actions (Lindigkeit et al. 2009). For example, after 
CP47,497 and its isomers were banned, a new compound, JWH-073 was identified in 
!55 
products within weeks, demonstrating that the drug manufacturers are cognizant of, and 
one step ahead of, government and law enforcement endeavors aimed at protecting 
public health and safety (Dresen et al. 2010; Lindigkeit et al. 2009).       
 The constant evolving nature of SCB drugs of abuse identified in HIPs precede 
the timeline of enacted legislation, with the first generation (2008-2011) including 
cyclohexylphenol (CP47,497; cannabicyclohexanol) and napthoylindole (JWH-018 and 
JWH-073) compounds; the second generation (2011-2012) phenylacetylindoles (JWH-
250), napthoylindoles (AM-2201, JWH-210, JWH-211) and benzoylindoles (RCS-4); the 
third generation (2012-2013) compounds, tetramethylcyclopropylindoles (UR-144, XLR-
11), with the most recently encountered fourth-generation (2013-present) 
adamantoylindoles (AKB48, ADB-PINACA) compounds (Dresen et al. 2010; Lindigkeit 
et al. 2009; Seely et al. 2013; Shanks et al. 2012; Vardakou et al. 2010). For complete 
description of each class with examples, please refer to the recent review by Presley et 
al. 2014 (see Appendix II for chemical structures).  
 Continuous analytical inspection and identification of chemical constituents in 
seized HIPs and powders over a three year period established the evolution of synthetic 
cannabinoid drugs, as JWH-018 was present in nearly all samples tested in 2010, then 
showed a downward trend while identification of structural analogs, AM2201, JWH-210, 
and JWH-211 steadily increased (Seely et al. 2013). The most recent seizure in 
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Germany identified the novel tetramethylcyclopropyl compound, commonly referred to 
as A796-260 (Westphal et al. 2014). 
 The European Monitoring Centre for Drugs and Drug’s Addiction early warning 
system estimated that more than 50 new synthetic cannabinoid substances were 
identified from 2011-2012, up from approximately 20 substances documented within the 
previous five year period of 2005-2009 (UNDOC 2013). In addition, since 2008 more 
than 140 compounds have been identified in HIPs confiscated in Japan (Kikura-Hanajiri 
et al. 2011).  Moreover, as of January 2014 in the United States, 15 cannabimimetic 
compounds have been placed in Schedule I nationally (and 7 temporarily scheduled), 
with various legislation enacted at the state level (United States Congress 2012).  
2.5 Effects of Synthetic Cannabinoids in Humans 
 
Synthetic Cannabinoid User Demographics 
 
 Data collected from internet-based surveys that include participants from an 
Australian cohort and worldwide indicate that the majority of HIP users are young 
(median age 25-27 years old), Caucasian (90-91%) males (77-83%) who have 
completed a university degree (30-48%) and were employed (47-78%) at the time of the 
questionnaire (Barratt et al. 2013; Vandrey et al. 2012; Winstock & Barratt 2013). Users 
report consumption of SCBs for reasons that include curiosity, positive recreational 
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effects, legal status and the inability to detect SCBs in traditional drug tests (Barratt et al. 
2013; EMCDDA 2009; Vandrey et al. 2012).  
 While self-reports of drug abuse are not without limitations in sampling and 
interpretation, these data are in good agreement with available poison control data. 
From 2009-2012, approximately 11,500 synthetic cannabinoid exposures were reported 
to the American Association of Poison Control Centers (Wood 2013). National user 
demographics illustrate callers reported intentional inhalation of synthetic cannabinoids, 
and calls were predominately from males (74%) ages 13-29 years old (83%) (Forrester 
et al. 2012; Wood 2013). However, relying of information from poison control centers 
likely over-represents extreme adverse effects requiring medical intervention but 
underrepresents milder side effects in other users. For example, the Colorado 
Department of Public Health and Environment (CDPHE) identified 263 potential 
incidents of synthetic cannabinoid exposure statewide over an approximate one-month 
period, whereas the state poison control center received only 15 reports during this 
same time interval (Monte et al. 2014). Overall, self-reports along with poison center 
and emergency department data support the finding that young males comprise the 
majority of synthetic cannabinoid users worldwide.  
 Since many synthetic cannabinoids evade detection by traditional drug testing, 
their use has also been popular among members of the U.S. military and professional 
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athletes (Bebarta et al. 2012; Berry-Cabán et al. 2013; Heltsley et al. 2012; Johnson et 
al. 2011). Adverse effects after smoking synthetic cannabinoids have been documented 
in active military members with clinical presentations of paranoia, delusions, agitation, 
somnolence, and hyperreflexia accompanied with tachycardia and hypertension after 
both acute and chronic exposure (Bebarta et al. 2012; Berry-Cabán et al. 2013; 
Johnson et al. 2011). As a consequence of these reports, the United States military has 
established restrictions against the novel psychoactive substances in an attempt to limit 
their use in active military members (Johnson et al. 2011).   
! A retrospective examination of 7,500 urine specimens from German athletes 
showed a 0.03% positivity rate for JWH-018 and its major metabolites, whereas U.S. 
athlete use was more prevalent as 4.5% of nearly 6,000 urine samples were positive for 
synthetic cannabinoids (Heltsley et al. 2012; Möller et al. 2011). A reason for higher 
positivity rates in U.S. versus German athletes may be that more SCB compounds were 
included in the U.S. analysis. Additionally, the data may reflect regional differences in 
drug use or highlight different sensitivities in analytical methods. 
 
Acute Synthetic Cannabinoid Use 
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 When compared to the primary psychoactive ingredient in marijuana, THC, the 
enhanced potency and efficacy of synthetic cannabinoid activation of CB1 receptors 
likely contributes significantly to the adverse effects and toxicities reported. Case reports 
from emergency departments, poison control centers and the military indicate that 
synthetic cannabinoid ingestion elicits anxiety, panic, disorientation, extreme agitation or 
somnolence, that is sometimes accompanied with visual and auditory disturbances 
(Auwärter et al. 2009; Forrester et al. 2012; Heltsley et al. 2012; Hoyte et al. 2010; 
Johnson et al. 2011; Simmons et al. 2011; Wood 2013). Physiological symptoms 
include conjunctival injection (bloodshot eyes), xerostomia (dry mouth), nausea/vomiting, 
hyperreflexia, cardiac arrhythmias, changes in blood pressure, and seizures 
(Castellanos & Thornton 2012; Harris & Brown 2013). Furthermore, these potent 
cannabimimetic compounds are thought to contribute to psychotic episodes in 
individuals with or without previous psychotic disposition (Every-Palmer 2011; Hurst et 
al. 2011; Müller et al. 2010). 
 Complex and life-threatening cardiac, renal, and seizure-related toxicities have 
been documented after synthetic cannabinoid use. Prolonged chest pain and abnormal 
heart rate was reported in a 17-year-old male shortly after “K9” consumption; 
subsequent analytical testing of the HIP positively identified JWH-018 and JWH-073 
compounds (Young et al. 2012). Additionally, three incidents of myocardial infarction 
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(MI) were diagnosed in otherwise healthy 16 year-old male adolescents within a few 
days of ingestion of “K2” (Mir et al. 2011). While increased risk of MI after recent 
marijuana use have been reported and complaints of chest pain are common among 
adolescents in emergency settings, it is extremely rare to observe MI in adolescents 
(Mittleman et al. 2001). Cardiac arrest leading to death in a 58-year-old man who 
smoked synthetic cannabinoids was reported; however, the effect of drug on cardiac 
arrest was undocumented (Hoyte et al. 2010). Taken together, these data support 
reasonable concerns of synthetic cannabinoid use and related cardiotoxicites and 
emphasize the need for enhanced analytical methods to detect SCBs as well as 
understand their pharmacology and toxicology.  
 Adverse renal effects have been documented in conjunction with synthetic 
cannabinoid use (Bhanushali et al. 2013; CDC & Centers for Disease Control 2013; 
Thornton et al. 2013). Sixteen individuals (15 males, 15 to 33 years old) from six states 
in the US presented with abdominal pain accompanied with nausea and vomiting after 
synthetic cannabinoid ingestion, and were subsequently diagnosed with acute kidney 
injury (AKI). Clinical specimens were not tested in each case but those analyzed 
showed association between renal toxicity and the SCB, XLR-11 and its known 
metabolites (CDC & Centers for Disease Control 2013). A separate case report 
implicated XLR-11 and UR-144 and common N-pentanoic-acid metabolite with AKI in a 
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26-year-old male that admitted to use of an HIP, “Mr. Happy” (Thornton et al. 2013). In 
addition, renal biopsy results of acute tubular necrosis was observed in three young 
adult male patients known to have recently used “Spice”; of note, each individual had a 
history or prolonged synthetic cannabinoid use (several weeks or months), and had 
recently increased consumption or used a different brand prior to seeking medical 
attention (Bhanushali et al. 2013). 
 Two fatal occurrences have been published involving the SCB, AM-2201 as 
confirmed by toxicological analysis; one resulted in a drug-induced panic attack and 
suicide of a 23-year-old male and the other was an unintentional overdose in a 59-year-
old male (Patton et al. 2013; Saito et al. 2013). The most recent outbreak affecting over 
250 users in Colorado required serious medical intervention (intubation in several 
patients) after individuals presented with altered mental status, bradycardia and seizure 
activity; this toxicity has been linked to the fourth generation synthetic cannabinoid drug, 
ADB-PINACA identified in “Black Mamba” HIPs (Monte et al. 2014). 
Chronic Synthetic Cannabinoid Use 
 
 Zimmerman et al. first reported the development of tolerance in a 20-year-old 
male who continually smoked “Spice Gold” over an 8-month period, reaching 3 grams 
consumption per day. Abstinence from drug produced withdrawal phenomena 
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characterized by drug craving, nervousness, irritability, nightmares, profuse sweating, 
headaches, nausea, tremors, and a sustained elevation in blood pressure (Zimmermann 
et al. 2009). Importantly, it should be noted that at least a subset of these symptoms 
have also been documented after marijuana cessation (Budney et al. 2008; Ramesh et 
al. 2011). Further, a user survey indicated that a subset of respondents met DSM-IV 
criteria of the American Psychiatric Association for abuse (37%) and dependence (17%), 
with users reporting tolerance (36%) and withdrawal symptoms including headaches, 
anxiety/nervousness, sleep disturbances, anger/irritability, difficulty concentrating, and 
restlessness (Vandrey et al. 2012). 
 While pulmonary dysfunction has been established in chronic marijuana users, 
pulmonary toxicity related to synthetic cannabinoid use has not been well documented. 
Severe pulmonary injury, characterized by diffuse lung infiltrates and inflammation was 
observed in a 21-year-old male who chronically smoked HIPs; analysis confirmed the 
presence of synthetic cannabinoid compounds, predominately AM-2201 and to a lesser 
extent JWH-122, JWH-210, and JWH-018 in blood, urine and saliva (Alhadi et al. 2013). 
Additionally, chronic and prolonged marijuana use results in an under-recognized 
cannabinoid hyperemesis syndrome (CHS), which causes gastrointestinal disturbances 
symptomatic of recurrent abdominal pain, nausea, and vomiting (Allen et al. 2004). A 
case study reported treatment of CHS in a 30-year-old as a consequence of smoking 
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synthetic cannabinoids almost hourly each day and several times at night over a 2 
month period (Hopkins & Gilchrist 2013). Subsequent laboratory examination identified 
JWH-018, JWH-073, and AM-2201 in urine samples, and upon hospital discharge and a 
two-week abstinent period from synthetic cannabinoids, the patient’s symptoms were 
completely resolved with good prognosis.  
 In contrast to THC, examples presented here illustrate the alarming rates of 
adverse effects and toxicities associated with synthetic cannabinoid use. As with most 
drugs of abuse, the severity and magnitude of toxicity is dependent on the specific 
synthetic cannabinoid compound(s) ingested, as well as user experience, and relative 
dosing.  A more comprehensive discussion with specific details pertaining to clinical and 
toxicological case reports can be found in recently published review articles (Gurney et 
al. 2014; Hermanns-Clausen et al. 2012a).  
  
2.6 Synthetic Cannabinoids Pharmacology and Toxicology  
 
 Previous research has characterized that synthetic cannabinoids bind to CB1 and 
CB2 receptors. While each ligand has a unique binding profile, compounds found within 
HIPs have been exploited for their ability to bind to and activate CB1 receptors, thereby 
producing cannabimimetic effects similar to the major psychoactive compound in 
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marijuana, THC. What distinguishes abused synthetic cannabinoids from THC is their 
high CB1 receptor binding affinity and increased efficacy in activating the receptor. 
These same properties are hypothesized to make them more dangerous than THC in 
humans. 
Mechanism of Action 
 
 Numerous studies have characterized binding of classical (THC analogs), 
nonclassical (cyclohexyphenols) and aminoalkylindole compounds at CB1 and CB2 
receptors (Aung et al. 2000; Compton et al. 1993; Huffman et al. 2005; Showalter et al. 
1996; Wiley, Marusich, Lefever, et al. 2013). However, for synthetic cannabinoid 
constituents found in HIPs, fewer studies have characterized functional activation of CB1 
receptors via agonist-stimulated [35S]-GTPγS binding assays. In contrast to the partial 
agonist efficacy of THC, several synthetic cannabinoids act as full efficacy ligands at 
CB1 (Brents et al. 2011; Brents et al. 2012; Huffman et al. 2005; Nakajima et al. 2011; 
Wiley, Marusich & Huffman 2013). In a neuronal cell culture model, synthetic 
cannabinoids JWH-018, JWH-073 and CP47,497-C8 inhibited excitatory 
neurotransmission (EPSCs) with a magnitude similar to the well-characterized 
cannabinoid agonist, WIN55,212-2 (Atwood et al. 2010; Atwood et al. 2011). Moreover, 
these compounds caused CB1 receptor internalization, albeit to different degrees, which 
supports the hypothesis that tolerance is likely to develop upon repeated use.  
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Metabolism and Pharmacokinetics 
 Metabolism of THC has been well elucidated (Agurell et al. 1986; Huestis 2007), 
and pharmacokinetic data are important to understanding the drug’s course of action in 
the body. One published report has described in vitro CP47,497 metabolite formation 
using human liver microsomes; mainly Phase-I oxygenated and hydroxylated 
metabolites were identified by LC/MS (Jin et al. 2013). Several studies investigating the 
metabolic profile of aminoalkylindole (JWH series) synthetic cannabinoids qualitatively 
demonstrated that the prevalent urine metabolites of JWH-018, JWH-073 and JWH-250 
in rodents were N-dealkylated and N-dealkyl monohydroxylated species (Grigoryev, 
Savchuk, et al. 2011; Grigoryev, Melnik, et al. 2011), whereas human metabolism 
involved production of monohydroxylated species that were further glucuronidated for 
excretion (Möller et al. 2011; Sobolevsky et al. 2010). These phase II glucuronidated 
metabolites have been identified in vitro and in authentic urine samples, but are not 
detected in whole blood specimens (Möller et al. 2011; Kacinko et al. 2011; 
Wintermeyer et al. 2010). Similar to THC metabolism, involvement of the superfamily of 
cytochrome monooxygenase (CYP450) enzymes in the formation of hydroxylated 
metabolites has been established in several synthetic cannabinoid compounds using 
human liver microsomal preparations (Chimalakonda et al. 2012; Chimalakonda, 
Bratton, et al. 2011; Sobolevsky et al. 2010; Wintermeyer et al. 2010). When SCB 
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metabolite internal standards became commercially available, several validated 
methods were published which examined the quantitative measurement of JWH-018 
and JWH-073 glucuronic conjugates after self-administration studies (Chimalakonda, 
Moran, et al. 2011; Chimalakonda et al. 2012). Many subsequent studies have identified 
these metabolites in urine (Dowling & Regan 2011; Grigoryev, Savchuk, et al. 2011; 
Sobolevsky et al. 2012). 
 In contrast to THC and its major active metabolite 11-OH-THC, mono-
hydroxylated but not carboxylate metabolites of SCBs JWH-018, JWH-073 and AM-
2201, retain nanomolar binding affinity at CB1 receptors (Brents et al. 2011; Brents et al. 
2012; Chimalakonda et al. 2012). Furthermore, these monohydroxylated metabolites act 
as full efficacy agonists assessed in vitro by G-protein activation and in vivo, acting as 
cannabimimetics in mouse tetrad studies (Brents et al. 2011; Brents et al. 2012; 
Chimalakonda et al. 2012).  
 There is a lack of controlled pharmacokinetic studies evaluating peak drug effects 
and time-course, but users have anecdotally reported that synthetic cannabinoids have 
a shorter duration of action with a faster peak onset when compared to cannabis 
(Winstock & Barratt 2013). For example, two individuals who smoked a 0.3 g synthetic 
cannabinoid-containing cigarette reported alterations of mood and perception 
accompanied with conjunctival injection, xerostomia, and increased pulse rate, within 
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approximately 10 minutes after consumption (Auwärter et al. 2009). Not surprisingly, 
subjective effects were reported to vary depending on specific compound; when 
compared to THC, JWH-018 effects are short (1-2 h) while CP47,497-C8 effects are 
markedly longer lasting (5-6 h) (EMCDDA 2009).  
 Data from another anecdotal report attempted to quantify serum concentrations 
of JWH-018 with various pharmacological self-reports, such as feelings sickness, 
sedation, xerostomia and increased pulse rates (Teske et al. 2010). JWH-018 was 
successfully quantitated in serum from 5 minutes to 3 hours after smoking (< 10 ng/mL); 
while present at 6, 24, 48 hours, JWH-018 values were not reported because they were 
below analytical limit of quantitation. 
2.7 Analytical Testing and Detection of Synthetic Cannabinoids !
 
 Because the chemical structures of SCBs greatly vary from THC and its 
metabolites, 11-OH-THC and THC-COOH, they are not detected via established drug 
testing methods. In order to assess the consequences of synthetic cannabinoid abuse 
on public health and safety, the development and validation of sensitive and selective 
analytical techniques are critical for successful evaluation of preclinical and clinical 
pharmacological studies. In order to identify SCB compound(s) present in HIPs, 
analytical techniques needed to quantify them as well their major metabolites following 
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consumption. Subsequent analysis will permit pharmacokinetic and pharmacodynamic 
investigations that are necessary for interpretation of suspected intoxication and 
overdose reports.  
 Identification and quantification of many SCB have been reported in herbal 
incense products using high performance liquid chromatography tandem mass 
spectrometry (HPLC/MS/MS) and gas-chromatography mass spectrometry (GC/MS) 
techniques (Dresen et al. 2010; Hudson & Ramsey 2011; Logan et al. 2012; Amy Leah 
Patton et al. 2013; Uchiyama et al. 2010). Ensuing studies examined the presence of 
SCB compounds confirmed in HIPs in biological matrices, but many of these early 
validated methods were applied to authentic urine specimens (Heltsley et al. 2012; 
Möller et al. 2011). While this approach is suitable for workplace drug-testing and to 
establish drug history, it is of limited utility for interpretation of SCB impairment or 
toxicity (Dowling & Regan 2011; Chimalakonda, Moran, et al. 2011; ElSohly et al. 2011; 
Musshoff et al. 2013; Sobolevsky et al. 2010). Even though several studies have 
described the analysis of synthetic cannabinoid compounds in serum and whole blood, 
more work is needed to understand the relationship between circulating drug levels and 
physiological symptoms (Ammann et al. 2012; Dresen et al. 2011; Kacinko et al. 2011; 
Musshoff et al. 2013).  !
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Rationale and Hypothesis  !
  
 Data sourced from the scientific research and recent case reports support the 
abuse of synthetic cannabinoids for their THC-like properties. Since these chemicals 
were intended specifically for laboratory research, there is limited information regarding 
their pharmacological and toxicological effects in animals and humans. Importantly, the 
White House’s National Drug Control Strategy emphasized that synthetic cannabinoids 
are understudied substances due to limited scientific data; therefore, there is a need for 
further evaluation concerning the patterns and significance of abuse, as well as risk 
assessment for public health and safety (Sacco & Finklea 2013). To address these gaps 
in the literature, CP47,497 was chosen for evaluation in these studies as it was shown 
to be biologically active and has been prominently detected in HIPs. Additionally, 
information on its effects and identification in biological fluids can be used to address 
legal consequences of SCB use and abuse in humans (Compton, Johnson, et al. 1992; 
Hudson et al. 2010; Uchiyama et al. 2009; Uchiyama et al. 2010; Weissman et al. 1982).  
 It is hypothesized that CP47,497 elicits more potent and efficacious 
cannabimimetic effects than those of THC, through a CB1 receptor mechanism; and 
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therefore has an inherent risk for abuse, tolerance, and dependence. As a result, the 
objectives of this dissertation are to investigate the bioavailability of the prototypical 
synthetic cannabinoid, CP47,497 in the CNS and to characterize in vivo 
pharmacological effects of the drug when compared to the predominant psychoactive 
compound in marijuana, THC. 
Analytical Method Validation 
 In order to investigate drug actions in biological matrices, analytical methods for 
detection and quantification of SCB analytes need to be developed.  Analyte detection in 
biological matrices requires validation of experimental, clinical, and forensic toxicological 
analyses to ensure the efficacy and reliability of an analytical method (Services & 
Administration 2001; SWGTOX 2013). To achieve this, an HPLC/MS/MS method for the 
detection of CP47,497 in brain was validated. To test selectivity of the method, the 
structural analogs CP47,497-C8, and the aminoalkylindole compound JWH-250, were 
also examined in the analysis. These synthetic cannabinoids were chosen as their 
presence has been confirmed in HIPs and case reports (Hermanns-Clausen et al. 
2012b). To identify limitations of the HPLC/MS/MS method, experiments were designed 
to evaluate calibration model, bias, precision, matrix interference, ion suppression, 
carryover, stability, limit of detection, limit of quantification and dilution integrity which 
will be discussed further in Chapter 3 (SWGTOX 2013).  
!71 
 
CP47,497 Mechanism of Action 
 Determination of synthetic cannabinoid concentration in brain will enable us to 
examine the relationship between the bioavailability of CP47,497 and resultant behavior. 
Pharmacokinetic data on THC, the main psychoactive component of marijuana are well 
established. As there are limited data regarding pharmacokinetics of CP47,497, the first 
series of experiments examined whether dose-dependent and temporal effects of 
CP47,497 are similar to those of THC. Because CP47,497 CB1 receptor binding affinity 
is higher then the affinity of THC, we predicted that in mice, CP47,497 will produce more 
potent and efficacious cannabimimetic effects than THC. Next, we wanted to determine 
if CP47,497 achieved its neuropharmacological effects through a CB1 mediated 
mechanism of action. Studies employed a complementary pharmacological approaches 
using the CB1 antagonist, rimonabant, and combined with genetically modified mice 
lacking the CB1 receptor to ascertain whether CB1 receptors mediate the 
pharmacological effects of CP47,497. Given that CB1 receptor agonists, such as THC, 
cause conformational changes upon receptor binding with functional downstream 
signaling consequences, studies employing non-hydrolyzable GTPγS permitted 
assessment of functional GPCR activation by CP47,497.  
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CP47,497-mediated Development of Tolerance and Dependence  
 Due to severe adverse effects reported in chronic users, the consequences of 
prolonged synthetic cannabinoid use need to be systematically investigated. Chronic 
marijuana use leads to tolerance and dependence; therefore studies were conducted to 
examine the untoward effects upon repeated CP47,497 administration. Since CP47,497 
is known to bind to CB1 receptors in the low nanomolar range and produce 
cannabimimetic effects in vivo, we predict that repeated administration of CP47,497 will 
cause tolerance to tetrad behavioral effects in mice. Additionally, we hypothesize that 
mice treated repeatedly with CP47,497 will exhibit somatic withdrawal signs when 
challenged with rimonabant. Lastly, anecdotal accounts describe a THC-like high after 
synthetic cannabinoid use; as a result, drug-discrimination experiments were performed 
to test whether CP47,497 substitutes for THC. 
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Chapter 3 – HPLC/MS/MS Identification and Method Validation of 
Synthetic Cannabinoids in Brain !
3.1 Abstract  !! While Marijuana continues to be the most widely used illicit drug, abuse of 
synthetic cannabinoid compounds in “Spice” or “K2” herbal incense products has 
emerged as a significant public health concern in many European countries and in the 
United States.  Several of these synthetic cannabinoids have been declared Schedule I 
controlled substances but detection and quantification in biological samples remains a 
challenge. Therefore, we present a liquid chromatography-tandem mass spectrometry 
method after liquid-liquid extraction for the quantitation of CP47,497, CP47,497-C8, and 
JWH-250 in mouse brain. We report data for linearity, LOQ, accuracy/bias, precision, 
recovery, selectivity, carryover, matrix effects and stability experiments which were 
developed and fully validated based on (SWGTOX) guidelines for forensic toxicology 
method validation. Acceptable coefficients of variation for accuracy/bias, within- and 
between-run precision and selectivity were determined, with all values within ± 15% of 
the target concentration. Validation experiments revealed degradation of CP47, 497 and 
CP47,497-C8 at different temperatures, and significant ion suppression was produced in 
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brain for all compounds tested. The method was successfully applied to detect and 
quantify CP47,497 in brains from mice demonstrating significant cannabimimetic 
behavioral effects as assessed by the classical tetrad paradigm. 
3.2 Introduction !
Abuse of synthetic cannabinoids (SCBs) in herbal incense products (HIPs) has 
recently emerged as a significant national public health and safety concern. In the 
United States, emergency bans were swiftly mandated by the Drug Enforcement 
Administration (DEA) to regulate the barrage of synthetic cannabinoid compounds 
available to the public (Department of Justice 2013). To date, dozens of SCBs have 
been detected in HIPs, as their structures are continually modified to circumvent 
legislative efforts (Choi et al. 2013). Anecdotal accounts from user forums 
(www.bluelight.ru; erowid.org) suggest that SCB effects are reminiscent of the effects of 
marijuana (Vardakou et al. 2010) and while published user reports of synthetic 
cannabinoid effects are limited, studies indicate SCBs produce alterations in perception, 
conjunctival injection, xerostomia, and increases in pulse rate similar to that of 
marijuana (Auwärter et al. 2009; Teske et al. 2010). 
Synthetic cannabinoid compounds were incipiently developed as tools to gain 
insight on marijuana’s effects on the brain and to investigate potential therapeutic 
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applications of the endogenous cannabinoid receptor system (CB1 and CB2) modulation. 
The cyclohexylphenol (CP) series were synthesized by Pfizer beginning in the 1970’s, 
with CP47,497  serving as a prototypical bicyclic analgesic compound (Weissman et al. 
1982).  Research from scientists at the Winthrop-Sterling company over two decades 
ago led to the development of the novel aminoalkylindole synthetic cannabinoid, 
WIN55,212-2, which behaves as a full receptor agonist at both CB1 and CB2 receptors 
(Haubrich et al. 1990; Compton, Gold, et al. 1992). Stemming from this research, John 
W. Huffman continued development of an aminoalkylindole (or JWH) class of synthetic 
cannabinoids, which include compounds such as JWH-250 (Huffman et al. 2005). Over 
the last several years, these SCB compounds, intended solely for research purposes, 
have been sold as a “legal high” alternative to marijuana, with the first identification of 
CP 47,497 in 2008 from the Wisconsin State Crime Laboratory (The Drug Enforcement 
Administration 2009).  
Marijuana remains the most widely used illicit substance worldwide (UNDOC 
2013), but the fact that standard drug screens do not typically include SCBs, may 
contribute to the recent popularity of these substances. The sudden spike in SCB abuse 
will likely continue to threaten public health and safety. Repeated abuse of SCBs has 
led to tolerance and dependence symptoms after attempted drug cessation 
(Zimmermann et al. 2009; Nacca et al. 2013). Thus, there is a need for validated 
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methods to detect these SCB substances from biological material.  In the present study, 
we present a high performance liquid chromatography tandem mass spectrometry 
(HPLC/MS/MS) method for the detection and quantification of JWH-250, CP47,497 and 
CP47,497-C8, in brain. We chose to include CP47,497, CP47,497-C8, and JWH-250 in 
this method as they are among the first synthetic cannabinoid compounds to be 
positively detected in herbal products (Vardakou et al. 2010; Lindigkeit et al. 2009; 
Auwärter et al. 2009; Hudson et al. 2010; Uchiyama et al. 2009; Uchiyama et al. 2010). 
Of relevance to their abuse, these three SCBs have also been identified in SCB 
exposure case reports (Hermanns-Clausen et al. 2012b; EMCDDA 2009).  
It is hypothesized that the desired subjective effects of synthetic cannabinoids 
are mediated through activation of CB1 receptors in the central nervous system (CNS) 
similar to those of delta-9-tetrahydrocannabinol (THC), the primary psychoactive 
constituent of marijuana (EMCDDA 2009; Huffman et al. 2008; Atwood et al. 2011). In 
contrast to the partial-agonist activity of THC, many SCBs including CP47,497, 
CP47,497-C8, and JWH-250 possess enhanced binding affinity at CB1 receptors 
(Melvin et al. 1993).  Despite this proposed mechanism of action, few published studies 
have identified or quantified the presence of synthetic cannabinoids in brain after drug 
exposure (Wiebelhaus et al. 2012; Poklis et al. 2012; Poklis et al. 2012). Of clinical 
significance, it has been previously demonstrated that THC can be detected in brain 
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after the window of detection in blood/plasma has lapsed (Mura et al. 2005).  The 
method presented here demonstrates that SCBs from distinct cyclohexylphenol and 
aminoalkylindole structural classes (Figure 3.1) can be simultaneously detected in brain. 
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Figure 3.1 – Chemical structures of synthetic cannabinoid compounds CP47,497, CP47,497-C8 and 
JWH-250 included in HPLC/MS/MS method validation.  
 
3.3 Materials and Methods !
Drugs and reagents 
CP47,497, CP47,497-C8, and JWH-250 drugs and CP47,497-d11, CP47,497-
C8-d7 and JWH-250-d5 deuterated internal standards (ISTD) were purchased from 
Cayman Chemical (Ann Arbor, MI). HPLC grade or better acetonitrile, methanol, and 
ammonium formate were obtained from Fisher Scientific (Waltham, MA). Deionized (DI) 
water was obtained from an in-house water system (Millipore, Bedford MA). Nitrogen 
!78 
gas (medical grade) was obtained from National Welders Supply Company (Richmond, 
Virginia).   
Animals, behavioral measures and tissue collection  
 Drug naïve, male, ICR (CD-1) mice (Harlan Laboratories, Dublin, VA) weighing 
25-35 grams were obtained and housed in Virginia Commonwealth University’s (VCU) 
animal care facilities at 22 ± 2 °C on a 12-hour light/dark cycle with ad libitum water and 
standard rodent chow (7012 Teklad Mouse/Rat Diet, Harlan Laboratories). For proof of 
method experiments, mice received intraperitoneal (i.p.) injections of either vehicle 
(ethanol:emulphor:saline in a ratio of 1:1:18) or 30 mg/kg CP47,497 administered at a 
volume of 0.1mL per 10 g of body mass, as this SCB dose produced measurable 
cannabimimetic effects in previous dose-response studies in vivo (Samano et al. 2013).  
 For tetrad behavioral testing, mice were acclimated to the test environment for at 
least 1 h prior to testing for spontaneous activity, catalepsy, antinociception, and 
hypothermia (Wiley 2003; Martin et al. 1991). Locomotor activity was assessed by 
placing mice into individual photocell activity boxes (28 × 16.5 cm chambers containing 
two sets of eight photocells; Omnitech, Columbus, OH) five minutes after vehicle or drug 
treatment. Photocell beam interruptions were recorded for 10 minutes using Digiscan 
Animal Activity Monitor software (Med Associates, Inc., St. Albans, VT) with data 
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expressed as the average number of photocell beam breaks. Mice were assessed for 
catalepsy, antinociception and hypothermia thirty minutes after vehicle or drug treatment. 
Catalepsy was measured using the bar test in which both forelimbs of the mouse were 
placed on a horizontal bar, with the duration of a fixed and motionless posture recorded 
over a 60 second interval.  Antinociception was determined using a warm water (52 °C) 
tail immersion test. The distal end (approximately 1 cm) of the tail was immersed in the 
water bath and the latency of the mouse to withdrawal its tail was recorded (to the 
nearest tenth of a second) using a 10 second cut-off to minimize tail damage. 
Antinociception data was transformed to represent a maximum percent effect (%MPE) 
by the following formula: %MPE = [(test latency − pretreatment 
latency)/(10−pretreatment latency)]×100. Body temperature measurements were 
collected by inserting a rectal probe attached to a telethermometer (Yellow Spring 
Industries Inc., Yellow Springs, OH) to a 2 cm depth with measurements recorded to the 
nearest 0.1 °C.  
One hour post-injection, mice were deeply anesthetized via 3% isoflurane-
containing oxygen induction and sacrificed by cervical dislocation. Whole brain was 
harvested and stored at -80 °C until analysis. All experiments were approved by the 
Institutional Animal Care and Use Committee at Virginia Commonwealth University in 
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accordance with the National Institutes of Health’s Guide for the Care and Use of 
Laboratory Animals. 
Brain homogenate preparation 
Brains from ICR and C57BL/J6 mice was harvested, pooled and used to obtain 
drug-free tissue for the method validation. Brain homogenates were prepared in a 4:1 
ratio (w/w) using deionized water with a stand homogenizer (Janke and Kunkel Ultra 
Turrax T25). For selectivity experiments, 10 individual lots of tissue (each lot required 
two pooled brains) were used to prepare each of 10 separate homogenate tissue lots. 
For mouse studies, after homogenization of whole brain tissue, 0.5 mL aliquots of 
homogenate were used from drug-treated and vehicle-treated mice to isolate CP47,497 
using the liquid-liquid extraction (LLE) method described herein. 
Internal standard and stock solution preparation 
 Separate working stock solutions containing each CP47,497, CP47,497-C8 and 
JWH-250 at 250 ng/mL, 2,500 ng/mL, and 10,000 ng/mL were prepared by dilution with 
methanol of commercially purchased drug compounds. The deuterated ISTD mixture 
containing 2500 ng/mL of CP47,497-d11, CP47,497-C8-d7, and JWH-250-d5 was 
prepared by dilution of purchased ISTDs with methanol. Working stock and ISTD stock 
solutions were stored at -20 °C.  
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Calibrator and quality control preparation 
 Calibrators were prepared by fortifying 0.5 mL aliquots of drug-free mouse brain 
homogenates with appropriate drug and ISTD concentrations for each calibrator. Prior 
to every analytical run, fresh calibrators containing CP47,497, CP47,497-C8 and JWH-
250 were prepared in duplicate at 20, 40, 80, 200, 400, 1000 and 2000 ng/g 
concentrations and used to construct a 7-point calibration curve. A single lot of quality 
control (QC) specimens containing CP47,497, CP47,497-C8 and JWH-250 were 
prepared at the start of the method validation and analyzed at the following levels: limit 
of quantification quality control (LOQ), target concentration of 20 ng/g; low quality 
control (LQC), target concentration 60 ng/g; medium quality control (MQC), target 
concentration 300 ng/g; and high quality control (HQC), target concentration 1600 ng/g. 
A dilution quality control (DQC), target concentration 400 ng/g upon dilution (1:10), was 
included to ensure accurate quantification of authentic samples in instances where 
quantified specimen concentrations surpass the established calibration range, or when 
the sample volume is insufficient for testing. Calibrators and QCs specimens each 
contained all three SCB analytes along with their respective deuterated ISTDs (final 
concentration 800 ng/g). A negative control (drug-free) containing ISTD, and a double 
negative control (drug-free without ISTD) were also included in each analytical run. All 
QC lots and standards were stored at 4 °C for the duration of the validation.  
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SCB extraction procedure 
CP47,497, CP47,497-C8 and JWH-250 were isolated using a liquid-liquid 
extraction (LLE) method for isolation of cannabinoids from blood as described by Foltz. 
et al. (Foltz et al. 1983) and previously adapted specifically for cannabinoid isolation 
from brain tissue (Poklis et al. 2010). To each set of calibrators, QCs, or treated mouse 
tissue, 10 µL of ISTD mix consisting of 2500 ng/mL of each CP47,497-d11, CP47,497-
C8-d7 and JWH-250-d5 were added and vortex-mixed thoroughly. Samples were then 
refrigerated overnight at 4 °C to ensure equilibration. The next day, 2 milliliters of “ice-
cold” acetonitrile was added to homogenates in a drop-wise manner while samples were 
constantly vortex-mixed. Samples were then centrifuged for 10 minutes (2500 x g) to 
separate solid and liquid phases. Extracted samples were stored overnight at -20 °C to 
allow for complete phase resolution. The following day, the organic layer was isolated 
using a glass pipet, transferred to a clean glass tube, and evaporated to dryness in a 
Savant Speed Vac Concentrator (SPD1010, Thermo Scientific). Samples were 
reconstituted in 100 µL of 20/80 water/acetonitrile and transferred to auto-sampler vials. 
The vials were stored on the sample tray maintained at 4 °C until analyzed.  
HPLC/MS/MS conditions 
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 The HPLC/MS/MS system was an Applied Bio Systems 3200 Q Trap with Turbo 
V source for TurbolonSpray coupled to a Shimadzu SCL HPLC system with data 
acquisition controlled by Analyst 1.4.2 software. Chromatographic separation was 
achieved with a Zorbax Eclipse XBD-C18 (4.6 x 75 mm, 3.5 µm) column (Agilent 
Technologies). The mobile phase consisted of water/acetonitrile (20:80 v/v) with 0.1 mM 
ammonium formate and had an isocratic flow rate of 0.5 mL/min. The ionspray voltage 
was set at 5000V with ion source gases 1 and 2 maintained at a flow rate of 60 mL/min. 
The source temperature was programmed at 650 °C, with a curtain flow rate of 30 
mL/min. Multiple reaction monitoring (MRM) acquisition mode was used. Transition ions 
monitored along with the corresponding deprotonation (DP) and collision energies (CE) 
utilized for each analyte are presented in Table I.  The injection volume was 10 µL and 
the method had a total chromatographic run time of 12 minutes. Figure 3.2 shows the 
chromatographic method successfully resolved CP47,497, CP47,497-C8 and JWH-250.  
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Table I
Synthetic Cannabinoid Retention Time, Multiple Reaction Monitoring (MRM) Transition Ions, 
and Corresponding Collision Energies (CE)
Analyte RT (min) Quant Ion (m/z) CE (eV) Qual Ion (m/z) CE (eV)
Positive Mode:
JWH-250 4.3 336>121 27 336>91 61
JWH-250-d5 4.2 341>121 27 341>91 61
Negative Mode:
CP-47,497 5.1 317>245 44 317>299 34
CP-47,497-d11 4.9 328>245 44 328>299 34
CP-47,497-C8 6.7 331>259 42 331>313 34
CP-47,497-C8-d7 6.3 338>266 42 338>320 34
 
Quantitative assay performance 
The presented HPLC/MS/MS method validation for the detection and 
quantification of SCBs in brain was based on recommendations of the Scientific 
Working Group for Forensic Toxicology (SWGTOX) Standard Practices for Method 
Validation in Forensic Toxicology (SWGTOX 2013). The assay was evaluated over six 
days with each run including calibrators prepared in duplicate, a negative control, a 
double negative control, and batch prepared LOQ, LQC, MQC, HQC, and DQC samples 
in replicates of 3 or 6.             
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Linearity and LOQ  
 A 7-point calibration curve was prepared in duplicate at 20, 40, 80, 200, 400, 800, 
and 2000 ng/g in homogenized brain tissue for determination of SCB drug 
concentrations. The linear-regression calibration model was verified using the ratio of 
the peak area of the abundance quantification ion of SCBs to the peak area abundance 
quantification ion of each SCBs’ deuterated ISTD versus the concentration.  The lower 
limit of quantification (LOQ) and lower limit of detection (LOD) were administratively set 
at 20 ng/g. LOQ QCs were prepared for each run to verify that the LOQ was within ± 
20% of the target value and had a response at least five times greater than the signal to 
noise ratio of drug-free brain.   
Accuracy/bias and precision 
Accuracy/bias and precision (within- and between-run) were determined for the 
method by analysis of prepared QC samples over six separate analytical runs. The 
method bias was determined by calculating the ratio of the mean SCB concentration of 
six aliquots of each QC (LOQ, LQC, MQC, HQC, and DQC) to the target concentration 
of the QC specimen, then multiplying by 100 to obtain a percentage. Data was 
considered acceptable when the accuracy/bias results were within ± 20% of the QC’s 
target value. Precision was assessed at five concentrations (LOQ, LQC, MQC, HQC, 
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and DQC) in triplicate over six analytical runs. Within-run and between-run precision 
were calculated after performing a one-way Analysis of Variance (ANOVA) using 
GraphPad Prism® statistical software (Version 5.0; LA Jolla, CA) with calculated values 
from the analysis reported. 
Absolute recovery and matrix effects 
Absolute recovery was determined at 60, 300 and 1600 ng/g covering the linear 
range of the assay by comparing the mean SCB peak area of six aliquots where drug 
was added to homogenates prior to extraction (i.e. before, B) to six blank homogenate 
extracts to which drug was added to the extracted matrix (i.e. after, A). To calculate 
absolute recovery, the following equation was used: (Mean area of B/Mean area of A) X 
100. For determination of matrix effects of LQC, MQC, and HQC specimens, the mean 
SCB peak area of unextracted (i.e. neat, N) samples were compared to the SCB peak 
area of blank homogenate samples fortified with drug after extraction (A). Percent ion 
suppression/enhancement was determined by use of the following equation: [(Mean 
area of N/Mean area of A) - 1] X 100.   
Stability studies 
Since little is known regarding the stability of SCB compounds in biological 
samples, SCB stability experiments were conducted to assess bench top stability, 
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freeze/thaw stability, storage parameters and post-preparative stability using LQC (60 
ng/g), MQC (300 ng/g) and HQC (1600 ng/g) specimens. LOQ (20 ng/g) and DQC (400 
ng/g) samples were also examined for post-preparative stability. For bench top stability 
studies, the effects of routine specimen transportation and laboratory handling were 
investigated. Six aliquots of each LQC, MQC, and HQC specimens were left exposed at 
room temperature for 72 hours, extracted as described herein, then analyzed. Brain 
tissue is commonly stored frozen prior to analysis so the consequences of freeze/thaw 
treatment were also evaluated. To account for reanalysis of frozen specimens, three 
freeze/thaw cycles were performed on six aliquots of each LQC, MQC and HQC. QC 
samples were frozen at -20 °C, allowed to thaw at room temperature unassisted, and 
refrozen for a minimum of 24 hours before the next thaw cycle. Upon the third thaw 
cycle, the QC specimens were extracted then analyzed using freshly prepared 
calibrators. Short-term storage was also assessed. Thirty days after QC batches were 
prepared for the validation study, six aliquots from each LQC, MQC, and HQC lots were 
extracted and analyzed using freshly prepared calibrators.  Post-preparative stability of 
processed samples was examined after 72 hours, to simulate situations where prepared 
samples cannot be immediately analyzed. LQC, MQC, and HQC samples were 
extracted normally and quantified using freshly prepared calibrators. These same QC 
extracts were kept at room temperature, re-injected after 72 hours and quantified 
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against the original calibration curve. SCB analytes were considered stable if the 
concentrations were within ± 20% of the target concentrations.  
Analyte and ISTD stock stability was assessed at LQC, MQC, and HQC 
concentrations after room temperature exposure over a 6 hour period as previously 
recommended (Services & Administration 2001), with stability determined by comparing 
instrument response of the stocks kept at room temperature to freshly prepared analyte 
and ISTD stocks.  Stock standards were considered stable if analyte or ISTD peak area 
was within ± 20% of freshly prepared stock peak areas. 
 
3.4 Results  !
For each analytical run, the calibrators analyzed in duplicate were back 
calculated and determined to be within ± 15% of their nominal value. Additionally, linear 
regression correlation coefficients (r2) means (n = 21) across runs were 0.9964 ± 0.003 
(CP47,497), 0.9963 ± 0.003 (CP47,497-C8) and 0.9960 ± 0.003 (JWH-250), with ranges 
of 0.9984-0.9992, 0.9904-0.9992, and 0.9932-0.9996, respectively. It was verified that 
the LOD of each SCB demonstrated at least five times the signal-to-noise ratio of the 
response seen for both qualifier and quantifier ions in drug-free brain. 
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Figure 3.2 – Representative total ion chromatogram (TIC) and fragmentation pattern of CP47,497, 
CP47,497-C8 and JWH-250 analytes.  
 
Accuracy/bias shown in Table II of the tested SCBs ranged at the LOQ (20 ng/g) 
from 90% to 98%, the LQC (60 ng/g) from 87% to 100%, the MQC (300 ng/g) from 93% 
to 101%, the HQC (1600 ng/g) from 96% to 100%, and the DQC (400 ng/g) from 86% to 
97%. Values for the coefficient of variation (CV), expressed as a percentage, for LOQ, 
LQC, MQC, HQC, and DQC were all within ± 15% of the target concentration, with a 
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range of 3% to 12%. Accuracy/bias determined over the linear range varied from a low 
of 86% exhibited by CP47,497-C8 at the DQC target value of 400 ng/g to a high of 
101% for CP47,497 at the MQC target value of 300 ng/g. 
Table II
Accuracy/bias (n = 6) for JWH-250, CP-47,497 and CP-47,497-C8 in mouse brain; values represent mean ± SD (CV)
LOQ LQC MQC HQC DQC
Murine Brain (ng/g): (20 ng/g) (60 ng/g) (300 ng/g) (1600 ng/g) (400 ng/g)
     JWH-250 22 ± 1.2 (6) 68 ± 2.3 (3) 319 ± 35 (11) 1601 ± 150 (9) 411 ± 22 (5)
     CP-47,497 20 ± 0.7 (4) 60 ± 3.6 (6) 303 ± 26 (9) 1598 ± 161 (10) 369 ± 40 (11)
     CP-47,497-C8 19 ± 1.5 (8) 56 ± 3.6 (6) 278 ± 17 (6) 1536 ± 182 (12) 344 ± 33 (10)
LOQ, Limit of quantitation; LQC, low quality control; MQC, medium quality control; HQC, high quality control 
DQC, dilution quality control; CV, coefficient of variation
 
Within-run and between-run precision is shown in Table III for LOQ, LQC, MQC, 
HQC and DQC samples. Within-run precision was acceptable with all CV values within 
± 15% the expected concentration and a range of 4.8% to 9.1% CV for JWH-250, 7.7% 
to 13.4% CV for CP47,497 and 6.3% to 11.2% CV for CP47,497-C8. The between-day 
precision across each analyte at five QC levels was within ± 15% of the expected CV, 
with a range of 5.2% to 15.3% across the SCB analytes tested.  
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Table III
Within- and between-run precision for JWH-250, CP-47,497 and CP-47,497-C8 in mouse brain (n = 21)
Analyte Concentration Within-run CV (%)  Between-run CV (%)  
JWH-250 LOQ (20 ng/g) 7.1 8.0
LQC (60 ng/g) 4.8 5.2
MQC (300 ng/g) 5.2 11.9
HQC (1600 ng/g) 6.0 11.6
DQC (400 ng/g) 9.1 10.1
CP-47,497 LOQ (20 ng/g) 11.2 9.9
LQC (60 ng/g) 7.9 7.9
MQC (300 ng/g) 7.7 10.7
HQC (1600 ng/g) 8.4 12.2
DQC (400 ng/g) 13.4 15.3
CP-47,497-C8 LOQ (20 ng/g) 11.2 12.5
LQC (60 ng/g) 7.5 8.9
MQC (300 ng/g) 9.0 9.6
HQC (1600 ng/g) 6.3 10.5
DQC (400 ng/g) 9.7 12.4
LOQ, limit of quantitation; LQC, low quality control; MQC, medium quality control; HQC, high quality control 
DQC, dilution quality control; CV, coefficient of variation  
Absolute recovery shown in Table IV for the SCBs at the LQC ranged from 94% 
to 117%, at the MQC from 98% to 116%, and at the HQC from 115% to 118%. 
Recovery determined over the linear range varied from a low of 94% exhibited by 
CP47,497-C8 at a target concentration of 60 ng/g (LQC) to a high of 118% for JWH-250 
and CP47-497 both at target concentrations of 1600 ng/g (HQC). Matrix effects shown 
in Table IV demonstrated significant ion suppression across the SCBs tested. Matrix 
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effects for JWH-250 ranged from 35 to 45%, CP47,497 from 32 to 69% and CP47,497-
C8 from 27 to 69%.   
Table IV
Recovery and ion suppression/enhancement of synthetic cannabinoids (n = 6)
and their respective internal standards (n = 18) in brain
Murine Brain: % Recovery Ion Suppression
Synthetic cannabinoid
     JWH-250 LQC (60 ng/g) 117 ± 20 35 ± 10
MQC (300 ng/g) 116 ± 18 43 ± 12
HQC (1600 ng/g) 118 ± 2 45 ± 8
     CP-47,497 LQC (60 ng/g) 96 ± 16 48 ± 9
MQC (300 ng/g) 105 ± 10 32 ± 17
HQC (1600 ng/g) 118 ± 11 69 ± 28
     CP-47,497-C8 LQC (60 ng/g) 94 ± 11 44 ± 20
MQC (300 ng/g) 98 ± 11 27 ± 18
HQC (1600 ng/g) 115 ± 5 69 ± 26
ISTD
     JWH-250-d5 800 ng/g 120 ± 19 42 ± 15
     CP-47,497-d11 800 ng/g 102 ± 19 47 ± 18
     CP-47,497-C8-d7 800 ng/g 93 ± 19 43 ± 26
LQC, low quality control; MQC, medium quality control; HQC, high quality control 
ISTD, internal standard
Mean ± CV
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Selectivity was assessed using 10 separate lots of drug-free brain. Samples from 
each lot included a drug-free aliquot with and without ISTD, and three aliquots fortified 
with 60 ng/g of each SCB analyte. Each fortified tissue lot was run in triplicate and 
calculated CVs were within ± 15% for CP47,497, CP47,497-C8 and JWH-250. The 
selectivity bias range was 100% to 116% for CP47,497, 80% to 116% for CP47,497-C8 
and 104% to 119% for JWH-250. Bias for all samples were ± 20% of the target value 
with the exception of one tissue lot that demonstrated 130% bias for CP47,497.  
Sample carryover was assessed using two different procedures. First, 
immediately following the injection of the 2000 ng/g calibrator, a negative control was 
injected. No carryover was detected in the negative control.  Second, an injection of the 
HQC (1600 ng/g) was immediately followed by injection of the LQC (60 ng/g) sample.  
This procedure was routinely applied each time HQC and LQC samples were analyzed.  
Lack of carryover was confirmed, as the SCB LQC concentration bias was less than 
20% of the LQC’s target concentration. 
Data in Table V demonstrate that CP47,497 is unstable after 72 hours at room 
temperature, with the MQC (300 ng/g) and LQC (60 ng/g) samples exhibiting only 56% 
and 74% of their target values, respectively. Stability of CP47,497, CP47,497-C8 and 
JWH-250 were unaffected by freeze/thaw treatment, and were considered acceptable 
as all QC samples were within ± 20% of the target concentration. JWH-250 and 
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CP47,497 QC samples were stable short-term (4° C), demonstrating values ± 20% of 
the target concentration. However, CP47,497-C8 fortified QCs exhibited significant 
analyte loss at all levels tested (Table V). All processed QC samples tested satisfied 
this criterion of ± 20% of the target concentration as seen in Table V. Finally, both ISTD 
and drug stock solutions were stable at room temperature for up to 6 hours, with all CV 
values within ± 15%.  
Table V
Post-Preparative, Benchtop, Freeze/Thaw and Short-Term Stability of CP-47,497, CP-47,497-C8 and JWH-250 in mouse brain.
Results are expressed as the % target value ± SD (%CV); n = 6
Analyte Sample Post-preperative (72 h) Benchtop (72 h) Freeze/Thaw (3X) Month (4° C)
 JWH-250 LQC (60 ng/g) 98 ± 6.7 (11) 116 ± 1.9 (3) 118 ± 1. (2) 116 ± 6.5 (9)
MQC (300 ng/g) 102 ± 41 (13) 111 ± 25 (7) 113 ± 18 (5) 105 ± 16 (5)
HQC (1600 ng/g) 80 ± 141 (11) 107 ± 107 (6) 113 ± 73 (4) 91 ± 67 (5)
DQC (400 ng/g) 87 ± 31 (9)
 LOQ (20 ng/g) 95 ± 2.3 (12)
CP47,497 LQC (60 ng/g) 111 ± 5 (7) 85 ± 14 (27) 107 ± 2.2 (3) 105 ± 3.5 (6)
MQC (300 ng/g) 117 ± 18 (5) 56 ± 44 (26) 103 ± 26 (8) 92 ± 33 (12)
HQC (1600 ng/g) 113 ± 134 (7) 74 ± 101 (9) 100 ± 140 (9) 92 ± 137 (9)
DQC (400 ng/g) 102 ± 53 (13)
LOQ (20 ng/g) 100 ± 2.7 (13)
CP47,497-C8 LQC (60 ng/g) 102 ± 6 (9) 84 ± 7.3 (15) 98 ± 8.3 (14) 50 ± 8.1 (27)
MQC (300 ng/g) 105 ± 33 (11) 97 ± 43 (12) 98 ± 25 (8) 58 ± 18 (10)
HQC (1600 ng/g) 98 ± 167 (11) 91 ± 98 (7) 102 ± 150 (9) 68 ± 115 (11)
DQC (400 ng/g) 95 ± 43 (11)
LOQ (20 ng/g) 97 ± 2.2 (11)
LOQ, limit of quantitation; LQC, low quality control; MQC, medium quality control; HQC, high quality control 
DQC, dilution quality control; CV, coefficient of variation
Stability Parameter
 
Application of method to animal samples 
Table VI illustrates locomotor activity (5-15 minutes post-injection), catalepsy, 
antinociception and temperature data (each taken at 30 min post-injection) with 
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corresponding brain concentrations (60 min post-injection) after a 30 mg/kg challenge of 
CP47,497 (Table VII). Drug-treated mice exhibited significant (p < 0.05) decreases in 
locomotor activity, expressed as number of beam breaks, compared to vehicle-treated 
mice. Catalepsy and antinociception (%MPE) were not detected after vehicle treatment, 
whereas CP47-497-treated mice displayed statistically significant catalepsy and 
antinociception (p < 0.0001 and p < 0.05, respectively). Pre-treatment (i.e. baseline) 
means ± SEM for body temperature (°C) were 37.0 ± 0.3 for vehicle-treated and 37.5 ± 
0.3 for CP47,497-treated mice, demonstrating no significant differences in baseline 
measurements between vehicle and drug treated mice. CP47,497-treated mice showed 
significant (p < 0.001) hypothermia (i.e., a 6.9 ± 0.6 °C drop in temperature) compared 
to vehicle-treated (i.e., a 1.5 ± 0.4 °C increase in temperature) mice. Table VI illustrates 
the cannabimimetic behavioral effects observed from the same group of mice with 
corresponding brain concentrations of CP47,497 (Table VII) ranging from 1660 ng/g to 
1890 ng/g (mean 1804 ± 93 ng/g), with no analyte peaks detected in brains from 
vehicle-treated mice.  
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Table VI
Significant cannabimimetic effects in mice after CP47,497 (30 mg/kg) in measures of spontaneous activity, catalepsy, antinociception and 
body temperature. Values represent the mean (± SEM); n= 4-5 mice per group.  
Spontaneous Activity Catalepsy (s), Antinociception (MPE), Body temperature (°C),
Treatment  (beam breaks), mean ± SEM mean ± SEM mean ± SEM mean ± SEM
Vehicle (1:1:18) 601 ± 78 ND ND 1.3 ± 0.3
CP47,497 (30 mg/kg) 194 ± 120 50.7 ± 2.2 51 ± 14 -6.9 ±  0.3
p-value < 0.05 < 0.0001 < 0.05 < 0.0001
Pre-treatment (i.e. baseline) means ± SEM for temperature (°C) = 37.4 ± 0.2 vehicle-treated and 37.9 ± 0.2 CP47,497-treated mice. 
Baseline tail withdrawal latencies (s) for vehicle-treated were 1.5 ± 0.4 and 1.6 ± 0.3 for CP47,497-treated mice.
MPE: maximum percent effect (10 second cut-off); ND: none detected  
 
 
 
 
 
 
Table VII
Quantification of CP-47,497 (ng/g) in mouse brain 1-hour   
after vehicle or CP-47,497 (30 mg/kg) injection (i.p.) 
Animal Vehicle CP-47,497 
1 ND 1890
2 ND 1660
3 ND 1840
4 ND 1780
5 ND 1850
Data represents the mean (± SD), n = 5 mice per group
ND = none detected; i.p. = intraperitoneal
Treatment
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3.5 Discussion !
We have previously quantified JWH-018 in blood of mice exposed to synthetic 
cannabinoids in “Buzz” smoke (Haggerty et al. 2010; Wiebelhaus et al. 2012). Using the 
same LLE and HPLC/MS/MS parameters as the presented method, prior experiments 
demonstrated this analytical approach is capable of concurrently detecting THC, its 
carboxylic acid metabolite, JWH-073, JWH-250, JWH-398, CP47,497, and HU-210 in 
whole blood (Haggerty et al. 2010). Dresen et al. (Dresen et al. 2011) reported an 
HPLC/MS/MS method for detection of aminoalkylindole compounds in human serum 
using a LLE, with sensitivity ranging from 0.1 to 2.0 ng/mL. They concluded that 
cyclohexylphenyl-containing cannabimimetics should be analyzed by Gas 
Chromatography-Mass Spectrometry (GC-MS) methods, as both electrospray ionization 
and chemical ionization showed poor responses during method optimization. While our 
method used a less sensitive linear range, it was shown to be suitable for the objective 
of this study. Additionally, Kacinko et al. (Kacinko et al. 2011) published an 
HPLC/MS/MS method validation for quantification of JWH-018, JWH-073, JWH-019, but 
with only one transition ion found for JWH-250, reported this method was only 
appropriate for qualitative identification of this analyte. An HPLC/MS method was 
determined for the detection of twenty-five synthetic cannabinoid compounds, including 
CP47,497, CP47,497-C8 and JWH-250 in blood which required only a 100 µL sample 
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volume (Ammann et al. 2012). Similar to results presented in this study, significant 
matrix effects were seen with both CP47,497 (82-89%) and CP47,497-C8 (73-84%) in 
blood. Matrix effect experiments, summarized in Table IV, demonstrate that there were 
significant effects of ion suppression produced in brain specimens tested. 
We have previously reported the phenomenon of ion suppression in brain (Poklis 
et al. 2010) without adverse effects on the method validation, but a literature search 
provided no other data for ion suppression/enhancement effects of brain in HPLC 
systems. Data obtained from accuracy/bias studies, shown in Table II, along with 
assessment of SCB selectivity using 10 separate tissue lots (fortified with 60 ng/g of 
each analyte), for a total sample size of 30, provide evidence that the observed ion 
suppression does not affect other validation parameters. No peaks were detected that 
co-eluted with the analyte or ISTD peaks of interest in any of the 10 lots of brain, which 
demonstrates a lack of interference from endogenous components and solidifies 
selectivity of the assay. Importantly, the same pattern and magnitude of ion suppression 
was observed for each of the deuterated ISTDs (Table IV). Taken together, the ion 
suppression produced by endogenous brain components does not appear to affect the 
overall method validation. 
 Adverse effects of synthetic cannabinoids in humans are communicated primarily 
as case reports.  Thus, there is a gap in knowledge pertaining to synthetic cannabinoid 
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disposition and related toxicities. Mice were used for the present validation study in 
order to procure biological tissue and assess the pharmacological effects due to 
exposure of the synthetic cannabinoid, CP47-497. Following a 30 mg/kg injection of 
CP47,497, mice displayed cannabimimetic behavioral effects, consistent with CB1 
receptor activation (Compton et al. 1993), including a decrease in spontaneous 
locomotor activity with the presentation of catalepsy, antinociception and hypothermia 
as previously reported in our laboratory (Wiebelhaus et al. 2012) and in other 
laboratories (Wiley et al. 2012). These cannabimimetic behavioral results are in 
agreement with previously published reports of quantified SCB concentrations in brain 
after inhalation exposure (Wiebelhaus et al. 2012; Poklis, Amira, Wise, Wiebelhaus, 
Haggerty & Poklis 2012; Poklis, Amira, Wise, Wiebelhaus, Haggerty, Lichtman, et al. 
2012; Haggerty et al. 2010).    
 
3.6 Conclusion !
 The HPLC/MS/MS method validation presented herein is a straightforward, 
selective, and accurate method for the determination of three synthetic cannabinoid 
drugs belonging to the cyclohexylphenol and aminoalkylindole structural classes. The 
assay required a simple liquid-liquid extraction procedure before HPLC/MS/MS analysis. 
Importantly, this is the first full method validation of CP47,497, CP47,497-C8 and JWH-
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250 synthetic cannabinoid compounds in tissue. This study has important implications 
for preclinical research settings where it is pertinent to demonstrate that SCBs are 
present in the brain, bolstering support that cannabimimetic effects result from a CNS-
mediated mechanism of action. Additionally, providing a method to detect and quantify 
SCBs in brain may assist in further understanding the complex interplay between 
behavioral responses and SCB drugs, which is of particular interest in post-mortem or 
impaired driving cases where SCB use is suspected (Yeakel & Logan 2013). The 
development and validation of analytical methods for the detection and quantification of 
SCBs in complex biological matrices is critical for future investigation of the 
pharmacokinetic, pharmacodynamic and toxicological profiles of SCBs. Information 
garnered from animal studies will provide insight and lay the foundation necessary for 
approval of controlled human SCB studies, both which will provide invaluable 
knowledge for forensic toxicologists and law enforcement. 
 ! !!!
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Chapter 4 – Evaluation of in vitro and in vivo indices of CP47,497-
mediated effects  
4.1 Introduction  !
 Cannabis has been utilized for medicinal and recreational purposes for centuries 
and is still today the most commonly used illicit drug in the world (Schultes 1969; 
UNDOC 2013). However, much of our understanding of marijuana and specifically the 
primary psychoactive phytocannabinoid in cannabis, THC, has been elucidated over the 
last several decades due to the development and study of synthetic cannabinoids 
(SCBs), as reviewed in Chapters 1 and 2. Synthetic cannabinoids were first identified in 
Europe as designer drug components in herbal incense products through continuous 
surveillance of the illicit drug market (EMCDDA 2009; Lindigkeit et al. 2009; Ogata et al. 
2013; Uchiyama et al. 2009).  In 2009 in the U.S., the prototypical non-classical 
cannabinoid, CP47,497 was one of the first synthetic cannabinoid drugs detected as a 
powdered material confiscated by the Wisconsin state police (The Drug Enforcement 
Administration 2009).  
 CP47,497 was synthesized by Pfizer in the 1970’s and in contrast to THC, 
CP47,497 is a high affinity CB1 receptor agonist (Ki = 40.2 ± 0.47 nM versus Ki = 2.2 ± 
0.47 nM, respectively) (Compton, Johnson, et al. 1992; Compton et al. 1993; Melvin et 
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al. 1984; Melvin et al. 1993; Weissman et al. 1982). Initial studies demonstrated the 
analgesic activity of CP47,497 was equipotent to morphine across several pain models 
in mice and rats, and from this work it was established that the benzopyran ring of THC 
and related analogs are nonessential for analgesic activity (Melvin et al. 1984; Melvin et 
al. 1993; Weissman et al. 1982). 
 Although these SCB compounds were designated specifically for research 
purposes, SCBs have emerged as drugs of abuse, yet very few published studies have 
reported the pharmacological consequences of these compounds in controlled 
laboratory studies. This dissertation was specifically focused on studying the behavioral 
consequences of CP47,497 administration, as it is both known to bind at the CB1 
receptor and has been identified in biological specimens from clinical and toxicology 
reports, confirming its abuse in humans (Heltsley et al. 2012; Yeakel & Logan 2013).  
Importantly, in the time since the initial CP47,497 pharmacological studies were 
published, new research tools have been developed to investigate the mechanism of 
action including a selective CB1 receptor antagonist (rimonabant, or SR141617A) 
(Compton et al. 1996; Rinaldi-Carmona et al. 1994; Rinaldi-carmona et al. 1995) and 
genetically modified mice devoid of the CB1 receptor (Ledent et al. 1999; Zimmer et al. 
1999).  
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 Studies from our laboratory and other laboratories support the ability of 
cannabinoids to produce dose-dependent cataleptic, antinociceptive, hypothermic, and 
hypolocomotor effects in rodents (Agarwal et al. 2007; Cravatt et al. 2001; Lichtman et 
al. 1996; Martin et al. 1995; Meng et al. 1998; Monory et al. 2007; Varvel et al. 2006; 
Wiley et al. 2005). Additionally, CB1 binding information for most synthetic cannabinoids 
has been published and illustrate that in vitro binding affinity of cannabinoid agonists is 
a reliable predictor of observing cannabimimetic effects in vivo (Compton, Gold, et al. 
1992; Compton, Johnson, et al. 1992; Huffman et al. 1994; Huffman et al. 2005; Little et 
al. 1988; Wiley et al. 1998). Based on this correlate, and reports that CP47,497 is a 
higher affinity agonist compared to THC (Compton et al. 1993; Melvin et al. 1993), we 
predict that CP47,497 will demonstrate enhanced potency versus THC in behavioral 
assays, and this will be achieved through a CB1 receptor mediated mechanism. 
Therefore, similar to THC, CP47,497 poses a significant and perhaps, greater, risk for 
abuse, tolerance, and dependence. Moreover, the abuse of potent synthetic 
cannabinoids such as CP47,497 as “legal” THC substitutes may be very hazardous to 
public health and further scientific evaluation is required to understand consequences of 
use in humans. 
 The purpose of the present study was to examine in vitro and in vivo 
pharmacological effects of CP47,497 relative to THC. To do so, CP47,497 was tested in 
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assays capable of predicting abuse liability including activation of CB1 receptors 
(Compton et al. 1993; Wiley et al. 1998), evaluation of cannabimimetic activity in the 
tetrad (Compton, Johnson, et al. 1992; Little et al. 1988; Martin et al. 1991), and 
interrogation of CP47,497 subjective effects in mice trained to discriminate THC from 
vehicle (Järbe & Henriksson 1974; Justinova et al. 2003; Wiley, et al. 2011). Tolerance 
to cannabimimetic behavioral effects was evaluated after repeated administration of 
CP47,497, and additionally, cross-tolerance to CP55,940 and THC was explored. Lastly, 
mice repeatedly treated with CP47,497 were tested for the development of physical 
dependence, assessed by somatic withdrawal signs upon challenge with CB1 antagonist 
treatment. The studies herein will improve basic scientific knowledge of the acute 
pharmacological effects of the synthetic cannabinoid compound CP47,497, provided 
insight into its mechanism of action, and set the framework for further evaluating the 
behavioral consequences following chronic abuse (i.e., tolerance development and 
dependence liability).  
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4.2 Materials and Methods !
Subjects 
 Drug naïve, male, ICR (CD-1) mice (Harlan Laboratories, Dublin, VA) weighing 
22-32 grams (g) were obtained for use in cumulative dose-response, time-course, 
antagonism, tolerance, and withdrawal experiments. Male and female, CB1 (-/-) and CB1 
(+/+) mice (19-27 g) backcrossed at least 13 generations onto a C57BL/6J background 
were obtained from the Transgenic Colony at Virginia Commonwealth University (VCU). 
Male, C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) weighing 20–25 g were 
utilized in drug discrimination and cumulative dose-response experiments as described 
below.   
 Mice were housed in clear plastic cages in VCU’s temperature-controlled (22 ± 
2 °C) animal care facility on a 12-hour light/dark cycle with ad libitum water and 
standard rodent chow (7012 Teklad Mouse/Rat Diet, Harlan Laboratories), unless 
otherwise described. Mice were individually housed the day prior to behavioral testing 
for acute dosing and drug discrimination experiments, and housed 4-6 mice per cage for 
repeated administration (tolerance and dependence) experiments.  
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Drugs and Chemicals 
  CP47,497 was purchased from Cayman Chemical (Ann Arbor, MI), CP55,940 
from Tocris Bioscience (Minneapolis, MN), and THC and rimonabant were obtained 
from the National Institute of Drug Abuse (NIDA) Drug Supply Program (Rockville, MD). 
All vehicle (ethanol:emulphor:saline in a ratio of 1:1:18) and drug (CP47,497, THC, 
CP55,940 and rimonabant; i.p. or s.c.) injections were administered at a volume of 0.1 
mL per 10 g of body mass. For acute studies, mice (ICR, C57BL6/J, CB1(-/-) and CB1(+/+))  
received drug treatment via intraperitoneal injections. In antagonist and precipitated-
withdrawal studies, rimonabant was delivered subcutaneously (3 and 10 mg/kg). For 
drug-discrimination and tolerance and dependence experiments, C57BL6/J and ICR 
mice, respectively, received vehicle, CP47,497, THC and CP55,940 drug treatments via 
subcutaneous route of administration.  
 For binding studies, [35S]-GTPγS (1250 Ci/mmol) was purchased from 
PerkinElmer (Waltham, MA), scintillation fluid (ScintiSafe Econo 1) and Whatman GF/B 
glass fiber filters from Fisher Scientific (Pittsburgh, PA); and GDP, GTPγS, adenosine 
deaminase, and serum albumin (BSA) from Sigma-Aldrich (St. Louis, MO). 
Agonist-Stimulated [35S]- GTPγS Binding in Brain   
 
 Effects of CP47,497, CP47-497-C8 and JWH-250 compounds on 
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G-protein coupled signal transduction were investigated using agonist-stimulated 
guanosine-5’-O-(3-[35(S]thiotriphosphate) ([35S]- GTPγS) activation. For each 
experiment, whole brain tissue was thawed from frozen storage (-80 °C) and 
homogenized in membrane buffer (50 mM Tris-HCl, 3 mM MgCl2, 1 mM EGTA, pH 7.4), 
with resultant homogenates centrifuged at 50,000 x g for 10 min at 4°C. The 
supernatant was discarded and pellets were suspended with 5 mL of assay Buffer A (50 
mM Tris-HCl, 3 mM MgCl2, 0.2 mM EGTA, 100 mM NaCl, pH 7.4) with protein 
concentration determined by ultraviolet spectrophotometry. Samples were incubated for 
15 minutes at 30 °C with adenosine deaminase (3 mU/ml), to limit basal activity by 
adenosine receptors. Concentration-effect curves were constructed by incubating 5 μg 
of membrane protein in assay while adding increasing concentrations of CP55,940 
(0.001 μM to 30 μM), CP47,497 (0.0001 μM to 30 μM), CP47,497-C8 (0.0001 μM to 30 
μM), and JWH-250 (0.0003 μM to 30 μM). Next, 30 μM GDP, 0.1 nM [35S]-GTPγS and 
assay Buffer B (50 mM Tris-HCl, 3 mM MgCl2, 0.2 mM EGTA, 100 mM NaCl, pH 7.4, 
and 1.25 g/L BSA) were added to a total volume of 0.5 mL. Nonspecific binding of 
membrane preparations was assessed in the presence of 20 μM unlabeled GTPγS, with 
basal activity determined in the absence of agonist.  Samples were vortexed and the 
reaction (30°C) was terminated after 2 hours by rapid vacuum filtration through 
Whatman G/FB glass fiber filters, followed by three rinses in Tris buffer (50 mM Tris-
HCl, pH 7.4, 4°C). Bound radioactivity was determined in triplicate after a 10-hour 
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extraction of filters in ScintiSafe Econo 1 scintillation fluid using liquid scintillation 
spectrophotometry as previously described (Falenski et al. 2010). 
 
Tetrad Behavioral Assessment  
 Mice were acclimated to the test environment for at least 1 h prior to testing for 
tetrad components: spontaneous activity, catalepsy, antinociception, and hypothermia 
(Martin et al. 1991; Wiley 2003). For all locomotor studies, five minutes after vehicle or 
drug treatment, mice were placed into clear acrylic boxes (approximately 44.5 cm x 
22.25 cm x 20.0 cm) contained within sound-attenuating cabinets equipped with an LED 
light source and fans for general air circulation and creation of white noise (customized 
and constructed at VCU) five minutes after vehicle or drug treatment. The distance 
traveled (meters) and time spent immobile (seconds) for each mouse was collected and 
recorded for 10 minutes using Fire-i™ digital cameras purchased from Unibrain (San 
Ramon, CA) and ANY-maze™ video tracking software purchased from Stoelting 
Company (Wood Dale, IL).  
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Schematic 4.1 – Timeline of acute drug treatment and behavioral testing in mice  
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 Thirty minutes after vehicle or drug treatment, mice were assessed for catalepsy, 
followed by antinociception, and finally, hypothermia (see Figure 1.4 and Schematic 
4.1). Catalepsy was measured using the horizontal bar test in which both forelimbs of 
the mouse were placed on a horizontal bar (approximately 1.25 cm in diameter and 4.45 
cm parallel to the bench top), with the duration of a fixed and motionless posture (except 
normal breathing) recorded by stopwatch over a 60 second interval.  Antinociception 
was determined by warm water (52 °C) tail immersion whereby the distal end 
(approximately 1 cm) of the tail was immersed in the water bath and the latency of the 
mouse to withdrawal its tail recorded (to the nearest tenth of a second). A 10 second 
cut-off was used to minimize tail damage. Antinociception data was transformed to 
represent a maximum percent effect (%MPE) by the following formula: %MPE = [(test 
latency − pretreatment latency)/(10−pretreatment latency)] × 100. Body temperature 
measurements (recorded to the nearest 0.1 °C) were collected by inserting a rectal 
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probe, lubricated with mineral oil and attached to a telethermometer (Yellow Spring 
Industries Inc., Yellow Springs, OH), to a 2 cm depth.  
 
Cumulative Dose-Response Studies 
 A cumulative dosing-paradigm was used to construct dose-response curves. ICR 
mice received increasing doses of drug (CP47,497 or THC) or repeated vehicle every 
40 minutes, with behavioral testing performed 30 minutes after each injection. 
Therefore, results represent catalepsy, antinociception and hypothermia observations 
30 minutes after each of the respective cumulative doses of CP47,497 (0.3, 1, 3, 10, 
and 30 mg/kg) and THC (3, 10, 30, 100 and 200 mg/kg). For example, 30 minutes after 
the cumulative dose of 30 mg/kg CP47,497 was injected at 160 minutes, behavioral 
assessment will be performed the 190 minute time point (see Schematic 4.2 below). 
 
Acute Drug Administration Studies 
 For acute drug administration studies, ICR mice received CP47,497 (30 mg/kg) 
or THC (100 mg/kg THC), which approximate the ED50 value calculated from 
antinociception dose-response experiments. The treatment doses (30 mg/kg CP47,497 
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and 100 mg/kg THC) were chosen based on calculated ED84 values derived from linear 
regression analysis of antinociceptive data (see Results, Figure 4.2). For antagonism 
studies, ICR mice received by subcutaneous (s.c.) injection either 3 or 10 mg/kg 
rimonabant 10-minutes before test drug, and were assessed in the tetrad as previously 
described. For tetrad dose-response evaluation of CP47,497 in C57BL6/J mice, single 
injections of 1, 3.2, and 10 mg/kg (i.p.) were administered, followed by tetrad testing as 
described. In complimentary receptor studies, CB1(-/-) and CB1(+/+) mice received vehicle 
or 30 mg/kg CP47,497 and were tested for tetrad behaviors as described. 
 
Schematic 4.2 – Cumulative drug dosing and behavioral assessment timeline   
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Behavioral Evaluation of Somatic Withdrawal Signs 
 
 For dependence experiments, mice received CP47,497 (15 mg/kg), CP55,940 (2 
mg/kg) or THC (50 mg/kg) twice daily (approximately 0900 and 1700 hours (h)) for 5.5 
days, delivered subcutaneously. Half of the ED84 dose used for the acute experiments 
was administered during repeated administration experiments for CP47,497 and THC, 
and the dose of CP55,940 was chosen based on previously established literature 
examining tolerance of repeated CP55,940 administration in ICR mice (Fan et al. 1994; 
Fan et al. 1996). The same acrylic boxes and cabinets described for locomotor 
assessment were utilized. After final drug administration (day 6, 0900 h injection), mice 
were acclimated for 30 minutes to behavioral chambers, which consisted of an opaque 
acrylic box (20 x 20 x 20 cm), equipped with a clear front panel and mirrored back 
panel, enclosed inside of activity cabinets. After the 30-minute period, mice were 
removed from chambers, received rimonabant (10 mg/kg, i.p.), and were then 
immediately placed back into their boxes for a 1-hour observation period. The acrylic 
boxes were cleaned with water after the acclimation but before the observation period to 
remove urine and feces present. Somatic withdrawal signs (paw 
flutters/tremors/clapping, headshakes, and jumping) were captured through the clear 
front acrylic panel (and by mirrored reflection of the backside of box) by Fire-i™ digital 
cameras, and recorded by ANY-maze™ digital tracking software for one hour. Somatic 
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withdrawal signs were observed and scored by a researcher blinded to experimental 
treatment. 
  
Tolerance Experiments 
 
 The ability of CP47,497 to produce tolerance and/or cross-tolerance to catalepsy, 
antinociception and hypothermia was assessed by treating mice with CP47,497 (15 
mg/kg), CP55,940 (2 mg/kg) or THC (50 mg/kg THC) twice daily for five and a half days, 
with a cumulative CP47,497 (1, 3, 10, 30 and 56 mg/kg) dose-response regimen 
administered on day seven, 24-hours (to allow drug washout) after the last morning 
dose on day six. 
 
Drug Discrimination Assay 
 C57BL/6J mice were maintained at 85–90% of free feeding body weight by 
restricting daily ration of standard rodent chow, with ad libitum water available except 
during training and testing sessions. Training and test sessions were conducted at 
similar times during the light phase of a 12 h light/dark cycle. Sound- and light-
attenuated mouse operant conditioning chambers (MED Associates, St. Albans, VT) 
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were used for behavioral training and testing; each chamber housed an acrylic operant 
box (18 x 18 x 18 cm) equipped with a house light and two nose poke apertures (left 
and right) with a recessed well between the two apertures (pictured in Appendix II). 
Houselights were illuminated during all operant sessions and fan motors provided 
ventilation and masked outside noise. A computer with Logic ‘‘1’’ interface and MED-PC 
software (MED Associates) controlled contingency schedules and data recording. Mice 
were trained to respond in one aperture following administration of 5.6 mg/kg THC, and 
to respond in the opposite aperture following vehicle administration (Figure 4.1).  A 
sweetened pellet served as reinforcement and was delivered on a fixed-ratio 10 (FR10) 
schedule. Each incorrect response reset the FR requirement. Daily 15-min training 
sessions were performed Monday–Friday with dosing following a double alternation 
sequence of drug or vehicle (e.g., drug, drug, vehicle, vehicle) until mice met two criteria 
during nine of 10 consecutive sessions: (criterion i) correct completion of the first FR10 
(e.g., first 10 consecutive responses on condition appropriate aperture) and (criterion ii) 
>80% of the total condition (drug or vehicle) appropriate responding. During test 
sessions, responses in either aperture delivered reinforcement according to an FR10 
schedule. When these two criteria were met, acquisition of the discrimination was 
established and substitution testing began. Stimulus substitution tests were conducted 
on Tuesdays and Fridays during 15-min test sessions with training continued on 
remaining weekdays. Control tests were conducted with the training dose of the drug 
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(5.6 mg/kg THC) or vehicle. For substitution tests, CP47,497 was administered 
subcutaneously (doses of 0.03, 0.1, 0.3, 1 and 3.2 mg/kg) 30 minutes before the test 
session.  
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Figure 4.1 – Drug discrimination paradigm assays the subjective effects of drugs. C57BL/6J mice were 
trained to respond in one aperture following administration of 5.6 mg/kg THC and to respond in the 
opposite aperture following CP47,497 administration. During training sessions (a,b), reinforcement is 
provided for responses on treatment-appropriate lever; in contrast, reinforcement is delivered on either 
lever pressed during test sessions (c). Image adapted from (Solinas et al. 2006). 
   
Drug Extraction and Analysis from Biological Specimens 
  
 Blood, collected via cardiac puncture, and brain specimens were harvested one 
hour after drug administration unless otherwise stated, and placed in frozen storage      
(-80 °C) until analysis. Samples were thawed, homogenized if necessary, then extracted 
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and quantified by HPLC/MS/MS as described in Chapter 3, Materials and Methods 
section.  
Data Analysis and Statistics 
 
 Unless specifically stated otherwise, presented data are reported as mean (± 
SEM). Experimental data were analyzed by one- and two- way analysis of variance 
(ANOVA) with time, treatment, dose or genotype as between-subjects factors, where 
appropriate. Significant (p < 0.05) ANOVAs were followed by Bonferroni’s post-hoc test, 
unless stated otherwise, and used to make multiple comparisons to establish dose-
dependency and evaluate effects between agonist drug treatments. In drug-
discrimination studies, Dunnett’s post-hoc analysis was used to make comparisons 
versus control. Determination of ED50 values and 95% confidence limits (CL) were 
calculated by standard linear regression analysis of generated drug dose-response 
curves. Following a method described by Colquhoun et al., potency ratio with 95% CL 
were determined by comparing potency between drug treatments groups (Colquhoun, 
1971). Significance was denoted for p-values less than 0.05 with all statistical analyses 
performed using GraphPad Prism® statistical software (Version 5.0; LA Jolla, CA). 
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4.3 Results !
4.3.1 CP47,497, CP47,497-C8, and JWH-250 are high efficacy partial agonists at 
the CB1 receptor !
 As with the HPLC/MS/MS validation studies in Chapter 3, we examined if 
representative cyclohexylphenol (CP47,497, CP47,497-C8) and aminoalkylindole (JWH-
250) compounds would activate G-protein receptors in a similar manner to THC using 
an in vitro functional assay.  The ability of the synthetic cannabinoids, CP47,497, 
CP47,497-C8, and JWH-250 to bind to CB1 receptors has been previously reported 
(Compton et al. 1993; Huffman et al. 2005; Melvin et al. 1993). However, fewer data 
have been published regarding the ability of these abused synthetic cannabinoids to 
stimulate G-proteins upon CB1 receptor activation (Gurney et al. 2014). Resultantly, we 
investigated receptor activation of G-proteins by CP47,497, CP47,497-C8, and JWH-
250 using CP55,940-stimulated [35S]-GTPγS (GTPγS) binding in mouse brain 
membrane preparations (Burkey, Quock, Consroe, Roeske, et al. 1997; Selley et al. 
1996). 
 Figure 4.2 illustrates that all three SCBs - CP47,497, its C8 homologue, and 
JWH-250 behave similar to CP55,940 as partial agonists with a high level of activity in 
the GTPyS assay, which has previously been described as a high efficacy partial 
agonist (Burkey, Quock, Consroe, Ehlert, et al. 1997; Devane et al. 1988). 
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Figure 4.2 – Effects of synthetic cannabinoid agonist stimulation of [35S]-GTPγS binding in 
whole brain membrane preparations. Concentration-effect curves of CP47,497 (circles), 
CP47,497-C8 (squares) and JWH-250 (triangles) represent mean ± SEM (Table 4.1) from 
triplicate analyses; n = 3 brains per treatment group.  
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 A two-way ANOVA revealed main effects for drug treatment [F(2,66) = 25.3, p < 
0.0001] and concentration [F(10,66) = 89.4, p < 0.0001], however, no significant drug 
treatment and concentration interaction effect was observed [F(20,66) = 1.3, p < 0.21]. 
One-way ANOVA with Bonferroni’s post-hoc analyses revealed significant differences 
between drug EC50 (50% effective-concentration) values [F(3,14) = 18.7, p < 0.0001]. 
CP47,497, its C8 homologue, and JWH-250 had EC50 values that were higher than 
CP55,940 (p < 0.05). Significant differences in EMax values were observed between 
drugs [F(3,14) = 4.1, p < 0.03]. And the post-hoc analysis revealed CP47,497-C8 had 
an EMax significantly higher than CP55,940 (p < 0.05). 
 
Table 4.1 – Emax and EC50 values of SCB agonist-stimulated [35S]-GTPγS in brain 
membranes. Data represent mean ± SEM, from n = 3 experiments in triplicate.    
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Table 4.2 – Mean ± SEM data from SCB agonist stimulated [35S]-GTPγS binding 
experiments; values represent normalization to % stimulation of CP55,940 (Panel A) 
and calculated % stimulation for each analyte (Panel B). 
 
[Drug]'(μM) Mean SEM Mean SEM Mean SEM Mean SEM
0.0001 44 44 2.10 2.55 3.02 7.94 44 44
0.0003 44 44 2.47 1.60 40.54 1.13 0.03 2.58
0.001 13.51 5.30 6.20 3.01 11.31 5.21 11.32 2.35
0.003 20.95 2.60 40.21 0.81 1.99 1.33 10.16 3.51
0.01 30.44 3.99 2.81 1.22 9.47 4.12 14.05 12.33
0.03 49.43 4.66 17.80 3.34 23.05 4.00 18.09 10.39
0.1 60.35 4.50 26.50 1.44 48.65 3.63 34.83 10.29
0.3 69.60 5.43 39.71 3.97 62.52 2.19 47.72 5.83
1 71.01 4.96 53.69 3.36 72.16 3.55 58.05 5.78
3 77.88 7.85 53.35 3.86 73.67 2.42 62.01 5.07
10 74.71 4.95 69.18 7.48 94.59 3.74 71.02 6.41
30 71.69 2.83 61.69 1.76 84.54 7.60 61.20 2.78
n 9 9 3 3 3 3 3 3
CP47,497 CP47,497'C8 JWH'250CP55,940
[Drug]'(μM) Mean SEM Mean SEM Mean SEM
0.0001 2.27 2.76 3.70 9.72 99 99
0.0003 4.61 0.55 90.65 1.38 0.05 3.74
0.001 10.47 1.85 13.84 6.38 16.44 3.41
0.003 90.78 1.01 2.43 1.63 14.76 5.10
0.01 1.62 1.19 11.59 5.04 20.42 17.91
0.03 15.32 3.14 28.22 4.90 26.28 15.09
0.1 29.86 1.76 59.56 4.44 50.61 14.95
0.3 47.59 0.76 76.52 2.68 69.34 8.47
1 61.85 3.51 88.33 4.35 84.34 8.40
3 62.42 3.26 90.17 2.96 90.09 7.37
10 81.66 8.95 115.79 4.58 103.19 9.31
30 68.26 2.14 103.48 9.31 88.92 4.05
n 3 3 3 3 3 3
CP47,497 CP47,497'C8 JWH'250A"
B"
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4.3.2 CP47,497 elicits potent cannabimimetic effects in mice !
 After establishing functional in vitro responses, studies using CP47,497 were 
designed to investigate the physiological effects in mice using well-established 
behavioral models. In the present study, we investigated whether CP47,497 produces 
dose- and time-dependent cannabimimetic effects. Figure 4.3 depicts that cumulative 
vehicle dosing (5 total injections) alone did not produce cannabimimetic behavioral 
effects in any of the behavioral outcome measures. Acute CP47,497 treatment 
produced significant catalepsy [F (5,35) = 91.6, p < 0.0001] (Figure 4.3, Panel A), as 
administration of 3, 10, and 30 mg/kg produced significant increases in catalepsy 
compared to vehicle (Veh) (p < 0.05). Additionally, 10 and 30 mg/kg induced 
significantly longer durations of catalepsy versus 3 mg/kg (p < 0.05). Congruent with 
previous literature (Compton, Johnson, et al. 1992; Compton et al. 1996; Martin et al. 
1991; Monory et al. 2007; Weissman et al. 1982; Zimmer et al. 1999), THC treatments 
(30, 100, and 200 mg/kg) significantly induced catalepsy compared to vehicle treatment 
[F (5,35) = 2.7, p < 0.0001]. Furthermore, 30 mg/kg THC resulted in a significantly lower 
duration of catalepsy than 100 and 200 mg/kg (p < 0.05). These data demonstrate a 
dose-dependent relationship for CP47,497 and THC cataleptic effects. Comparison 
between CP47,497- and THC-induced catalepsy revealed a potency ratio of 7.2 (5.4- 
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9.6; 95% confidence limits (CL)), calculated from ED50 values; CP47,497 had an ED50 of 
4.7 (3.8-5.9) mg/kg and THC had an ED50 of 33.8 (26.1-43.7) mg/kg. Drug effects for 
CP47,497-induced catalepsy were significantly higher than the THC-treated group at 3 
mg/kg (p < 0.0001), 10 mg/kg (p < 0.0001) and 30 mg/kg (p < 0.01). 
 Antinociceptive data in Figure 4.3, Panel B, illustrate a significant effect [F (5,35) 
= 24.8, p < 0.0001], but only the highest CP47,497 dose tested, 30 mg/kg, significantly 
increased antinociception as compared to vehicle-treated mice. Dose-dependent 
antinociceptive effects were not observed for CP47,497, as no differences were 
observed versus vehicle for doses less than 30 mg/kg tested; however, 30 mg/kg 
CP47,497 produced significantly increased antinociception versus all other doses tested 
(p<0.05). Conversely, 30, 100, and 200 mg/kg THC doses significantly increased 
antinociception compared to vehicle [F (5,35) = 9.80, p < 0.0001]. Additionally, 100 and 
200 mg/kg THC resulted in significantly higher levels of antinociception compared to 10 
mg/kg (p < 0.05). Between drug comparisons showed that 30 mg/kg CP47,497 
produced significantly more antinociception than THC (p < 0.0001) (Figure 4.3, Panel 
B). 
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Figure 4.3 – CP47,497 and THC dose-responsiveness for catalepsy, antinociception, and 
hypothermia outcome measures. At the doses tested, both CP47,497 and THC produced 
dose-dependent effects of catalepsy in the horizontal bar test (A) and hypothermia (C). Significant 
antinociceptive effects in the warm water tail withdrawal assay were observed at the highest doses of 
CP47,497 and THC tested (B). Leftward shift in the catalepsy and hypothermia dose-response curves of 
CP47,497 (circles) from THC (squares) indicate increased potency of CP47,497 with calculated potency-
ratios and 95% confidence limits of 7.2 (5.4- 9.6) and 7.7 (4.6-12.8), respectively. As THC antinociceptive 
data lacked a complete dose-response range at the doses tested, ED50 values and potency ratio could not 
be calculated. Filled symbols denote significance versus vehicle (p < 0.05); *p < 0.05 versus 3 mg/kg, $p 
< 0.05 versus 10 mg/kg, #p < 0.05 versus 30 mg/kg. n = 8 per group. Pre-treatment (i.e. baseline) means 
± SEM for tail withdrawal latencies (s) for vehicle-treated mice were 2.0 ± 0.2, 2.6 ± 0.3 for CP47,497-
treated mice, and 2.0 ± 0.1 for THC-treated mice. Baseline temperatures (°C) were 37.7 ± 0.2 for vehicle-
treated, 37.1 ± 0.2 for CP47,497-treated, and 36.9 ± 0.1 for THC-treated mice. 
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The antinociceptive ED50 value for CP47,497 was 26.2 (11.0 - 62.0) mg/kg.  Since the 
doses of THC tested did not produce a 50% maximum effect, an ED50 value and 
potency ratio for THC could not be calculated.  
 CP47,497 produced significant hypothermic effects at 10 and 30 mg/kg doses 
compared to vehicle [F (5,35) = 55.42, p < 0.0001], with 10 mg/kg producing 
significantly less hypothermia than 30 mg/kg (p<0.05) (Figure 4.3, Panel C). Similar to 
catalepsy and antinociception measures, THC (30,100, and 200 mg/kg) produced 
significant hypothermia versus vehicle [F (5,35) = 29.81, p < 0.0001], with 30 mg/kg 
producing significantly less hypothermia than 200 mg/kg THC (p<0.05). The potency 
ratio (95% confidence limits) for hypothermia was 7.7 (4.6-12.8) with a calculated ED50 
of 12.1 (7.5-19.6) mg/kg for CP47,497 and an ED50 of 110.1 (69.7-172.7) mg/kg for THC. 
Determination of ED50 and potency ratio for hypothermia data were calculated using and 
Emax of -6 °C, which represents the maximal mean decrease in temperature from the 
CP47,497-treated group. Between drug comparisons revealed that CP47,497 produced 
significantly more hypothermia than THC at 10 mg/kg (p < 0.0001), and 30 mg/kg (p < 
0.0001). 
4.3.3 Cannabimimetic duration of action of CP47,497 is similar to THC !
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 Next, we sought to examine if the potent effects of CP47,497 were maintained 
over time, with particular interest in comparison to the temporal effects of THC. In these 
studies, mice received a single bolus dose of CP47,497 (30 mg/kg), THC (100 mg/kg) or 
vehicle with measurements taken at 0.5, 1, 2, 4, 8, 12 and 24 hours. Drug doses were 
selected from dose-response experiments as described in Materials and Methods 
(Section 4.2). 
 CP47,497 showed significant effects of time [F(6,126) = 201.4], dose [F(2,126) = 
81.7] and a significant interaction between time and dose [F(12,126) = 78.2], for 
catalepsy (p < 0.0001) (Figure 4.4, Panel A). CP47,497 significantly increased 
catalepsy at 2 and 4 hours versus THC (p < 0.05).  Both CP47,497 and THC induced 
significant catalepsy at 0.5, 1, 2, 4, and 8 hours versus vehicle (p < 0.0001). CP47,497 
(Figure 4.4, Panel B) showed significant increases in antinociception across time 
[F(6,120) = 23.9, p < 0.0001], dose [F(2,120) = 13.1, p = 0.0002], and there was a 
significant interaction between time and dose [F(12,120) = 5.4, p < 0.0001]. Bonferroni’s 
correction revealed that antinociception was produced by CP47,497 at 0.5, 1, 2 (p< 
0.0001), and 4 hours (p < 0.01), and by THC at 1, 2, and 4 hours (p< 0.01). Finally, 
CP47,497 elicited a transient increase in antinociception versus THC at 0.5 hours (p < 
0.05). Eight hours following drug administration, the nociceptive effects of the hot water 
bath were no different in CP47,497- and THC-treated mice compared to vehicle-treated 
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mice (p > 0.05). CP47,497-induced significant hypothermic effects across time [F(6,126) 
= 201.4], dose [F(2,126) = 81.7], and there was a significant interaction [F(12,126) = 
78.2] between time and dose (p < 0.0001) (Figure 4.4, Panel B). Both CP47,497 and 
THC caused significant hypothermia at 0.5, 1, 2  4 and 8 hours (p < 0.0001), compared 
to vehicle treatment.  
 One-way ANOVA for quantification of CP47,497 in blood revealed significant 
changes in concentration across the time points tested [F(5,13) = 9.63, p = 0.0005]. 
Specifically, blood concentrations of CP47,497 were significantly higher at 1 and 2 
hours versus circulating drug concentration at 8 hours (p < 0.05), and CP47,497 
concentrations were also significantly higher at 1 hour versus 4 hours (p < 0.05) (Figure 
4.4, Panel D). 
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!  Figure 4.4 – Temporal cannabimimetic effects of CP47,497 and THC were significant from vehicle 
beginning at 0.5 hours and persisted up to 8 hours, depending on individual measure (A, B, C).  Two-way 
repeated measures ANOVA revealed significant interaction effects for (A) catalepsy [F (12,108) = 29.49, 
p < 0.0001], (B) antinociception [F (12,120) = 5.39, p < 0.0001], and (C) hypothermia [F (12,126) = 78.16, 
p < 0.0001] which follow a similar pattern for CP47,497 drug concentrations in whole blood (D) quantified 
by HPLC/MS/MS. Time and treatment effects were also significant (p < 0.001). Filled circles denote 
significance from vehicle. #p < 0.05 versus THC; ^p < 0.05 versus 1 hour time point; &p < 0.05 versus 2 
hour time point. Data represent the mean ± SEM, n = 8 mice per group (A-C) or n = 2-4 mice per group 
(D). 
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4.3.4 CP47,497-induced catalepsy, antinociception, hypothermia and 
hypolocomotor effects are mediated by CB1 receptors 
 
 To determine if CP47,497-elicited cannabimimetic effects were mediated through 
a CB1 receptor mechanism, mice were pretreated with the selective CB1 antagonist, 
rimonabant (3 or 10 mg/kg, s.c.), 10-minutes before CP47,497 (30 mg/kg, i.p.) or THC 
(100 mg/kg, i.p.) administration and assessed in the tetrad (Schematic 4.1). 
Significance was determined by a two-way ANOVA with Bonferroni post-hoc utilized for 
multiple comparisons. Experiments were designed to investigate the ability of low dose 
(3 mg/kg) or high dose rimonabant (10 mg/kg) to attenuate agonist-induced behavioral 
effects.  
 Statistical assessment using antagonist and drug treatment as between subject 
factors, revealed significant effects of antagonist [F(2,69) = 122.90, p < 0.0001] and 
drug treatment [F(2,69) = 27.97, p < 0.0001] for the presence of catalepsy, with a 
significant interaction effect observed [F(4,69) = 33.35, p < 0.0001]. Figure 4.5, Panel A 
illustrates that CP47,497 and THC produced significant catalepsy versus vehicle 
controls (p < 0.0001). Both 3 mg/kg and 10 mg/kg rimonabant (Rim) pretreatment 
significantly reduced the development of CP47,497- and THC-induced (p < 0.0001) 
catalepsy, with no differences  
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Figure 4.5 – Antagonism of cannabimimetic effects by low dose and high dose rimonabant. 
Pretreatment with low (3 mg/kg) and high (10 mg/kg) dose rimonabant reversed cataleptic (A) and 
antinociceptive (B) effects elicited by both CP47,497 (30 mg/kg) and THC (100 mg/kg). Significant 
CP47,497- and THC-induced hypothermic effects were observed versus control, and each were dose-
dependently attenuated by rimonabant treatment (C). High dose, but not low dose rimonabant produced 
significant reversal of time immobile elicited by CP47,497 and THC (D). Compared to THC, administration 
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of CP47,497 caused a significant decrease in distance traveled, and was reversed by high dose 
rimonabant (E). Significance denoted *p < 0.05 versus Veh/Veh, $p < 0.05 vs. Veh/CP47,497, &p < 0.05 
versus Veh/THC, #p < 0.05 vs. Rimonabant(3)/Veh, %p<0.05 vs. Rimonabant(3)/CP47,497, and ^p < 
0.05 vs. Rimonabant(3)/THC. Data represent the mean ± SEM, n = 6-15 mice per group. Baseline means 
± SEM for tail withdrawal latencies (s) and temperature (°C) are listed in Table 4.3.  
 
observed between low and high dose rimonabant.  During evaluation of catalepsy, 50% 
of CP47,497-treated mice (8 of 16) demonstrated hyperreflexia (or  “popcorning”) 
(Dewey 1986), three of which met criteria for data exclusion; that is, a hyperreflexic 
response each of four attempts to place the mouse on the horizontal bar. In contrast, 
only 7.7% of THC-treated mice (1 of 13) exhibited hyperreflexia and this mouse was 
excluded from the data set.  
 The ability of rimonabant to antagonize antinociceptive effects of CP47,497 and 
THC was next investigated. A two-way ANOVA revealed significant effects of drug 
[F(2,73) = 12.29, p< 0.0001] and antagonist treatment [F(2,73) = 21.62, p < 0.0001], as 
well as a significant interaction effect between drug and antagonist pretreatment 
[F(4,73) = 4.86, p = 0.0016]. Significant antinociception (Figure 4.5, Panel B) was 
observed after CP47,497 and THC treatment, compared to vehicle controls (p < 0.0001). 
Pretreatment with 3 mg/kg or 10 mg/kg rimonabant reversed agonist-induced 
antinociception by CP47,497 (p < 0.001) and THC (p < 0.01). 
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 Rimonabant blocked the hypothermic effects of CP47,497 with significant effects 
observed for drug [F(2,75) = 96.86, p< 0.0001], and antagonist treatment [F(2,75) = 
109.7, p < 0.0001], accompanied by a significant interaction of drug and antagonist 
effect [F(4,75)= 36.88, p< 0.0001] (Figure 4.5, Panel C). Compared to vehicle-treated 
mice, significant, dose-related hypothermic effects were observed with both CP47,497 
and THC treatment (p < 0.0001) at 3 and 10 mg/kg rimonabant. Reversal of CP47,497- 
or THC-induced decreases in body temperature was observed with pretreatment of 3 
mg/kg and 10 mg/kg rimonabant (p < 0.0001). Furthermore, pretreatment by rimonabant 
produced significant dose-related antagonism of hypothermia in both CP47,497 (p < 
0.0001) and THC (p < 0.05) groups. 
 A two-way ANOVA of time immobile data, with antagonist and drug treatment as 
between subject factors, revealed main effects for antagonist [F(2,75) = 14.1, p < 
0.0001] and drug treatment [F(2,75) = 12.2, p < 0.0001], with a significant interaction 
effect [F(4,75)= 4.84, p < 0.01] (Figure 4.5, Panel D).  CP47,497 (p < 0.0001) and THC 
(p < 0.01) groups significantly increased time immobile, compared to vehicle treatment. 
CP47,497 treatment significantly increased time immobile compared to THC (p< 0.05). 
CP47,497 (p < 0.001) or THC (p < 0.05) groups pretreated by high dose rimonabant (10 
mg/kg) showed significant decreases in immobility from vehicle controls. 
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 Assessment of distance traveled revealed a significant main effect for antagonist 
treatment [F(2,75)= 16.9, p < 0.0001], but no significant differences were observed with 
drug treatment [F(2,75) = 0.6, p = 0.55] nor was there an interaction between antagonist 
and drug treatment [F(4,75) = 2.3, p = 0.06]. CP47,497-treated mice displayed 
significant decreases in distance traveled versus THC-treated mice (p < 0.05). 
Significant increases in distance traveled were observed in vehicle (p < 0.05) and THC 
(p < 0.01) treated groups receiving high dose rimonabant versus the low dose 
rimonabant control group. Lastly, high dose rimonabant significantly increased distance 
traveled in CP47,497-treated mice as compared to CP47,497-treated mice without 
antagonist pretreatment (p < 0.05).  
 
 
 
Table 4.3 – Baseline measurements for rimonabant antagonism experiments 
Drug Veha CP47,497b THCc Veh CP47,497 THC Veh CP47,497 THC
Mean 1.9 1.6 1.8 1.4 1.7 1.6 1.7 1.5 1.2
± SEM 0.3 0.2 0.2 0.2 0.2 0.2 0.4 0.3 0.2
Drug Veh CP47,497 THC Veh CP47,497 THC Veh CP47,497 THC
Mean 36.7 37.1 37.0 36.9 37.3 37.2 37.0 37.1 36.9
± SEM 0.1 0.2 0.1 0.1 0.3 0.2 0.1 0.2 0.2
aVehicle (1:1:18), bCP47,497 (30 mg/kg), cTHC (100 mg/kg)
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 To corroborate the pharmacological observations seen with the CB1-selective 
antagonist, rimonabant, studies were designed using mice genetically devoid of the CB1 
receptor (Zimmer et al. 1999). Age-matched CB1(-/-) mice and CB1(+/+) littermate mice 
were assessed in the tetrad after receiving an acute dose of CP47,497 (30 mg/kg, i.p.). 
CP47,497-treated mice showed significant increases in catalepsy [F(1,13) = 34.7, p < 
0.0001], antinociception [F(1,16) = 36.9, p < 0.0001], hypothermia [F(1,16) = 142.3, p < 
0.0001], and immobility [F(1,16) = 24.4, p= 0.0001], demonstrating significant 
cannabimetic effects compared to vehicle-treated mice (p < 0.0001) (Figure 4.6). 
CP47,497 treatment significantly decreased distance traveled [F(1,16) = 16.5, p = 
0.0009]. An interaction effect between CP47,497 treatment and genotype was observed 
[F(1,16) =31.04, p < 0.0001], but significant effects were not seen across genotypes 
[F(1,16) = 4.062]. 
 CB1(+/+) mice demonstrated significant increases in catalepsy [F(1,13) = 34.7, p < 
0.0001], antinociception [F(1,16) = 33.5, p < 0.0001], hypothermia [F(1,16) = 105.5, p < 
0.0001], and immobility [F(1,16) = 19.2, p = 0.0005], compared to CB1(-/-) mice, following 
CP47,497 administration. In fact, cannabimetic behavioral effects of CP47,497 were 
completely absent in CB1(-/-) mice, and no significant differences were seen between 
CP47,497-treated and vehicle-treated CB1(-/-) mice for any behavioral measure (p < 
0.001). During catalepsy testing, 67% of CP47,497-treated CB1(+/+) mice experienced 
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hyperreflexia, whereas this behavior was not displayed in CP47-497-treated CB1(-/-) mice. 
Lastly, significant interaction effect of drug and genotype were also observed for 
catalepsy [F(1,13) = 34.7, p < 0.0001], antinociception [F(1,16) = 33.1, p < 0.0001], 
hypothermia [F (1,16) = 89.2, p < 0.0001], and time immobile [F(1,16) = 29.3, p = 
0.0005]. 
 Quantification of CP47,497 in brain tissue suggested there was a trend toward 
higher drug concentrations in wild type mice with values quantified (mean ± SEM) for 
CB1(+/+) mice of 2575 ± 600 ng/g, and 1080 ± 120 ng/g in CB1(-/-) mice. However, 
statistical analyses revealed no significant differences in CP47,497 drug concentration 
in brains of CB1(+/+) mice versus CB1(-/-) mice, which were harvested one hour after 
treatment with an acute dose of 30 mg/kg CP47,497 [t = 2.4, df= 6, p = 0.0511). 
Table 4.4 – Baseline measurements in CB1 knockout experiments 
 
 
CB1 (+/+) CB1 (-/-) CB1 (+/+) CB1 (-/-)
Mean 1.8 2.4 2.5 1.9
± SEM 0.3 0.5 0.4 0.4
CB1 (+/+) CB1 (-/-) CB1 (+/+) CB1 (-/-)
Mean 37.1 36.8 36.8 37.0
± SEM 0.2 0.1 0.1 0.4
aVehicle (1:1:18), bCP47,497 (30 mg/kg)
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Figure 4.6 – CP47,497-induced effects of catalepsy (A), antinociception (B), hypothermia (C), and 
locomotor suppression (D, E) are abrogated in CB1(-/-) mice. Significant effects of treatment and 
genotype were observed in all measures tested, but no significant differences in brain concentrations of 
CP47,497 (F) were observed as quantified by HPLC/MS/MS. Data represent the mean ± SEM, n = 4 mice 
per CB1(-/-) group (male) and n = 6 mice per CB1(+/+) group (sexes collapsed within group). Significance 
denoted as *p < 0.0001 vs. vehicle-treated CB1(+/+) mice, #p < 0.0001 vs. CP47,497-treated CB1(-/-) mice 
and $p < 0.05 vs. vehicle-treated CB1(+/+) mice. Baseline means ± SEM for tail withdrawal latencies (s) and 
temperature (°C) are listed in Table 4.4.   
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4.3.5 CP47,497 potently substitutes for THC in the drug discrimination assay in 
C57BL6/J mice 
 
 Next, we evaluated whether CP47,497 would substitute for THC in the drug 
discrimination assay. These studies utilized C57BL6/J mice; therefore, a CP47,497 
dose-effect study using cannabimimetic tetrad measures was performed to establish a 
behaviorally active dose range for CP47,497 (Figure 4.7). In dose-response 
experiments, significant main effects were revealed for catalepsy in CP47,497-treated 
mice [F(3,8) = 21.9, p < 0.001], antinociception [F(3,8)= 34.0, p < 0.0001], hypothermia 
[F(3,8)= 44.6, p < 0.0001], time immobile [F(3,8)= 31.27, p < 0.0001] and distance 
traveled [F(5,55)= 9.9, p< 0.01] (Figure 4.7). The doses of 3.2 and 10 mg/kg CP47,497 
significantly increased catalepsy, hypothermia, time immobile, and significantly 
decreased distance traveled compared to vehicle-treated mice (p<0.05). Also, 1 and 3.2 
mg/kg CP47,497 produced significantly less antinociception than 10 mg/kg CP47,497 (p 
< 0.05), but only 10 mg/kg CP47,497 produced significant antinociception versus 
vehicle (p < 0.05). Hypothermia was significantly lower following the 3.2 mg/kg dose, 
compared to 10 mg/kg CP47,497 (p < 0.05). From these results, we concluded that a 
0.3 - 3.2 mg/kg dose range for CP47,497 would be sufficient to assess THC substitution 
in drug discrimination experiments while minimizing effects to normal motor activity.  
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 Prior to the start of drug discrimination studies, C57BL6/J mice were trained to 
discriminate 5.6 mg/kg THC from vehicle. Figure 4.8, Panel A illustrates that THC 
dose-dependently substituted for the training dose with an ED50 of 1.6 mg/kg (95% CL: 
1.2-2.1), with no observed decreases in response rates after vehicle treatment [F(5,55)= 
2.1, p=0.74] (Figure 4.8, Panel B). During non-test days, nose poke responding on the 
appropriate treatment-paired side were established in vehicle and THC-treated mice 
(the left side of Panel B, Figure 4.8). A one-way ANOVA with Dunnett’s post-hoc 
comparison revealed significant drug-like responding in THC-treated mice [F(5,55)=31.1, 
p<0.001] for 3, 5.6 and 10 mg/kg doses, compared to vehicle (p <0.001). Significant 
increases in drug-like responding were observed in CP47,497-treated mice 
[F(5,30)=19.5,  p <0.001], with 1 and 3.2 mg/kg doses significantly different than vehicle 
(p <0.0001). 
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Figure 4.7 – CP47,497 dose-response in C57BL6/J mice.  Significant effects of catalepsy (A), 
antinociception (B), hypothermia (C) and hypolocomotion (D,E) were observed after 3.2 or 10 mg/kg 
CP47,497 in C57BL6/J mice. Significance denoted *p < 0.05 versus vehicle, $p < 0.05 versus 1 mg/kg 
CP47,497, #p < 0.05 versus 3.2 mg/kg CP47,497, ^p < 0.05 versus 10 mg/kg CP47,497. Data represent 
the mean ± SEM, n = 3 mice per group. Baseline (means ± SEM) tail withdrawal latencies (s) for vehicle-
treated mice were 1.6 ± 0.2, 1.5 ± 0.1 for 1 mg/kg CP47,497-treated mice, 1.8 ± 0.2 for 3.2 mg/kg 
CP47,497-treated mice, and 1.7 ± 0.2 for 10 mg/kg CP47,497-treated mice. Baseline means ± SEM for 
temperature (°C)= 37.1 ± 0.3 for vehicle-treated, 37.0 ± 0.5 for 1 mg/kg CP47,497-treated mice, 37.0 ± 
0.1 for 3.2 mg/kg CP47,497-treated mice, and 37.4 ± 0.2 in 10 mg/kg CP47,497-treated mice. 
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 CP47,497-treatment substituted for THC as seen in Figure 4.8, Panel A and 
exhibited more than 4-fold higher potency than THC, with a corresponding ED50 value of 
0.26 mg/kg (95% CL: 0.15-0.45)]. Full substitution was observed at both 1 mg/kg and 3 
mg/kg of CP47,497, with a significant effect of drug on response rates [F(5,30)=4.23, 
p<0.01]. Post-hoc analyses indicated that response rates only at the highest dose 
tested, 3 mg/kg CP47,497, were significantly (p< 0.001) reduced when compared to 
vehicle (Figure 4.8, Panel B). 
4.3.6 Tolerance to CP47,497 and cross-tolerance between THC and CP55,940 
effects are observed after repeated CP47,497 administration 
 
 Synthetic cannabinoids have varied binding characteristics and some possess 
greater affinity for CB1 receptors versus THC. In rodents, repeated exposure to THC 
and synthetic cannabinoid agonists, WIN55,212-2 and CP55,940, produces 
desensitization of cannabinoid mediated G-protein activity, CB1 receptor downregulation 
and diminished inhibition of adenylyl cyclase (Martin et al. 2004; Sim-Selley 2003). In 
humans, the development of tolerance and withdrawal symptoms after repeated oral 
administration of THC have been characterized (Jones et al. 1976), and has recently 
been documented for synthetic cannabinoid compounds (Nacca et al. 2013; 
Zimmermann et al. 2009).  
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Figure 4.8 – CP47,497 drug discrimination in C57BL6/J mice. CP47,497 (1 and 3.2 mg/kg) fully 
substituted for THC in mice trained to discriminate 5.6 mg/kg THC from vehicle (A). CP47,497 [ED50= 
0.26 mg/kg, 95% CL (0.15-0.45)] was 4.7 times more potent than THC [ED50= 1.6 mg/kg, 95% CL (1.2-
2.1)] in the drug discrimination assay. Response rates were affected only at the highest CP47,497 (3.2 
mg/kg) dose tested (B). Significance denoted CP47,497 versus vehicle (#p< 0.001), and THC versus 
vehicle (*p < 0.0001). Data represent the mean ± SEM, n = 8-10 mice per group. Experiments and data 
analysis performed by Dr. B. Ignatowska-Jankowska. 
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Therefore, not only do these SCB drugs show potential for abuse, but also their 
repeated abuse may lead to the development of tolerance and dependence as these 
pharmacodynamic properties may promote increased drug consumption to sustain 
desired effects.  
 Based on the evidence that tolerance to the cannabimimetic effects of THC is 
seen upon chronic exposure (Abood et al. 1993; Fan et al. 1994; Hruba et al. 2012; 
Jones et al. 1976; Pertwee et al. 1993), we hypothesize that repeated administration of 
CP47,497 will produce tolerance to its cataleptic, antinociceptive and hypothermic 
effects. As is the case with THC, we predict that cross-tolerance to other synthetic 
cannabinoids, such as CP55,940 will develop (Fan et al. 1994; Pertwee et al. 1993). 
Our data indicate that acute administration of CP47,497 elicits more potent behavioral 
effects than THC; therefore, we predict that repeated CP47,497 administration will 
produce tolerance to tetrad behavioral effects. 
 Sim-Selley et al. has previously demonstrated tolerance and dependence using a 
twice daily sub chronic dosing regimen for 5.5 days with THC (Falenski et al. 2010, 
McKinney et al. 2008). Half of the dose of either CP47,497 or THC that produced 
approximately equal efficacy in acute tetrad behavioral experiments (Figure 4.3), were 
administered repeatedly. CP55,940 was used as a positive control with doses 
previously reported using ICR mice in the literature (Fan et al. 1994; Fan et al. 1996). In 
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these studies mice were treated (s.c.) twice daily for 5.5 days with either vehicle, 
CP47,497 (15 mg/kg), THC (50 mg/kg), or CP55,940 (2 mg/kg).  
 A two-way ANOVA of catalepsy tolerance data, with dose and drug treatment as 
between subject factors, revealed main effects for dose [F(4,28)=!50.0, p<0.0001], drug 
treatment [F(3,28)=!37.1, p<0.0001], and a significant interaction between drug and 
dose [F(12,28)=!14.2,  p<0.0001]. As shown in Figure 4.9, Panel A, CP47,497-
experienced animals displayed significant less catalepsy when challenged with 
CP47,497 (10, 30, and 56 mg/kg) versus vehicle-treated animals (p <0.0001). Likewise, 
animals repeatedly treated with THC and CP55,940 exhibited cross tolerance to 
CP47,497 at 10 mg/kg (p <0.001), 30 mg/kg (p <0.0001), and 56 mg/kg (p <0.0001) 
versus animals repeatedly given vehicle injections. 
 Assessment of tolerance to CP47,497-mediated antinociceptive effects revealed 
a significant main effect for dose [F(4,28) = 36.9, p < 0.0001], treatment [F(3,28) = 11.9, 
p < 0.0001], and interaction effect of dose and treatment [F(12,28) = 10.5, p < 0.0001]. 
Significant antinociceptive tolerance (Figure 4.9, Panel B) was detected for CP47,497, 
THC, and CP55,940 at cumulative doses of 30 and 56 mg/kg versus vehicle (p < 
0.0001).  No significant differences in tolerance to antinociceptive effects were observed 
across agonist treatments.  
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Figure 4.9 - Tolerance and cross-tolerance to CP47,497 was produced after repeated 
administration of CB1 agonists THC, CP55,940 and CP47,497. Challenge with increasing doses of 
CP47,497 elicited significant tolerance to effects of catalepsy (A), antinociception (B), and hypothermia 
(C) in mice treated with twice-daily injections of vehicle, CP47,497 (15 mg/kg), THC (50 mg/kg) or 
CP55,940 (2 mg/kg) for 5.5 days. Filled symbols denote significance from vehicle. Data represent the 
mean ± SEM, n = 6-10 mice per group. Baseline (means ± SEM) tail withdrawal latencies (s) and 
temperatures (°C) are shown in Table 4.4.  
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 Comparison of tolerance development to hypothermic effects in Figure 4.9, 
Panel C revealed significant differences for dose [F(4,28)= 38.2, p < 0.0001], drug 
treatment [F(3,28)= 149.3, p < 0.0001], and for an interaction effect of dose and drug 
[F(12,28)= 17.3, p < 0.0001]. Significant cross-tolerance was observed for THC at 3 
mg/kg (p < 0.05), 10, 30, and 56 mg/kg (p < 0.0001) in comparison to repeated 
administration of vehicle. Significant tolerance developed to decreases in body 
temperature upon CP47,497 treatment in mice receiving repeated CP47,497 and 
CP55,940 (10, 30, 56 mg/kg) versus vehicle treated mice challenged with cumulative 
CP47,497 drug (p < 0.0001).  At the highest dose tested, CP47,497 (56 mg/kg) elicited 
significantly less hypothermia than THC (p < 0.05). Overall, tolerance to CP47,497-
induced catalepsy, antinociception, and hypothermia was produced, but statistical 
analyses revealed no significant differences in the magnitude of tolerance development 
between animals treated repeatedly with CP47,497, THC or CP55,940 as compared to 
control mice.   
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Table 4.5 – Baseline tail withdrawal latency and temperature measurements for 
tolerance experiments 
Drug Veha CP47,497b CP55,940c THCd
Mean 1.5 1.0 0.9 1.6
± SEM 0.2 0.1 0.1 0.3
Drug Veh CP47,497 CP55,940 THC
Mean 37.2 37.7 38.1 37.5
± SEM 0.2 0.2 0.4 0.3
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aVehicle (1:1:18), bCP47,497 (15 mg/kg), cCP55,940 (2 mg/kg), dTHC (50 mg/kg)  
 
4.3.7 Rimonabant-precipitated somatic withdrawal signs are observed in mice 
treated repeatedly with CP47,497  
 
 Rodents repeatedly treated with cannabinoid receptor agonists display signs of 
precipitated withdrawal after challenge with rimonabant as previously reported (Rubino 
et al. 1998; Tsou et al. 1995). Therefore, we sought to determine if repeated CP47,497 
exposure will give rise to dependence phenomena, characterized by presentation of 
somatic withdrawal signs. For this experiment, mice were treated twice daily for 5.5 
days with subcutaneous delivery of vehicle, CP47,497 (15 mg/kg), THC (15 mg/kg), or 
CP55,940 (2 mg/kg), and on day 6, mice received a rimonabant injection (10 mg/kg) 
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and were monitored for somatic withdrawal signs (head shakes, paw flutters, and 
jumps). 
  Following a one-way ANOVA, significant main effects were observed for head 
shakes [F(3,28)= 7.2, p < 0.001] and paw flutters [F(3,28)= 10.8, p < 0.0001] as seen in 
Figure 4.10. For each treatment group, jumping was recorded but no significant 
differences were seen among any groups [F(3,28)= 1.3, p = 0.29]; these data are not 
shown as jumping was observed to a much lesser extent than head shakes and paw 
flutters. Significant increases in head shakes were observed in CP47,497-treated and 
THC-treated mice (p < 0.05) versus vehicle-treated mice, with CP47,497-treated mice 
displaying significantly more head shakes than CP55,940-treated mice (p < 0.05). 
Rimonabant-precipitated paw flutter withdrawal signs were significant in CP47,497- and 
THC-treated groups as compared to either CP55,940- or vehicle-treated groups (p < 
0.05). No significant differences in head shakes or paw flutters were seen between 
CP55,940 and vehicle groups or CP47,497 and THC groups. 
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Figure 4.10 – Assessment of somatic withdrawal signs in mice following repeated CP47,497, THC 
and CP55,940 administration. Precipitated withdrawal by rimonabant (10 mg/kg) challenge elicited 
significant increases in both head shakes (A) and paw flutters (B) in CP47,497 and THC-treated, but not 
CP55,940-treated mice. No significant differences were observed between groups for jumping behavior.  
Significance denoted *p < 0.05 versus Veh/Rim and #p < 0.05 versus CP55/Rim groups. Data represent 
the mean ± SEM, n = 6-10 mice per group. !!!!
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4.4 Discussion !
 The body of work presented in this dissertation sought to determine if the 
synthetic cannabinoid, CP47,497, would produce potent and efficacious CB1 receptor-
mediated cannabimimetic effects as compared to the primary psychoactive component 
of marijuana, THC. Synthetic cannabinoids were insipiently created as biomedical 
research tools but they have been commandeered from their intended laboratory use 
and have surfaced as novel cannabinoid drugs of abuse. Because hundreds of SCBs 
have been synthesized, and since they are not detected in traditional drug screens, their 
popularity as “legal” alternatives to THC continues to increase. Furthermore, there is 
insufficient data regarding their abuse liability, and medical consequences of acute or 
repeated use including toxicity, pharmacodynamic, and pharmacokinetic effects remains 
largely unexplored. As a result, the objectives of this dissertation were to develop a 
bioanalytical assay for the extraction and quantification of CP47,497, to assess in vitro 
effects of CP47,497, and to examine in vivo pharmacological effects of acute and 
repeated CP47,497 drug administration, including determination of the discriminative 
stimulus effects of CP47,497 as compared to THC. 
! Previous studies have established that CP47,497 binds to CB1 receptors  with 
low nanomolar (Ki < 10 nM) affinity versus THC (Ki ~ 40 nM) (Compton et al. 1993; 
Melvin et al. 1993). Cannabinoid agonists bind to CB1 receptors, the receptor undergoes 
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a conformational change that promotes activation of downstream signaling events 
(Howlett et al. 1999). To determine the first step in CB1 receptor signaling, the effect of 
G-protein activation by synthetic cannabinoid CP47,497-, CP47,497-C8- and JWH-250-
stimulated [35S]-GTPγS binding was examined. Prior to cloning of cannabinoid receptors, 
Devane et al. used radiolabeled CP55,950 as a potent, efficacious, and stereoselective 
tool to characterize the binding site of the central cannabinoid receptor, CB1 (Devane et 
al. 1988). Since then, CP55,940 remains a highly utilized pharmacological tool and is 
one of the best characterized SCBs (Compton, Johnson, et al. 1992; Fan et al. 1996; 
Little et al. 1988; Rubino, Viganò, et al. 2000). Therefore, CP55,950 was used as a 
comparison to the SCBs investigated in this thesis. At CB1 and CB2 receptors, 
CP55,940 exhibits both high efficacy, described as producing measurable responses at 
low receptor occupancies, and partial agonism, producing 80-90% of maximal percent 
stimulation above basal in the [35S]-GTPγS binding assay. Agonist stimulated [35S]-
GTPγS binding of the SCBs of interest were normalized to maximum percent stimulation 
of CP55,940 to permit comparison across SCB compounds as each synthetic 
cannabinoid was assessed alongside CP55,940 in three separate experiments.  
 No significant differences were observed for maximum stimulation effect (Emax) 
between CP55,940, CP47,497, CP47,497-C8- and JWH-250 compounds tested, 
suggesting that the efficacy of each of the synthetic cannabinoids examined is similar to 
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the efficacy of CP55,940. Therefore, like CP55,940, these data strongly suggest that 
CP47,497, CP47,497-C8- and JWH-250 are high efficacy partial agonists. Additionally, 
EC50 values for CP47,497, CP47,497-C8- and JWH-250 were significantly higher than 
CP55,940. These results indicate that even though the SCBs tested are equally 
efficacious as CP55,940 in this assay, they demonstrate lower potencies. While the 
sample size used in these studies met the minimum threshold for statistical 
requirements (n = 3, run in triplicate), performing additional replicates would further 
strengthen the data. 
 Interestingly, the dimethyloctyl homologue of CP47,497, CP47,497-C8 elicited a 
significant increase in percent stimulation (Emax) when compared to CP47,497 in these 
studies, which illustrates a higher efficacy for CP47,497-C8 versus CP47,497. The 
efficacy of CP47,497-C8 has also translated to potent in vivo antinociceptive effects as 
addition of one methyl group confers higher CB1 receptor binding affinity in rat brain 
membranes versus CP47,497 (Melvin et al. 1993). Moreover, our results in [35S]-GTPγS 
studies authenticate a study reporting partial efficacy of CP47,497 in agonist stimulated 
[35S]-GTPγS binding in both rat cerebellum and in CHO cell constructs expressing 
human cannabinoid receptors (hCB1 and hCB2) (Govaerts et al. 2004).   
 The SCB agonist [35S]-GTPγS binding studies support our hypothesis that 
CP47,497 is an efficacious cannabimimetic agent that initiates signal transduction by 
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activating G-proteins associated with GPCRs. The data presented herein provide the 
first evidence of G-protein activation by CP47,497-C8 and JWH-250 synthetic 
cannabinoid compounds. The ability of bicyclic compounds, CP47,497 and CP47,497-
C8, to activate G-proteins is not surprising based on their close structural resemblance 
to CP55,940. On the other hand, we might have expected the Emax of the 
aminoalkylindole, JWH-250, would be higher than those of the other compounds due to 
its structural resemblance to the CB1 full-efficacy aminoalkylindole agonist, WIN55,212-
2 (Breivogel & Childers 2000; Selley et al. 2004; Sim-Selley & Martin 2002). With no 
significant differences in Emax values, these data support that compounds with varying 
structures demonstrate similar efficacy in this assay. Based on available in vitro data 
presented here and in previously published work, we suspect that the lower nanomolar 
binding affinity of CP47,497 to CB1 receptors, together with increased efficacy of G-
protein activation may, at least, partially explain the potent THC-like behavioral effects 
observed by CP47,497.     
 CB1 receptors are the most abundantly expressed GPCRs in the brain (Devane 
et al. 1988; Herkenham et al. 1991) and are, therefore, suspected to be responsible for 
G-protein activation of CP47,497 in this experiment.  However, since many of the SCB 
compounds being abused are not well-studied, and because our studies do not 
definitively identify the GPCR eliciting G-protein activation, further research is warranted 
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to omit the possibility of off-targets of CP47,497 in brain. Exemplifying this possibility, 
the activation of G-proteins by WIN55,212-2 has been observed in brain membrane 
preparations from CB1(-/-) mice (Breivogel et al. 2001; Nguyen et al. 2010), suggesting 
non-CB1 binding activity by WIN55,212-2 in brain. To test whether CP47,497-stimulated 
G-protein activation is mediated by CB1 receptors, SCB agonist stimulated [35S]-GTPγS 
could be assessed in membranes treated with a CB1 receptor selective antagonist, such 
as rimonabant, or with preparations from CB1(-/-) mice. As an alternative to functional 
activation of G-proteins by CP47,497, species-specific differences could be determined 
by displacement of [3H]-SR141617A binding (Breivogel & Childers 2000) by CP47,497 
in Chinese hamster ovary (CHO) cells transfected with a construct expressing hCB1 
(Thomas et al. 2007). Furthermore, while CB2 receptors play a role in immunity and are 
present primarily in the spleen and on circulating macrophage cells (Munro et al. 1993), 
but CB2 expression is observed in the CNS as well (Atwood & Mackie 2010; Van Sickle 
et al. 2005). Additionally, stimulation of neuronal CB2 receptors have been proposed to 
attenuate reward and the psychomotor stimulating effects of cocaine (Xi et al. 2011). 
Thus, CP47,497-stimulated [35S]-GTPγS activity at CB2 should be also be examined as 
CB2 receptor affinity of CP47,497 has been previously published in CHO cells 
transfected with human CB2 receptors (Govaerts et al. 2004).  
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 Another important objective of this dissertation was to determine whether 
CP47,497 mimics the actions of THC in vivo, and whether CB1 mediates these effects. 
This goal is important because SCB compounds are presently being abused by some 
individuals in lieu of THC (see Chapter 2 and Hillebrand et al. 2010; Vandrey et al. 
2012), and research has established that the psychoactive effects of THC are mediated 
by CB1 receptors (Martin et al. 1991; Matsuda et al. 1993). Moreover, the distribution of 
CB1 receptors in the CNS via autoradiographic and immunohistochemical techniques in 
rodents have demonstrated that regions expressing high CB1 receptor density 
(Herkenham et al. 1991; Matsuda et al. 1993; Tsou et al. 1998) overlap with brain areas 
well-known to mediate perception and cognition (cerebral cortex), memory 
(hippocampus), reward (nucleus accumbens), anxiety (amygdala), and motor functions 
(basal ganglia, cerebellum) (Casswell & Marks 1973; Herkenham et al. 1990; Karniol & 
Carlini 1973; Sim-Selley 2003; Varvel et al. 2001; Verrico et al. 2014). Human studies 
have shown that both developing and mature brains exhibit mostly similar receptor 
distribution, with cognitive and motor region-specific patterns of dense CB1 expression 
(Biegon & Kerman 2001; Glass et al. 1997). These studies also demonstrate CB1 
receptor binding in areas associated with higher cognition (forebrain), movement 
(forebrain, midbrain, and hindbrain), and motor functioning (hindbrain), which 
demonstrate prominent CB1 receptor expression in brain regions that correlate well with 
the known behavioral, psychomotor and psychological effects of THC.  
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 Finally, to increase the understanding of CP47,497 efficacy, specific brain 
regions should be examined, since whole brain preparations were used for our agonist-
stimulated [35S]-GTPγS binding experiments and because agonist efficacy is shown to 
significantly vary across brain regions, depending on specific drug treatment and 
duration (Breivogel et al. 1997; Breivogel 1998; McKinney et al. 2008). Investigation of 
receptor desensitization, downregulation, or binding affinites in specific brain regions 
known to contain CB1 receptors (i.e. cortex, hippocampus, cerebellum, striatum) could 
provide evidence for actions of CP47,497 distinct from other cannabinoid agonists, such 
as THC and WIN55,212-2 (Breivogel & Childers 1998; Selley et al. 1996). Reductions in 
agonist-stimulated [35S]-GTPγS binding are seen in the hippocampus, cingulate cortex, 
periaqueductal gray, and cerebellum after repeated treatment with 10 mg/kg THC or 
with an escalating dosing paradigm, but higher doses are required to see decreases in 
caudate putamen, nucleus accumbens, and preoptic areas (McKinney et al. 2008). 
Based on behavioral observations of CP47,497 mice in the tetrad, we would predict that 
decreased [35S]-GTPγS binding would occur in areas known to mediate cannabinoid 
behavioral effects and are high in CB1 receptor expression, such as cortex, 
hippocampus, and cerebellum (Sim et al. 1996; Sim-Selley 2003). Additionally, 
hyperreflexia was prominent in CP47,497-treated mice in studies presented here, and 
has been observed in humans after SCB abuse (Harris & Brown 2013; Simmons et al. 
2011). Therefore, differences in CB1 activity may be observed in the cerebellum and 
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basal ganglia, as these areas are known to mediate movement and motor coordination 
behavior (Breivogel & Childers 1998; Patel & Hillard 2001). Examination of the 
hippocampus would reveal the potential role of CP47,497 effects on impairment of 
learning and memory, as has been observed with THC (Varvel et al. 2001; Wise et al. 
2011) and the synthetic cannabinoid, JWH-081 (Basavarajappa 2014).  
 Extensive examination of CP47,497 in the tetrad behavioral assay was presented 
herein as it provides a sensitive index of cannabimimetic potency, and has been well-
characterized for nonclassical (Compton et al. 1993; Little et al. 1988; Melvin et al. 
1993), aminoalkylindole (Compton, Gold, et al. 1992; Wiley, Marusich & Huffman 2013) 
and structurally related synthetic cannabinoid compounds (Huffman et al. 2005; Wiley et 
al. 1998; Wiley et al. 2012). Perhaps the most convincing evidence that CB1 receptors 
mediate actions of tetrad behaviors was the reversal of cannabimimetic effects via 
antagonism with rimonabant (Compton et al. 1996; Rinaldi-Carmona et al. 1994; 
Wiebelhaus et al. 2012) and the absence of cannabimimetic effects in genetically 
modified mice lacking CB1 receptors (Ledent et al. 1999; Monory et al. 2007; Zimmer et 
al. 1999). Drugs from other classes (e.g. CNS depressants) can produce a subset of 
cannabimimetic effects, but in general, cannabimimetic compounds exhibit dose-
dependent and reproducible behaviors in all four components (catalepsy, 
antinociception, hypothermia and locomotor suppression). For example, a 
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comprehensive examination of centrally acting drugs in the tetrad revealed that CNS 
depressants, such as ethanol, diazepam, and phenobarbital do not produce effects in all 
four tests; hypothermia was not observed with diazepam, catalepsy was absent in 
ethanol treated mice, and catalepsy nor antinociception was observed with 
phenobarbital (Wiley 2003). In this same series of experiments, antipsychotic agents, 
clozapine, haloperidol, and chlorpromazine exhibited effects in all four parameters; 
however, the magnitude of catalepsy produced exceeded the maximum response 
observed with THC. As verification of CB1 receptor involvement, rimonabant completely 
antagonized the effects of THC, but not the effects of any of the other drugs examined 
(Wiley 2003). Thus, these data highlight that tetrad effects are not exclusive to 
cannabinoid compounds, as pharmacological drugs from different classes can exhibit 
tetrad behavioral effects. Therefore, the use of the tetrad assay in combination with 
pharmacological, genetic, and molecular tools to assess CB1 receptor involvement 
represent a powerful approach to assess the effects of suspected novel cannabinoid 
compounds in the whole animal. 
 The experiments presented herein show that CP47,497, consistent with a 
cannabimimetic drug, produces all tetrad measures including catalepsy, antinociception, 
hypothermia, and locomotion, and displays increased potency (5- to 7- fold) over THC. 
Additionally, our results indicate CP47,497 is potentially more behaviorally efficacious 
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than THC, as 30 mg/kg of CP47,497 produced approximately 70% maximal 
antinociception versus approximately 20% maximal antinociception at 30 mg/kg THC. 
The ED50 value for antinociceptive effects of CP47,497 was 26.2 (11.0 -62.0), whereas, 
200 mg/kg THC produced approximately 20% maximum antinociceptive effect in the 
warm water tail withdrawal assay. In order to discern whether the antinociceptive 
efficacy of THC is lower than that of CP47,497, it would be necessary to test higher 
doses of drug than those tested in the present study. 
 Determination of ED50 values for antinociception (radiant heat tail flick) for 
intravenous administration of THC (1.4 mg/kg) and CP47,497 (0.3 mg/kg) and 
subcutaneous administration of THC (72 mg/kg) and CP47,497 (4 mg/kg) have been 
reported previously (Compton et al. 1992; Little et al. 1988; Weissman et al. 1982). 
However, these previous results are discrepant from those presented here as the ED50 
value for CP47,497 antinociceptive effects was 26.2 (11.0 - 62.0) mg/kg, and an ED50 
value for THC could not be calculated because a 50% effect was not observed at doses 
as high as 200 mg/kg. The differences in data are likely due to several factors. First, the 
routes of administration varied. The present series of experiments used intraperitoneal 
administration, while previous publications used subcutaneous and tail vein (i.v.) routes 
of administration. Second, a variation of the (radiant heat) tail flick assay used in 
previous studies (Le Bars et al. 2001; King et al. 1997), the warm water (52 °C) tail 
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withdrawal assay, was used herein. The choice for these differences in experimental 
methods was intentional as they are more amenable to cumulative-dosing, which 
subsequently maximizes data collection, increases statistical sensitivity using a within-
subjects experimental design, and reduces the number of animals necessary for each 
experiment. Differences in precise drug concentrations in cumulative versus bolus drug 
injections may also account for observed variability, as some drug metabolism occurs 
over the course of a cumulative-dose response experiment. Third, the specific strain of 
mice (Swiss CD or albino CF-1) used in each individual study was not clearly 
documented in this paper (Weissman et al. 1982). Resultantly, it is reasonable to 
conclude the differences in route of administration, nociceptive stimulus, and mouse 
strains explain the discrepant results.    
 It is important to note that in our studies, an additional behavior, known as 
hyperreflexia (Adams & Martin 1996; Dewey 1986), was prominent in CP47,497-treated 
(30 mg/kg), but not THC-treated mice, even at the high doses of THC (200 mg/kg) 
tested. Hyperreflexia was observed after CP47,497 treatment across acute drug 
administration experiments in ICR, C57BL6/J and CB1(+/+) mice, but was absent in mice 
treated with either low or high dose rimonabant.  The expression of hyperreflexia has 
been previously reported in dogs treated with THC (Wilson & May 1976), and in our 
laboratory in mice after inhalation exposure to synthetic cannabinoids, JWH-018 and 
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JWH-073 (Poklis, et al. 2012; Wiebelhaus et al. 2012). Cannabinoid-induced cerebellar 
dysfunction is characterized by motor incoordination, loss of muscle tone, and gait 
disturbances in mice as well as static ataxia in dogs (Dewey 1986; Patel & Hillard 2001; 
Weissman et al. 1982; Wilson & May 1976; Wilson & May 1979). Supporting a CB1 
component of these motor disturbances, hyperreflexia in mice (Patel & Hillard 2001) and 
ataxia in dogs (Lichtman et al. 1998) are blocked by rimonabant treatment. While the 
precise neuroanatomical mechanism(s) responsible for hyperreflexia and motor 
deficiency observed by endogenous, phytocannabinoid or synthetic cannabinoids 
remains to be elucidated (Patel & Hillard 2001; Weissman et al. 1982; Wilson & May 
1976; Wilson & May 1979), human fMRI studies report decreased cerebellar function 
after THC exposure (Bloom et al. 1999), suggesting cerebellar changes are relevant to 
the cannabinoid-induced physiological motor impairments. Interestingly, commonly 
reported clinical features of SCB exposure include hyperreflexia, and to a lesser extent, 
jerking of limbs (Harris & Brown 2013; Simmons et al. 2011). As a result, these 
preclinical hyperreflexia data appear to demonstrate good face validity as a behavioral 
screen of abused synthetic cannabinoids in mice. However, further studies are needed 
to test this observation, specifically with SCB across aminoalkylindole and derivative 
structural classes, alongside evaluation of structurally similar non-cannabinoid 
compounds (control for false positives).  
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 The quantification of CP47,497 in blood over time suggest that peak drug effects 
are achieved between 1 and 2 hours after intraperitoneal drug administration, although 
no significant differences are seen between drug present at 0.25-, 0.5-, 1- or 2- hour 
time points. Also, it is important to examine drug concentration at 12- and 24-hour time 
points against decreases in behavioral effects in future studies. We predict that 
CP47,497 concentrations would decrease at these later times as no significant 
behavioral effects are seen. These additional experiments will also assist in determining 
metabolic clearance of CP47,497 in blood.  CP47,497 blood concentration appears to 
mirror effects within the behavioral time course, with decreases in catalepsy, 
antinociception, and hypothermia corresponding to a significant decrease in CP47,497 
blood concentration at 8 hours.   
 While these data support the possibility that parent CP47,497 drug is likely 
responsible for the majority of behavioral effects seen, additional studies should 
examine drug brain concentrations to correlate CP47,497 behavioral effect with 
concentration of CP47,497 concomitantly present in brain. Metabolites of THC (Agurell 
et al. 1986; Foltz et al. 1983; Wilson & May 1975), as well as synthetic cannabinoid 
metabolites of JWH-018 and JWH-073 (Brents et al. 2011; Brents et al. 2012), are 
active at CB1 receptors and responsible for cannabimimetic effects. Therefore, studies 
should also examine in vivo metabolic profiles of CP47,497 in blood and brain, as 
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Phase 1 hydroxylation and oxygenation reactions have been detected by human liver 
microsomal analysis (Jin et al. 2013). Furthermore, recent work implies this finding 
extends to cannabimimetic effects of SCB metabolites of JWH-018 (Brents et al. 2011) 
and JWH-073 (Brents et al. 2012). Data from these studies will allow us to determine if 
only the CP47,497 parent compound is mediating the behavioral effects or if, like THC, 
metabolites of CP47,497 possess bioactivity at CB1 and play a role in the observed 
cannabimimetic actions. 
 Temporal effects of CP47,497 closely mirror those of THC, with sustained 
presentation of catalepsy, antinociception and hypothermia from 0.5 to 8 hours after 
drug administration. At 24-hours post-treatment, all behavioral effects returned to 
baseline levels. Maximum effects of catalepsy and hypothermia by CP47,497 were 
observed between 2 and 4 hours after administration, and levels were significantly 
higher than THC at these time points. Unexpectedly, a significant antinociceptive effect 
was not observed between THC and vehicle at 0.5 hours, as was shown in the dose-
response experiments. A possible explanation is that slow absorption kinetics of THC 
via intraperitoneal administration could produce variable antinociceptive effects before 
peak drug distribution of THC are achieved. Nonetheless, CP47,497 produced 
significantly more antinociception than THC at this time point. From these data, we can 
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conclude that CP47,497-induced tetrad cannabimimetic effects display a similar 
duration as THC.  
 The identification of cannabinoid receptors, CB1 (Matsuda et al. 1990) and CB2 
(Munro et al. 1993), permitted researchers to screen novel compounds for their ability to 
bind to cannabinoid receptors. Many structure activity relationship studies utilized a 
complementary approach to screen novel SCB compounds; specifically, compounds 
were tested in vitro for their CB1 binding affinity and in vivo for their ability to elicit a 
characteristic cannabimimetic behavioral profile in the tetrad. Studies have illustrated 
that relative potencies of cannabinoid analogs, derived from in vitro CB1 binding data, 
positively correlate with physiological effects observed from in vivo behavioral 
evaluation in animals (Compton et al. 1993; Wiley et al. 1998) and humans (Herkenham 
et al. 1990). Because SCB drugs are reportedly being abused for their THC-like 
psychoactive effects, studies were designed to investigate CB1 receptor involvement in 
vivo.  Importantly, pharmacological and genetic tools have been developed since initial 
CP47,497 studies were performed in the late 1980’s. Therefore, to examine CB1 
receptor involvement in CP47,497-mediated effects, the CB1 receptor antagonist, 
rimonabant, was utilized at both low (3mg/kg) and high (10 mg/kg) doses. Low dose 
rimonabant was sufficient to reverse cataleptic and antinociceptive effects of both 
CP47,497 and THC. For decreases in temperature, low dose rimonabant significantly 
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attenuated effects of CP47,497 and THC. High dose rimonabant was required for full 
reversal of hypothermia and time spent immobile. Treatment with high dose rimonabant 
blocked all measures of cannabimimetic tetrad activity produced by both THC and 
CP47,497. Lastly, high dose rimonabant was required to successfully inhibit time spent 
immobile produced by both CP47,497 and THC treatment. These data offer strong 
evidence confirming CP47,497 actions are CB1 mediated. 
 Interestingly, rimonabant (10 mg/kg) elicited statistically significant increases in 
distance traveled across all treatment groups.  This presents a potential confound of the 
experiment because it is not possible to decipher whether the increased distance 
traveled following the combination of rimonabant and CP47,497 are CB1 mediated. 
Nevertheless, these effects of rimonabant are in agreement with published reports of 
locomotor stimulating effects of rimonabant produced at doses above 3 mg/kg 
(Compton et al. 1996). Additionally, these previously published studies reported an ED50 
for rimonabant-induced locomotor stimulation of approximately 5 mg/kg; therefore, 
previous findings corroborate our results of significant locomotor activation at 10 mg/kg 
rimonabant, but not with 3 mg/kg. Comparison of CB1 receptor binding affinities of 
CP47,497 (Ki = 2.2 ± 0.47 nM), THC (Ki = 40.7 ± 1.7 nM), and rimonabant (Ki = 1.98 ± 
0.36 nM) support why increasing doses of the competitive antagonist are required to 
surmount the effects produced by the doses of CB1 receptor agonists, 30 mg/kg 
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CP47,497 and 100 mg/kg, used in the experiment (Compton et al. 1993; Melvin et al. 
1993; Rinaldi-Carmona et al. 1994). To overcome the confound in these experimental 
results and test the ability of rimonabant to block CP47,497-induced locomotor 
depressant effects, additional studies could utilize a lower dose of CP47,497 which still 
produces immobility, and examine if rimonabant, at doses less than 3 mg/kg, could 
effectively blunt the motor depressant effects.  
 A caveat to using rimonabant at the high doses required to antagonize our 
cannabinoid agonist effects is the potential of off-target effects. GTPγS studies in brains 
of CB1(-/-) mice (Breivogel et al. 2001; Cinar & Szucs 2009) provide evidence of non-CB1 
targets for rimonabant. Therefore, to support these antagonism findings, we tested 
CP47,497 in mice genetically devoid of CB1 receptors. To deconstruct whether CB1 
receptors were involved in the locomotor depressant effects of CP47,497, CB1(+/+) and 
CB1(-/-) mice were utilized in the next series of experiments. THC-like behavioral effects 
of catalepsy, antinociception, hypothermia, and immobility were completely abolished in 
CB1(-/-) mice. Vehicle-treated CB1(-/-) mice traveled less than their wild-type counterparts, 
which has been documented before in CB1 mutant mice (Zimmer et al. 1999). 
Furthermore, HPLC/MS/MS quantitation of CP47,497 in brain confirmed the presence of 
drug concomitant with absence of cataleptic, antinociceptive, and hypothermic 
behavioral effects in CB1(-/-) mice. Taken together, these complementary 
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pharmacological and genetic data support CB1 mediation of THC-like effects of 
CP47,497 in the tetrad.  
 Based on dose-response studies in ICR and C57BL6/J mice, this dose of 
CP47,497 was a sufficient, if not a supramaximal dose, to elicit cannabimimetic effects 
in CB1 genetically modified mice (backcrossed onto a C57BL6/J background). From 
these dose-response studies in ICR and C57BL6/J mice, we also observed that, 
depending on the measure, C57BL6/J mice exhibited greater cannabimimetic sensitivity 
to CP47,497 versus ICR mice; the differences in drug potency and efficacy suggest 
differential effects of CP47,497 across strains in the tetrad. This is not surprising, as 
behavioral responses to various pharmacological compounds have been found to vary 
among species and strains. For example, differential sensitivity to the endogenous 
cannabinoid, AEA, was observed in measures assessing motor function and 
emotionality, across ICR, DBA/2 and C57BL/6 mouse strains (Chakrabarti et al. 1998).  
Moreover, northern blot analysis identified increased CB1 gene expression in ICR mice 
versus C57BL6/J after systemic and intracerebral administration of THC (Onaivi et al. 
1995). This phenomena is not specific to cannabinoid drugs as an examination of 
morphine sensitivity across six mouse strains showed that morphine-pelleted mice 
demonstrated differential amounts of mortality, ranging from 5% in ICR, to 84% in A/J 
mice (Brase et al. 1977). Furthermore, differences in brain cannabinoid receptor binding 
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was observed between C57BL/6 and DBA/2 mice (Hungund & Basavarajappa 2000). 
Collectively, these data implicate that many drugs of abuse produce strain-specific 
phenotypes, and indicate potential neurobehavioral differences may be due, in part, to 
underlying genetic differences. Therefore, choice of mouse strain must be considered 
when designing experiments with synthetic cannabinoid compounds, such as CP47,497.  
 As previously discussed, drugs from many classes produce a subset, of 
behavioral effects in the tetrad assay and some (El-Alfy et al. 2009; Pava et al. 2012) 
even produce all four measures (Wiley 2003) . Historically, behavioral methods used to 
examine abused drugs include pharmacological comparison to other well-characterized 
drugs, self-administration, drug discrimination, and assessment of physical dependence 
(Wiley 1999). In contrast to other drugs of abuse, such as cocaine (Tanda et al. 2000), 
morphine (Navarro et al. 2001), and ethanol (Hungund et al. 2003), animals do not 
readily self-administer cannabinoids (Gardner 2005). However, THC self-administration 
has been reported in cocaine-experienced (Tanda et al. 2000) as well as drug-naïve 
(Justinova et al. 2003) squirrel monkeys. But this effect may be also be strain or species 
specific, as these findings are from the same research group and have not been 
reproduced across laboratories or in other self-administration animal models.  
 In contrast, numerous studies have shown that the discriminative stimulus effects 
of THC in animals are specific to marijuana-like drugs (Balster & Prescott 1992; Barrett 
!167 
et al. 1995), a behavior that has also been demonstrated in humans (Lile et al. 2009). 
As a result, the drug discrimination assay is the most selective model available to study 
drug mechanism of action in terms of cannabinoid-like intoxicating effects (Balster & 
Prescott 1992; Wiley 1999). Discrimination of THC or other psychoactive drugs has 
been established using a two-lever paradigm in rodents, non-human primates, and 
humans (Barrett et al. 1995; Järbe & Henriksson 1974; Justinova et al. 2003; McMahon 
et al. 2008; Vann et al. 2009). Traditionally, these studies were conducted with rats and 
non-human primates, but recent examinations of drug discrimination in C57BL/6 mice 
have reported successful discriminative stimulus training (McMahon et al. 2008; Vann et 
al. 2009). The advantage of utilizing mice is the ability to test genetically modified mice, 
thus greatly enhancing the utility of the drug discrimination paradigm.  
 Drug discrimination experiments presented here revealed full substitution and 
dose-dependent effects of CP47,497 in C57BL/6J mice trained to discriminate THC 
from vehicle, illustrating subjective effects of CP47,497 are THC-like. Doses of 3.2 
mg/kg CP47,497 in drug discrimination studies produced significant decreases in 
response rates, yet, this dose still fully displayed full substitution for 5.6 mg/kg THC. The 
drug discrimination data substantiate results from dose-response tetrad experiments in 
C57BL/6J mice, as 3.2 mg/kg CP47,497 caused significant immobility with a trend 
toward decreases in distance traveled. A remaining question of the drug discrimination 
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experiment is whether the discriminative stimulus effects of CP47,497 are CB1 receptor 
mediated. For example, rimonabant has been systemically shown to block 
discriminative stimulus effects of endogenous (Wiley 1999; Wiley, et al. 2011), plant-
derived (McMahon et al. 2008; Vann et al. 2009; Wiley 1999; Wiley, et al. 2011), and 
synthetic (Ginsburg et al. 2012; McMahon et al. 2008; Wiley et al. 1995; Wiley, et al. 
2013) cannabinoids. Consequently, it would be of value to examine whether the THC-
like effects of CP47,497 in the drug discrimination assay are blocked by rimonabant. 
 Our results are consistent with the structurally-related compound CP55,940, 
which fully substitutes for THC, and demonstrates enhanced potency in drug 
discrimination assays, which can be ameliorated by rimonabant treatment (McMahon et 
al. 2008; Wiley et al. 2011; Wiley et al. 2005). Further, these data are consistent with 
reports of other currently abused synthetic cannabinoids, primarily of the nonclassical 
(CP47,497 and HU-210) and aminoalkylindole (JWH-018 and JWH-073) classes, which 
have demonstrated complete substitution for THC in rats (Brents et al. 2013; Järbe & 
Gifford 2013; Weissman et al. 1982) and monkeys (Ginsburg et al. 2012). Importantly, 
rimonabant produced surmountable antagonism for the discriminative stimulus effects of 
JWH-018 and JWH-073 in monkeys (Ginsburg et al. 2012), as well as JWH-018 in rats 
(Järbe et al. 2012), but studies have not yet tested antagonism of CP47,497 by 
rimonabant. At the very least, our drug discrimination results substantiate that 
interoceptive effects of CP47,497 substitute for THC, which supports known abuse 
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potential of this synthetic cannabinoid in humans. However, additional studies are 
needed to assess whether rimonabant will block these discriminative stimulus effects. If 
rimonabant successfully blocks the discriminative stimulus effects of CP47,497, the 
animals would respond on the vehicle-appropriate lever, thus, strongly suggesting that 
CB1 receptors are involved in the discriminative stimulus.  
 As discussed in detail in Chapter 2, when compared to different preparations of 
cannabis, SCB drugs have largely gained notoriety due to their magnitude and 
frequency of reported adverse effects including anxiety, hypertension, tachycardia, and 
seizures (Forrester et al. 2012; Hermanns-Clausen et al. 2012a; Seely et al. 2012; 
Wood 2013). Furthermore, reports of development of tolerance to the desired synthetic 
cannabinoid effects have been reported in humans (Gunderson et al. 2012; 
Zimmermann et al. 2009). Tolerance to behavioral effects of THC, and other 
cannabinoids has been well-characterized preclinically in rodents (Abood et al. 1993; 
Fan et al. 1994; Hruba et al. 2012; Jones et al. 1976; McKinney, et al. 2007; Pertwee et 
al. 1993; Sim-Selley, 2002). In particular, repeated cannabinoid administration leads to 
tolerance to acute effects of locomotion (Abood et al. 1993; Oviedo et al. 1993), 
hypothermia (Pertwee et al. 1993; Fan et al. 1996), and antinociception (Lee et al. 2003; 
Martin et al. 1996). Accordingly, studies were designed to test whether tolerance to the 
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CP47,497-induced cannabimimetic effects of catalepsy, antinociception and 
hypothermia develop with repeated administration in mice.  
 The data presented here show that repeated CP47,497, THC and CP55,940 
treatment in mice resulted in the development of tolerance to CP47,497-induced 
catalepsy, antinociception, and hypothermia. Interestingly, CP47,497, THC and 
CP55,940 produced similar magnitudes of tolerance in antinociception, catalepsy and 
hypothermia, despite their differences in potency (binding affinity) and efficacy (as 
defined by agonist stimulation of [35S]-GTPγS binding). Additionally, it was previously 
discussed that acute administration of CP47,497 produced pronounced hyperreflexia, 
but mice repeatedly given vehicle treatment and then administered increasing doses of 
CP47,497, did not exhibit hyperreflexic behavior. A possible explanation for this 
observed difference is that repeated handling, as well as exposure to repeated ethanol-
containing vehicle injections, may have reduced sensitivity to CP47,497-induced 
hyperreflexic behavior. Studies have reported that mice treated chronically with ethanol 
demonstrate less sensitivity to hypothermic, locomotor depressant, and antinociceptive 
effects of WIN55,212-2 (Pava et al. 2012). The amount of ethanol was a minimal 
component of the vehicle used in our studies as compared to chronic ethanol exposure, 
but this may account for the modest decrease in hyperreflexia, with no other overt 
behavioral effects present.  
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 Based on spare receptor theory, the magnitude of tolerance development to 
repeated CP47,497 administration is inversely related to spare receptor reserves 
(Kenakin 2004; Negus 2006). As a result, as a high efficacy partial agonist, CP47,497 
should produce less tolerance than the low efficacy partial agonist, THC at equi-
effective doses. However, in our experimental system, it appears that even though THC 
is a low efficacy agonist, no differences in tolerance may be due to the abundant 
cannabinoid receptor reserve in the CNS (Gifford et al. 1999). Thus, the ample number 
of spare receptors may account for the finding by which tolerance to the 
pharmacological effects of THC in the tetrad assay is indistinguishable from high 
efficacy partial agonists, CP55,4940 and CP47,497. It is also possible that testing 
additional points might reveal differences in tolerance among agonists, as tolerance was 
assessed only at as single time-point in these studies. For example, rats chronically 
treated with THC displayed a time-dependent loss of cannabinoid receptors and 
cannabinoid receptor-activated G proteins in both membranes and brain sections tested 
after 3, 7, 14, and 21 days of THC treatment (Breivogel et al. 1999). To rectify these two 
possibilities, time-course experiments are needed to examine time-dependent effects of 
tolerance to CP47,497 for each behavioral measure.  
 The localization of CB1 receptors varies across brain regions (Herkenham et al. 
1990), as does CB1 receptor efficiency, defined as the number of G-proteins activated 
per CB1 receptor (Breivogel et al. 1997; Burkey, Quock, Consroe, Ehlert, et al. 1997; 
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Howlett 2004). Studies have shown that repeated THC or WIN55,212-2 treatment 
produced tolerance to cannabinoid-induced behaviors concomitantly with receptor 
desensitization and downregulation, with brain-region specific desensitization observed 
(Sim-Selley & Martin 2002). Similarly, CB1 receptor desensitization and downregulation 
effects were reproduced after repeated THC with diminished inhibition of adenylyl 
cyclase also observed (Selley et al. 2004). Studies with β-arrestin2 knockout mice 
reported enhancement of acute THC-mediated antinociception and hypothermia; upon 
repeated THC-administration, β-arrestin2 knockout mice showed reduced CB1 receptor 
desensitization and downregulation in cerebellum, spinal cord and periaqueductal 
accompanied with reduced THC-mediated antinociceptive, but increased THC-mediated 
cataleptic tolerance (Nguyen et al. 2012). These data provide the best direct evidence of 
CB1 receptor involvement of tolerance development to THC-mediated behaviors. Taken 
together, these data illustrate that molecular adaptations at the receptor and effector 
level underlie the presentation of behavioral tolerance. Moving forward, it is important to 
determine to what extent chronic CP47,497 administration causes CB1 receptor 
desensitization and downregulation, with investigation of time-course, dose-response 
and brain-region specificity.  
 Our tolerance results are in agreement with previous studies that demonstrate 
cross-tolerance of CP55,940 and WIN55,212-2 develops to THC-induced 
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cannabimimetic effects, which suggests these drugs effects are mediated by the same 
receptor signaling mechanism(s) (Fan 1994, Pertwee 1993). Quantitative 
autoradiographic analysis of post-mortem brains obtained from chronic marijuana 
smokers showed decreases in CB1 receptor binding in the dorsal striatum, nucleus 
accumbens and globus palladus, with pharmacodynamic adaptations including 
decreases in CB1 cDNA expression and CB1 receptor mRNA levels thought to 
contribute to the development of tolerance to THC effects in chronic cannabis users 
(Villares 2007). Furthermore, positron emission tomography (PET) imaging studies 
reported CB1 downregulation in cortical, but not basal ganglia and midbrain structures, 
from chronic daily smokers (Hirvonen et al. 2012), which overlaps with observed CB1 
receptor downregulation in rodents.  Although additional preclinical investigations of 
receptor adaptations following chronic synthetic cannabinoid exposure are needed, in 
the future, it may be possible to extrapolate data regarding tolerance to chronic THC to 
consequences of chronic abuse of CP47,497 or other full CB1 receptor agonists in 
humans.   
 Consequently, prolonged use of cannabinoids and subsequent CB1-mediated 
neuroadaptations promotes development of cannabis dependence, and is thought to be 
responsible for behaviors that lead to drug abuse and addiction. A withdrawal or 
abstinence syndrome, characterized by mood and sleep disturbances, with changes in 
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appetite have been previously described (Cooper & Haney 2008; Desai et al. 2013; 
Maldonado 2002; Ramesh et al. 2011). For rimonabant-precipitated withdrawal 
experiments, CP55,950 was used as a control with the dose of 2 mg/kg based on 
previously published studies that successfully achieved behavioral tolerance in ICR 
mice (Fan et al. 1994; Fan et al. 1996). To maximize the development of dependence, 
the dose of CP47,497 (15 mg/kg) and THC (50 mg/kg) was derived from catalepsy ED84 
values from acute dose-response experiments. Using this approach, mice treated 
repeatedly with CP47,497 or THC, then challenged with rimonabant displayed 
significant increases in somatic withdrawal signs including paw flutters and head shakes 
versus vehicle-treated animals. Withdrawal from CP55,940 has been previously 
demonstrated in mice (Oliva et al. 2003) and rats (Rubino et al. 1998). Considering no 
differences in efficacy or potency were observed between CP47,497  or THC and 
CP55,940 in [35S]-GTPγS binding, it is not likely that differences in G-protein activation 
are responsible for these effects. However, differences in downstream effector signaling 
may account for these observations, as basal cAMP and PKA levels were increased 
after repeated THC (15 mg/kg (i.p.) twice daily, 6.5 days) versus no alterations after 
repeated CP55,940 (0.4 mg/kg (i.p.) twice daily, 6.5 days) in rats (Rubino, Vigano’, et al. 
2000; Rubino, Viganò, et al. 2000). In one study, significant somatic withdrawal signs 
were observed after twice daily injections of CP55,940 (0.5 mg/kg) for 6.5 days (Oliva et 
al. 2003); however differences in mouse strain (Swiss albino vs. ICR), route of 
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administration (i.p. vs. s.c.), and agonist dose (0.5 vs. 2 mg/kg) may account for lack of 
significance observed in studies presented herein. Furthermore, as we are interested in 
THC-like effects of CP47,497, and significant somatic withdrawal were observed after 
repeated administration with CP47,497 and THC. Therefore, our studies suggest 
CP47,497 is more potent and efficacious (G-protein level) than THC, and when given 
repeatedly, produces significant withdrawal signs upon CB1 antagonist treatment.  
Conclusion  
 Considering that CP47,497 possesses low nanomolar CB1 receptor binding 
affinity (Compton et al. 1993; Melvin et al. 1993), promotes functional activation of the 
CB1 receptor upon ligand binding, produces cannabimimetic effects in the tetrad and 
drug discrimination assays, and these effects do not occur in CB1(-/-) mice or wild type 
mice treated with a CB1 receptor antagonist, it can be concluded that our results 
strongly support that CP47,497 achieves its potent and efficacious THC-like effects 
through CB1 receptor involvement. Furthermore, our repeated administration studies 
demonstrated that similar to the consequences of repeated THC dosing (Abood et al. 
1993; McKinney et al. 2008; Pertwee et al. 1993; Rubino, Vigano’, et al. 2000), repeated 
CP47,497 led to behavioral tolerance of cannabimimetic effects in the tetrad assay and 
CP47,497-dependent mice exhibited somatic withdrawal signs upon rimonabant 
challenge. 
!176 
Concluding Remarks and Future Directions 
 
 Data presented in this body of work developed a quantitative bioanalytical 
identification method and examined the pharmacological profile of acute and repeated 
administration of a new class of abused drugs, synthetic cannabinoids, and in particular, 
the prototypical bicyclic cannabinoid, CP47,497. Prior to the 1960’s, much research 
exploring the effects of marijuana (medicinal and psychotropic) in humans were largely 
anecdotal. The decades of research following the isolation of THC and production of 
synthetic cannabinoids led to the discovery of an endogenous cannabinoid system, the 
elucidation of CB receptors (CB1 and CB2), their endogenous ligands (AEA and 2-AG), 
and elucidated molecular signaling events upon the subsequent activation of these 
receptors. However, with the expropriation of research tools as drugs of abuse, the 
scientific field finds itself challenged to examine pharmacological and toxicological 
consequences of their abuse in a timely and relevant manner. Synthetic cannabinoids, 
as a new class of designer drugs, present a persistent challenge to researchers, 
toxicologists, and law enforcement as the chemical constituents rapidly evolve to 
circumvent legislative bans and to evade biological detection.  
 Presented here are studies that investigated!the mechanism(s) by which 
CP47,497 achieves THC-like effects, that is, through CB1 receptor mediation, eliciting 
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potent behavioral effects in mice that develop tolerance and display dependence liability 
upon repeated administration. Equally important, we present an HPLC/MS/MS method 
previously used to quantify THC and its major metabolites, which has been adapted to 
detect several synthetic cannabinoids (CP47,497, CP47,497-C8, JWH-250) in biological 
tissues. Importantly, these experiments demonstrate bioavailability of CP47,497 in the 
brain, and with future method validation, traditional cannabinoid analytes as well as 
designer synthetic cannabinoids can be analyzed simultaneously. Taking into account 
the novelty of the analytical and pharmacological data presented in this dissertation, 
these studies provide the preclinical knowledge necessary for potential hypothesis-
driven, scientific-based studies to be performed in humans in the future. Since tolerance 
to classical cannabinoid behavior was observed, with no difference in CP47,497-
stimulated [35S]-GTPγS binding observed, we propose that differences in brain region 
specific receptor downregulation, desensitization and second messenger adaptations 
are responsible for cannabimimetic effects observed. Furthermore, with the 
development and validation of an analytical method for detection of CP47,497 in 
biological tissues, studies can address the hypothesis that active metabolites of 
CP47,497 are involved in producing CP47,497-mediated behavioral effects in animals 
and humans. This is crucial as essentially all of the data collected regarding synthetic 
cannabinoid effects in humans has come from clinical case reports, poison control 
centers, and internet-based surveys. Data from the experiments presented herein may 
!178 
assist clinicians, toxicologists and law enforcement by providing pharmacological and 
toxicological data, which can be used to extend what is known of THC to better 
understand THC-like effects of synthetic cannabinoids. 
 The clandestine synthesis and distribution of synthetic cannabinoids as designer 
drugs of abuse remains a continuously moving target. Therefore, in the future, studies 
need to be conducted that assess the: (1) activation of G-proteins in human cannabinoid 
receptor expression systems, (2) development of bioanalytical methods for detection of 
novel SCB compounds, and (3) screening of cannabimimetic behavioral effects in the 
tetrad and drug discrimination paradigms, with judicious use of the selective CB1 
antagonists, such as rimonabant, to determine the involvement of CB1 receptors.  
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Appendix I – Chemical Structures !
A796-260 ! ADB-PINACA!
AM-2201!AKB48!
AKA, APINACA  (N-(1-
adamantyl)-1-pentyl-1H-
indazole-3-carboxamide)!  
!213 
Cannabidiol! Cannabinol!
9-nor-9β-Hydroxyhexahydro-
cannabinol (HHC)" (±)-CP55,940!
 
!214 
CP47,497! CP47,497-d11!
CP47,497-C8! CP47,497-C8-d7!
 
!215 
Δ9-THC"
(−)-11-nor-9-carboxy-Δ9-THC"
!
11-OH-THC"
!
 
!216 
JWH-018! JWH-073!
JWH-122! JWH-210!
 
!217 
JWH-250! JWH-250-d5!
HU-211!HU-210!
 
!218 
Pravadoline! RCS-4!
WIN55,212-2!Rimonabant (SR141617A)!
!"
"
 
!219 
UR-144! XLR-11!
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Appendix II – Drug Discrimination Apparatus !
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